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ABSTRACT
Members of the TNF superfamily play important roles in the development and maintenance of an
effective immune response. One such member of this superfamily, LIGHT, can act as a ligand for
three receptors, HVEM, LTβR and DcR3. The engagement of LIGHT and HVEM, an important
secondary signal for the full activation of T cells, results in a strong Th1 type response with
increased production of cytokines such as INF-γ. The LIGHT-LTβR pathway plays a role in the
recruitment of immune cells to sites of inflammation and can induce apoptosis in certain cells.
DcR3, a soluble receptor, is speculated to function in modulating LIGHT’s activity by preventing it
from binding with HVEM and LTβR. Two studies published in 2001 highlighted the in vivo effects
of constitutive expression of LIGHT on T cells in transgenic mice. The phenotype observed in
these mice indicated that there was a loss of self-tolerance leading to systemic autoimmunity as
characterised by the presence of multiple autoantibodies and inflammation of numerous organs.

The aim of this thesis is to investigate the expression of LIGHT and associated receptors in
systemic lupus erythematosus (SLE) and coeliac disease (CD). Based on the disease manifestations
seen in LIGHT transgenic mice we speculated that patients with these conditions would have
altered mRNA expression patterns of LIGHT or possibly its receptors.

To achieve our aim,

quantitative Real-time PCR was to be employed to perform a gene expression study using a control
group of healthy volunteers as well as cohorts of CD and SLE patients. A cohort of Wegener’s
granulomatosis (WG) patients was also included in this study.

Real-time PCR has emerged as a powerful technique for quantifying the expression of genes.
However, before embarking on a logistically complex and expensive gene expression study it was
felt that gaining hands-on experience in developing Real-time PCR assays for simpler studies,
where the end results could be predetermined, would yield benefits in the long-term. To this end,
we chose two models to study various aspects of Real-time PCR assay design.

I

Cystic fibrosis is the most common lethal recessive genetic disease in Caucasian populations and
thus serves as a good model for developing a Real-time PCR assay for mutation detection. After
identifying insufficiencies with how mutation detection is traditionally performed, we developed a
novel approach on the LightCycler instrument by combining ARMS PCR with melting curve
analysis. This approach allowed better design of hybridisation probes and facilitated more than one
mutation to be detected per fluorescent colour channel on the LightCycler. Our optimised assays
allow the detection of the five most common mutations, accounting for 90% of mutant alleles, in
approximately 35 mins, which is significantly quicker than other traditional techniques.

As a model for examining the capabilities of quantitative Real-time PCR, we examined the gene
dosage of peripheral myelin protein 22 (PMP22). Alterations in gene copy number of PMP22 can
result in two distinct neurological diseases Charcot-Marie-Tooth disease type 1A (CMT1A) and
hereditary neuropathy with liability to pressure palsies (HNPP), respectively caused by a gain or
loss of a copy of the PMP22 gene. In this study, we successfully developed a quantitative multiplex
Real-time PCR that can diagnose CMT1A and HNPP patients with altered PMP22 gene copy
numbers. Our assay provides a rapid alternative to traditional techniques used for gene dosage
quantification and could be adapted for use in the diagnosis of many genetic diseases.

Having gained knowledge in the use of Real-time PCR we proceeded to performing the gene
expression study.

During this study we have provided strong evidence that LIGHT and its

associated receptors may play an important role in the pathogenesis of both SLE and CD and less so
in WG. Our results demonstrated that LIGHT is elevated in both peripheral blood and the small
intestine of patients with active CD. In SLE, there is a more profound dysregulation of LIGHT and
associated receptors. Elevated levels of LIGHT and its three receptors, HVEM, LTβR and DcR3,
were identified in the peripheral blood of our SLE patients. The WG and control cohorts showed
similar levels of expression for LIGHT and its receptor indicating that these signalling pathways are
not involved in its pathogenesis.

II

Studies we performed using P/I activated Jurkat cells demonstrated that there is good correlation
between LIGHT mRNA upregulation and the appearance of soluble LIGHT protein in tissue culture
supernatants. The analysis of soluble LIGHT levels using ELISA demonstrated that there was a
significant elevation of soluble LIGHT in the SLE cohort also a large percentage of the CD patients
were strongly positive.

The WG patients showed a significant reduction in soluble LIGHT

compared to the controls, which provides further proof that it is not involved in its pathogenesis.

Overall, our research shows that LIGHT is upregulated in both CD and SLE and given its function
in promoting a strong Th1 response it is likely to contribute in the pathogenesis of both diseases.
We speculate that increased LIGHT activity in SLE may promote the development of
glomerulonephritis one of the more serious clinical manifestations of the disease, which can
ultimately lead to renal failure and death. CD patients have a high incidence of developing
secondary autoimmune disease. We hypothesize that in addition to its immediate effects in CD
pathogenesis, sustained levels of soluble LIGHT may also contribute to a breakdown of selftolerance and lead to autoimmune disease development. Further research into the expression and
function of LIGHT will lead to a better understanding of the mechanisms causing these diseases. In
the future, this should lead to the development of new therapies for these and related diseases.

III
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Chapter 1

GENERAL INTRODUCTION

Chapter 1.1

LIGHT, ASSOCIATED RECEPTORS AND
IMMUNE-MEDIATED DISEASES

1.1.1

Activation and co-stimulation of T cells

Naïve T cells are initially stimulated via T cell receptor (TCR) engagement with a MHCpeptide complex made available by antigen presenting cells (APC). This primary signal,
while it is essential, is not on it’s own enough to induce a fully committed immune
response. A secondary co-stimulatory signal is required and this signal determines the fate
of the T cell. The two main groups of co-stimulatory receptors present on T cells are the
immunoglobulin superfamily such as CD28 and inducible co-stimulator (ICOS) and the
tumour necrosis factor receptor (TNFR) superfamily that includes CD27, CD30, OX40,
41BB and HVEM among others (Croft, 2003).

CD28 is probably one of the best-

characterised co-stimulatory receptors, which ligates with B7 present on APCs. CTLA-4
can also bind B7 to transduce inhibitory signals into T cells.

The balance between

stimulatory and inhibitory secondary signals helps to maintain T cell self-tolerance and
prevents the induction of autoimmunity.

Many members of the TNFR superfamily

transduce positive co-stimulatory signals, however some members can induce apoptosis in
T cells thereby regulating T cell responses by cellular elimination (Locksley, 2001).

1.1.1.1

Tumour Necrosis Factor receptor superfamily

The TNFR superfamily are all type I transmembrane proteins (C-terminus is exposed to the
cytosol) (Kashii, 1999) and are characterised by the presence of 3-6 cysteine rich domains
(30-40 aa) in their extracellular portion (Kwon, 1997). The cytoplasmic tails of these
receptors are generally short and share very little sequence homology, as would be
expected, to allow for their diverse cellular signalling.
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TNFR superfamily members

mediate their signals in T cells via the TNFR associated factor (TRAF) family (Chung,
2002). Ultimately the signalling cascade leads to the activation of transcription factors such
as NF-κB and AP-1 and upregulation of survival and proinflammatory genes (Beg, 1996).
Members of the TNFR superfamily that can induce apoptosis such as TNFR1 and Fas have
a sequence in their cytoplasmic tails called the “death domain”. Docking proteins such as
TRADD (TNF receptor associated death domain) and FADD (Fas associated death domain)
can bind to this domain leading to caspase activation and cell death by apoptosis (Dempsey,
2003).

1.1.1.2

TNF superfamily

Ligands for the TNFR superfamily have been categorised into the ever-growing TNF
superfamily. Members of the TNF superfamily play important roles in cell activation,
proliferation, differentiation, apoptosis, immunoglobulin class switching, immune evasion
and immune suppression (Zhia, 1998). The majority of TNF superfamily members are
clustered within the MHC on chromosome (Chr) 6 and paralogous regions on Chr 1, 9 and
19 (Collette, 2003).

These ligands, with the exception of LTα, are all type II

transmembrane proteins (N-terminus is exposed to the cytosol) that can also exist as soluble
cytokines following cleavage by membrane metalloproteases (Chen, 2000). Most of these
molecules have an intracellular N terminus, a single transmembrane-spanning domain and
an extracellular C terminus. The extracellular domain folds into a β-pleated sheet “jellyroll
sandwich” structure that trimerises, usually as a homotrimer (Locksley, 2001). LTα only
consists of the C terminus domain and is therefore directly secreted as a homotrimer or can
be membrane bound when anchored with LTβ as a heterotrimer (Kashii, 1999).
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1.1.2

LIGHT

LIGHT (homologous to Lymphotoxins, exhibits Inducible expression, and competes with
Glycoprotein D for HVEM, a receptor expressed on T lymphocytes) also called HVEM-L
or TNFSF14, is a member of the TNF superfamily (Mauri, 1998; Zhai, 1998; Harrop,
1998). LIGHT binds to three members of the TNFR superfamily (Fig 1.01), herpes virus
entry mediator (HVEM), Lymphotoxin beta receptor (LTβR) (Mauri, 1998; Zhai, 1998;
Harrop, 1998) and decoy receptor 3 (DcR3/TR6) (Yu, 1999) each of which will be
discussed in more detail later in sections 1.1.3, 1.1.4 and 1.1.5 respectively.

1.1.2.1

Gene location and genomic organisation

The gene for LIGHT was initially located to Chr 16 using fluorescent in situ hybridisation
(FISH) (Zhai, 1998), however, this was proved not to be the case, and it was subsequently
shown to be located at Chr 19p13.3 (Granger, 2001). This positions LIGHT within a large
genetic region paralogous to the MHC on Chr 6. The LIGHT gene is closely linked with
the genes for C3, CD27L (TNFSF7) and 4-1BBL (TNFSF9). Interestingly, both CD27L
and 4-1BBL play a role in T cell co-stimulation, placing the LIGHT gene within a T cell
co-stimulatory locus (Granger, 2001).

The LIGHT gene spans 5.1 Kb and is comprised of four exons. The cytoplasmic tail,
transmembrane domain and beginning of the extracellular stalk region are encoded by exon
1. The second and third exons, encode the remainder of the stalk region and the beginning
of the trimerisation domain. Exon 4 encodes the rest of the trimerisation domain and the
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receptor-binding domain and at Asp102 there is a site for N-linked glycosylation (Granger,
2001).

In 2002, Castellano and colleagues cloned the 2.1 Kb 5’ region upstream from the LIGHT
gene. Deletion analysis using reporter constructs showed that the – 441 bp flanking the
gene was sufficient for substantial activity. Within this putative promoter region, they
identified several recognition sequences for transcription factors such as NFATc/NFATp (T
cell specific isoforms), which play a role in inducing LIGHT expression in activated T cell
through Ca++ signalling pathways (Castellano, 2002). They also showed that the LIGHT
promoter region contained both NF-κB and AP-1 binding motifs.

1.1.2.2

LIGHT messenger RNA (mRNA) expression

The mRNA transcript of LIGHT was proposed to be 2.5 (Zhai, 1998; Mauri, 1998) – 2.7
Kb (Harrop, 1998) and is found abundantly in spleen and lymph nodes with lower
expression detected in peripheral blood lymphocytes, colon, small intestine, bone marrow,
thymus and lung (Harrop, 1998). Another transcript of LIGHT mRNA (3.5 Kb) was
detected in the brain (Mauri, 1998) and no mRNA was detected in any tumour cell lines of
nonhemopoetic/myeloid origin or fetal tissue, though LIGHT is prominently expressed on
the villi of the placenta (Gill, 2002). LIGHT is also expressed on activated CD4+ and CD8+
T cells as well as immature dendritic cells (Morel, 2000).
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Fig 1.01 The TNF/TNFR core family (Adapted from Schneider, 2004; Ware, 2003;
Granger, 2003). Ligand and receptor interactions are indicated with arrows. The red
arrows indicate interaction directly associated with LIGHT. LTβR signalling can result in
both NF-κB activation and apoptosis.
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1.1.2.3

Three functional forms of LIGHT

The full-length LIGHT mRNA transcript codes for a 29 KDa (240 aa) type II
transmembrane glycoprotein (Mauri, 1998) that is expressed on the surface of activated T
lymphocytes (Granger, 2001) and immature dendritic cells (Morel, 2001). There are two
additional forms of the LIGHT protein, one is produced by alternative splicing (Fig 1.02),
this results in translation of a 204 amino acid, non-glycosylated protein that lacks a
transmembrane region and has been named deltaLIGHT (Granger, 2001). DeltaLIGHT
could not be detected in cell culture supernatant but was precipitated from cell extracts
indicating it is not a secreted protein but is held within the cytosol of the cell (Granger,
2001). The third form of LIGHT is soluble, approximately 25 KDa in size and is the result
of LIGHT being cleaved from the cell surface by matrix metalloproteases (Granger, 2001;
Morel, 2000). A metalloproteinase cleavage site that is found in FasL is also present in
LIGHT (aa 81-84). Many members of the TNF superfamily such as TNF-α (Black, 1997),
FasL (Kayagaki, 1995) and TRANCE (Lum, 1999) undergo cleavage from the cell surface
by matrix metalloproteinases and the cleaved fragments retain biological activity.
Likewise, the soluble form of LIGHT has been shown in several in vitro studies to retain its
activity (Tamada, 2000; Zhang, 2003; Kim, 2005). As there are three different forms of
LIGHT in different compartments (cell surface, intracellular and extracellular), it is thought
that they may exert different biological functions.
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Fig 1.02 Alternative splicing of the LIGHT gene (Adapted from Granger, 2001)

1.1.2.4

T cell expression of LIGHT

As mentioned previously, LIGHT is transiently expressed on the surface of activated T
cells (Morel, 2000). Following stimulation of peripheral blood T cells using PMA and
ionomycin (P/I) the levels of LIGHT protein increase from low basal levels to peak at
~24hrs followed by a return to basal levels. The protein synthesis inhibitor cycloheximide
(CHX) causes a reduction in the upregulation of cell surface LIGHT. However, this
blockade is incomplete indicating that surface expression of LIGHT may be due to both relocalisation of preformed LIGHT and de novo protein synthesis (Morel, 2000). Stimulation
of highly purified CD4+ and CD8+ T cell subsets shows that LIGHT expression is more
rapidly induced and attains a much higher level of expression in CD8+ T cells (Morel,
2000).
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The CD4+ T cell population can be divided into two subsets naïve and memory. The
expression of CD45RA defines the naïve subset, which has never been exposed to antigen
(Ag), and memory CD4+ T cells that have had previous exposure to Ag express CD45RO
(Dutton, 1998). CD4+CD45RO+ T cells express much higher levels of LIGHT (~8-10 fold)
than naïve CD4+ T cells (Cohavy, 2004).

The memory CD4+ T cell population can be further subdivided based on the expression of
CCR7. CCR7 is a chemokine receptor that controls homing of T cells and dendritic cells to
secondary lymphoid organs (Forster, 1999). Its expression defines two subsets of memory
CD4+ T cells (Sallusto, 1999). The CCR7+ “central” memory population can recirculate
through lymph nodes and can produce IL-2. The CCR7- “effector” memory population can
migrate to peripheral sites and can produce effector cytokines such as INF-γ and IL-4.
Naïve, central and effector memory T cells have different kinetics with regard to the
appearance of LIGHT on their cell surface, taking approximately 24 hrs, 4 hrs and 2 hrs
respectively post stimulation (Morel, 2003). It has been demonstrated that resting CCR7+
and CCR7- memory CD4+ T cells have an intracellular pool of LIGHT (Morel, 2003),
however this study did not state which splice variant of LIGHT they were detecting in their
system.

1.1.2.5

Maturation of dendritic cells by LIGHT

Dendritic cells (DCs) are professional antigen presenting cells (APCs) that play a vital role
in the initiation of primary immune response (Bayry, 2004). Immature DCs (iDCs) are
found in many tissue types where they specialise in the capture and processing of Ags.
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After Ag capture DCs begin to mature and migrate from peripheral tissues to the T cell
areas of lymphoid organs. Maturation of DCs results in reduced Ag uptake/processing
capabilities and increased ability to stimulate T cells by upregulating the expression of costimulation molecules such as B7 (Banchereau, 1998). Mature dendritic cells also acquire
the capacity to secrete IL-12, which promotes a Th1 type response (McDonald, 2001).

LIGHT is expressed at high levels on iDC and during maturation of DCs it is
downregulated from the cell surface (Tamada, 2000). LIGHT is cleaved from the surface
of DCs as they mature and it is speculated that it could play a subsequent role in T cell
activation as a soluble cytokine (Tamada, 2000). LIGHT has also been shown to modulate
iDC maturation in conjunction with CD154 (CD40L) (Morel, 2001). CD154 is mainly
expressed on activated CD4+ T cells and signalling through its receptor, CD40, it is well
known to induce phenotypic and functional maturation of DCs (Van Kooten, 1997). Crosslinking CD40 on DCs in vivo replaces the need for CD4+ T cell help for the induction of
cytotoxic T cell (CTL) responses (Schoenberger, 1998; Bennett, 1998) When iDCs are
stimulated with LIGHT they also develop a mature phenotype as characterised by the
expression of CD83 and high levels of HLA class II molecules (Morel, 2001). However,
LIGHT and CD154 can act in synergy to induce enhanced DC maturation, which results in
significantly higher expression of IL-12, IL-6 and TNF-α, than achieved with either CD154
or LIGHT alone.

In turn these LIGHT and CD154 matured DCs can enhance CTL

mediated immune responses (Morel, 2001).

1.1.2.6

Reverse signalling via LIGHT
9

Some members of the TNF superfamily can receive stimuli from their receptors and
transduce signals into cells. This process is called “reverse signalling” as the molecule,
which was once a ligand, now functions as a receptor. This is a common phenomenon
among TNF superfamily members with CD40L (Wiley, 1996), TRANCE (Chen, 2001),
TNF-α (Eissner, 2000), CD30L (Cerutti, 2000) and FasL (Suzuki, 1998) all reported to be
capable of reverse signalling. There is growing evidence that reverse signalling is possible
through LIGHT (Shi, 2002; Wan, 2002). Wan et. al., concluded from their study that
reverse signalling using solid-phase DcR3-Fc through LIGHT promotes Th1 but not Th2
cytokine production, enhances T cell proliferation and CTL development (Wan, 2002). A
similar reverse signalling response was obtained using T cells from mice (Shi, 2002). This
may indicate that not only can LIGHT+ T cells simulate HVEM+ T cells but they could also
receive a signal back again.

1.1.2.7

Negative selection of thymocytes

Some members of the TNF/TNFR superfamilies, including CD40-CD40L, TNF-αTNFRI/II and Fas-FasL (Sebzda, 1999; Kishimoto, 2000), have been identified to play a
role in the negative selection of thymocytes. LIGHT has also been demonstrated to have a
role in negative selection of thymocytes that have high affinity TCR (Wang, 2001; Wang,
2002). Constitutive expression of LIGHT on thymocytes leads to apoptosis of double
positive (CD4+CD8+) cells and atrophy of the thymus (Shaihk, 2001). Thymocytes can be
rescued from LIGHT mediated apoptosis by using a blocking soluble receptor (Wang,
2001).
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Due to the wide range of effects LIGHT has within the development and maintenance of an
immune response it is not surprising that great interest is being generated in its potential
role in immune-mediated diseases.

Studies examining the role of LIGHT in chronic

inflammatory and autoimmune diseases shall be further discussed in chapter 3.

1.1.3

Herpes Virus Entry Mediator

Herpes Virus Entry Mediator (HVEM, TR2, ATAR, HveA) is a member of the TNFR
superfamily. HVEM was first identified by its ability to mediate herpes simplex virus
(HSV) infection into Chinese hamster ovary (CHO) cells (Montgomery, 1996). The gene
encoding HVEM was located to Chr 1p36, which puts it into close proximity with several
other members of the TNFR superfamily, such as CD30, OX-40, 4-1BB and TNFRII
(Kwon, 1997). HVEM is a 283 aa, type I transmembrane glycoprotein that contains 3
cysteine-rich domains (CRDs) and a 50 residue cytoplasmic region that lacks a death
domain (Kwon, 1997; Morel, 2000).

HVEM is like other members of the TNFR

superfamily and forms a homotrimeric structure that is mobilised to the surface of cells.

1.1.3.1

Expression of HVEM

HVEM is prominently expressed in lymphoid tissues such as the spleen and thymus and is
moderately expressed in bone marrow and the small intestine (Harrop, 1998). It is also

11

expressed on various cells including CD4+ and CD8+ T cells, CD19+ B cells, monocytes,
DCs (Harrop, 1998; Morel, 2001) and neutrophils (Kwon, 2003).

High basal levels of HVEM are expressed by resting naïve and memory T cells. Following
T cell activation cell surface levels are rapidly down-regulated, a reciprocal expression
pattern to that of LIGHT, and activated CD8+ T cells show a more pronounced downregulation of HVEM than CD4+ T cells (Morel, 2001). Many members of the TNFR
superfamily can undergo cleavage from the cell surface by matrix metalloproteinases
(MMPs). Evidence using MMP inhibitors suggests that HVEM is not down-regulated by
cleavage from the cell surface, indicating that rapid down-regulation is most likely due to
internalisation of the receptor (Morel, 2001). Incubation of 48-hr activated T cells with the
protein synthesis inhibitor CHX prevents the reappearance of HVEM on the cell surface
suggesting that the receptor is newly synthesised and not recycled (Morel, 2001).

1.1.3.2

Ligands for HVEM

HVEM is recognised to bind to two other ligands besides LIGHT, these are LT-α3 (Mauri,
1998), and glycoprotein D (gD) (Montgomery, 1996). LT-α3 is a soluble cytokine and has
an important role in the development of secondary lymphoid organs. It can act as a ligand
for TNFR1 and TNFR2 as well as HVEM (Spahn, 2005). Little is known about the role of
LT-α binding to HVEM but it is speculated that this interaction is weak (Mauri, 1998;
Ware, 2005). Glycoprotein D is a structural protein found in the envelope of herpes
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simplex virus (HSV). The interaction of gD with HVEM allows the virus to gain entry into
the host cell (Montgomery, 1996; Whitbeck, 1997).

1.1.3.4

B and T lymphocyte attenuator utilises HVEM as a ligand

B and T lymphocyte attenuator (BTLA) a recently discovered member of the
immunoglobulin superfamily (Watanabe, 2003) utilises HVEM as a ligand (Sedy, 2005;
Gonzalez, 2005). Its ability to bind to HVEM is the first instance of immunoglobulin
superfamily/TNFR superfamily crosstalk. BTLA signalling results in co-inhibition and
suppresses T cell responses. This was confirmed using BTLA deficient cells, which show
hyper-reactivity (Watanabe, 2003) and BTLA knockout mice have enhanced in vivo
immune responses (Han, 2004).

1.1.3.5

Ligand and receptor interactions with HVEM

Mutagenesis studies have shown that LIGHT and LT-α3 bind to distinct regions located
within the CRDs 2 and 3 (Sarrias, 2001; Rooney, 2000). It has been demonstrated that
BTLA binds to CRD1 (Sedy, 2005) and HSV gD also binds to CRD1 and can block HVEM
ligating to both LIGHT (Mauri, 1998) and BTLA (Cheung, 2005).

It has been

demonstrated that LIGHT and BTLA can occupy their binding sites on HVEM at the same
time in vitro (Gonzalez, 2005; Cheung, 2005). It remains to be ascertained whether a
trimolecular HVEM-LIGHT-BTLA structure can form in vivo. The hierarchy of HVEM
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binding to its ligands still needs to be fully elucidated. However, the binding affinity of the
LIGHT-HVEM complex is an order of magnitude higher than HVEM-BTLA ligation
(Cheung, 2005). As gD can inhibit binding of HVEM to both LIGHT and BTLA it is likely
to have a higher affinity than LIGHT for HVEM.

1.1.3.6

TRAF mediated intracellular signalling

As mentioned previously TNFR superfamily members utilise the TRAF family of proteins
to mediate signals in the cell. The TRAFs are a family of six proteins named TRAF1-6,
which are characterised by a highly conserved region at the C terminus, termed the TRAF
domain. They also have an N terminus ring finger domain as well as several zinc finger
motifs (Dempsey, 2003). TRAFs bind directly to a TRAF interacting motif (TIM) within
the cytosolic domains of TNFRs allowing transduction of signals to downstream effectors.
HVEM is known to interact with TRAFs 2 and 5 (Hsu, 1997) leading to activation of the
NF-κB and AP-1 pathways resulting in cell survival, cell proliferation and proinflammatory
cytokine production.

The NF-κB family of transcription factors regulate hundreds of genes involved in the
development of cells and organs involved in both the innate and adaptive immune response
(Caamano, 2002; Karin, 2002; Li, 2002). The NF-κB family comprises five members:
RelA (p65), RelB, c-Rel, NF-κB1 (p50 and its precursor p105) and NF-κB2 (p52 and its
precursor p100) (Ware, 2005). These proteins can form homodimers or a collection of
heterodimers that can function as transcriptional activator or inhibitors (Ware, 2005). The
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NF-κB family are regulated by inhibitory proteins collectively termed I-κB, which retain
the transcription factors in a latent form by direct association with them (Wallach, 1999).
Signal transduction pathways that lead to activation of NF-κB must first cause
phosphorylation of I-κB, resulting in its degradation by the proteosome. The degradation
of I-κB releases an active form of NF-κB, which is translocated to the nucleus where it can
dock with its specific binding site and initiate transcription of its associated genes (Karin,
2005).

AP-1 (activating protein-1) is a collective term referring to dimeric transcription factors
composed of Jun and Fos protein families (Karin, 1997). These proteins associate to form a
variety of homo- and hetrodimers that bind to a common site (Karin, 1995). The activation
of AP-1 is involved in cellular proliferation, apoptosis, differentiation, and carcinogenesis
(Shaulian, 2002). AP-1 is known to cooperate with the nuclear factor of activated T cells
(NFAT) to enhance the expression of various cytokines including IL-2, IL-4, IL-8, GMCSF, INF-γ and TNF-α (Hogan, 2003; Rao, 1997).

1.1.3.7

HVEM and T cell responses

The importance of HVEM signalling in development of an optimal T cell response was
highlighted in a study where HVEM was blocked using monoclonal antibodies (Harrop,
1998). This resulted in reduced CD4+ T cell proliferation, sub-optimal levels of IL-2, TNFα and INF-γ being secreted and limited the expression of several cell surface receptors such
as CD25 (IL-2Rα), CD71 (proliferation marker) and CD54 (ICAM-1) among others.
Unexpectedly however, HVEM-/- mice have an enhanced response to various T cell stimuli
15

and these mice were more susceptible to developing autoimmune diseases, indicating that
HVEM also has the potential to inhibit T cell responses (Wang, 2005). Depending on
which molecule HVEM is attached to, it has the ability to act as an on/off switch for T cell
activation (Fig 1.03). BTLA-HVEM may act as a constitutive off pathway for T cells as
both are expressed on resting lymphocytes (Hurchla, 2005). When T cells are activated,
HVEM is down-regulated and LIGHT is upregulated.

It has been demonstrated that

ligation of LIGHT to HVEM is the cause of HVEM down-modulation at both the mRNA
and protein level (Morel, 2001). Since LIGHT has a greater binding affinity for HVEM
than BTLA, LIGHT should preferentially bind when HVEM is present at lower
concentrations (Cheung, 2005). This would disrupt the BTLA-HVEM circuit, therefore
releasing the T cell from this inhibitory pathway and allowing the development of a Th1
type response. This indicates that manipulation of the LIGHT-HVEM pathway could be
very significant for the treatment of Th1 cytokine mediated diseases.
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Fig 1.03 Proposed mechanism of BTLA co-inhibition (Adapted from Croft, 2005). A:
Interaction of BTLA and HVEM results in co-inhibitory signals; B: The interaction of
LIGHT-HVEM will result in co-stimulation; C: Interaction of both LIGHT and BTLA with
HVEM will result in a net negative signal into the cell.
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1.1.4

Lymphotoxin β receptor

Lymphotoxin β receptor (LTβR) is another member of the TNFR superfamily for which
LIGHT is a ligand (Mauri, 1998; Zhai, 1998; Harrop, 1998). The LTβR gene spans 10
exons and is located at Chr 12p13.31. LTβR is expressed on most cell types including cells
of the fibroblast, epithelial and myeloid lineage, but it is not expressed on T/B lymphocytes
(Browning, 1997). The receptor is a 435 aa type 1 transmembrane protein of 46.7 KDa that
has four CRD domains (Granger, 2003).

1.1.4.1

Ligands for LTβ
βR

LTα can form a homotrimeric structure that lacks a transmembrane domain and is therefore
released as a soluble cytokine. As mentioned previously LTα3 acts as a ligand for TNFRI,
TNFRII and HVEM. LTα can also form a heterotrimeric structure with LTβ in either
LTα1β2 or LTα2β1 conformations (Spahn, 2004). LTα1β2 is the predominant form of the
heterotrimer, LTα2β1 is expressed at very low concentrations and its function is not known
(Ware, 2005). The association of LTα with LTβ anchors it to the cell membrane where its
receptor binding properties are altered allowing it to interact with LTβR.

LTα1β2

hetrotrimer is expressed mainly on activated lymphocytes and a subset of resting B cells
(Gommerman, 2004).

With the expression of LIGHT and LTα1β2 restricted to

lymphocyte populations and LTβR expressed on most non-lymphoid cells, this pathway
may act as a communication link between activated lymphocytes and surrounding cells.
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1.1.4.2

Intracellular signalling pathways

LTβR has been shown to mediate its cellular signals via TRAF2, TRAF3 and TRAF5
(Nakano, 1996). It has been established that two signalling pathways stem from LTβR
(VanArsdale, 1997). One pathway using TRAF2/5 leads to NF-κB activation (Nakano,
1996; Degli-Esposti, 1997) and the other pathway mainly involving TRAF3 can lead to
apoptosis of certain tumour cells (Browning, 1996; Zhia, 1998; Harrop, 1998; Rooney,
2000).

The activation of NF-κB by LTβR leads to the up-regulation of genes involved in the
proinflammatory process. These include chemokines, such as macrophage inflammatory
protein 1-β (MIP-1β) and MIP-2, as well as various integrins, such as vascular cell
adhesion molecule 1 (VCAM-1) (Dejardin, 2002), intracellular adhesion molecule 1
(ICAM1) (Zhang, 2003) and mucosal addressin cellular adhesion molecule-1 (MAdCAM1) (Wang, 2004), which can all play a role in attracting and localising leukocytes to areas of
inflammation.

LTβR-LIGHT mediated cell death is dependent on TRAF3, as TRAF3 dominant negative
colon adenocarcinoma cells (HT29.14) are resistant to LIGHT mediated cell death
(Rooney, 2000). When LIGHT binds to LTβR, a complex of proteins is formed at the
cytoplasmic tail of the receptor including TRAF3 and cellular inhibitor of apoptosis 1
(cIAP1). cIAP1 is an anti-apoptotic protein that directly interacts with caspases to inhibit
their activity. The initial LIGHT-LTβR signalling also triggers the mitochondrial apoptotic
pathway by an unknown mechanism, this results in the release of a protein called Smac into
the cytosol which can then bind to cIAP1 (Kuai, 2003). Smac is a pro-apoptotic protein
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that prevents cIAP1 from interacting with caspases and therefore releases them to
eventually cause apoptosis in the cell.

INF-γ may also be required to induce LTβR

mediated apoptosis (Browning, 1997) to support this INF-γ has been shown to induce de
novo synthesis of Smac (Yoshikawa, 2001). However, LTβR use of TRAF3 to mediate
intracellular signalling is not as clear-cut as this. LTβR can also activate NF-κB through
TRAF3. This opposing function of LTβR-TRAF3 signalling may be explained by the fact
that there are several splice variants of TRAF3, some of which are known to activate NFκB (van Eyndhoven, 1999).

1.1.4.3

Secondary lymphoid organogenesis

An effective immune response requires the interaction of multiple cell types. These cellular
interactions are facilitated in the secondary lymphoid tissues such as the spleen, lymph
nodes (LNs) and Peyer’s patches (PPs). These organs have a specialised micro-architecture
that positions different cell types within distinct regions; this allows optimal interactions
between lymphocytes and APCs (Gommerman, 2004).

PPs are specialised lymphoid

organs found in the small intestinal wall that contain naïve B cells, follicular dendritic cells
(FDCs) and T cell rich areas (Spahn, 2005). PPs are associated with specialised epithelial
cells known as M cells. The function of M cells is to sample Ag within the lumen of the
intestine and deliver it directly to APCs within the PPs.

The LTαβ-LTβR pathway is essential for the formation and maintenance of these
secondary lymphoid organs (Gommerman, 2003; Schneider, 2004). Knockout mice for
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LTβR, LTα and LTβ have demonstrated their essential role in secondary lymphoid
organogenesis as these mice lack LNs and PPs and have altered splenic structure and B cell
follicles (Banks, 1995; Koni, 1997; Futterer, 1998; Fu, 1999). LIGHT -/- mice develop
secondary lymphoid organs indicating that it may not be essential for their development.
However, two studies suggest the LIGHT has a function in secondary lymphoid organ
development and maintenance. Double LIGHT-/- and LTβ -/- mice lack mesenteric LNs
(mLN), which are present in LTβ-/- knockout mice indicating that LIGHT can cooperate
with LTβ in their formation (Scheu, 2002). LTα-/- knockout mice that overexpress LIGHT
have a restored secondary lymphoid structure and function (Wang, 2002). This indicates
that increased signalling by LIGHT through LTβR can compensate for the lack of LTα1β2.
Furthermore, overexpressing LIGHT in LTβR-/- mice failed to restore secondary lymphoid
organ structure (Wang, 2002). This shows that restoration of secondary lymphoid structure
via LIGHT is LTβR dependent.

1.1.4.4

Ectopic lymphoid tissues

Ectopic or tertiary lymphoid tissues normally contain very few lymphoid cells but can
import lymphoid cells during an inflammatory response. The LIGHT/LT-LTβR pathway
also participates in the formation of tertiary lymphoid tissues (Hjelmstrom, 2000). These
structures have been identified in chronically inflamed tissue and their emergence has been
correlated with human disease (Gommerman, 2004). These tissues have been reported in a
wide range of autoimmune conditions such as rheumatoid arthritis (Takemura, 2001),
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Sjogren’s syndrome (Salomonsson, 2002), Crohn’s disease (Weyand, 2001) and many
others.

1.1.4.5

IgA production

Immunoglobulin A (IgA) is the first line of defence against microbes entering at mucosal
surfaces. This antibody prevents pathogens from colonising mucosal surface and facilitates
their phagocytosis. LTβR expression in the intestine is required for the production of IgA
as LTβR-/- mice have extremely low levels of serum and fecal IgA (Kang, 2002).
Transgenic (Tg) mice that overexpress LIGHT (LIGHT Tg) show a dysregulation of IgA
production (Wang, 2004). These mice have reduced fecal IgA but elevated levels of serum
IgA indicating a defect in IgA transportation to the lumen of the intestine, possibly due to
reduced epithelial cell function (Wang, 2004). LIGHT Tg mice show an elevated level of
polymeric IgA (pIgA), the intestinal source of IgA, in their serum. The ratio of pIgA to
monomeric IgA (mIgA) was significantly elevated, which suggests that the elevated levels
of IgA in the Tg mice originated from mucosal tissues (Wang, 2004). Polymeric IgA can
very efficiently form large immune complexes (ICs) (>500 KDa) owing to its multivalent
properties, these complexes can become trapped in the kidneys due to their size and their
ability to bind to receptors on mesangial cells in the kidneys (Gomez-Guerrero, 1993).
Deposition of ICs in the kidney results in inflammation and if not controlled leads to
nephropathy. In LIGHT Tg/LTβR-/- the elevation of serum IgA disappeared completely
even in the presence of the LIGHT transgene. These mice showed no gross abnormalities
or any significant T cell mediated inflammation of the intestine (Wang, 2004). This
indicates that LTβR is required for the resultant inflammation in the gut and hyperserum
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IgA in LIGHT Tg mice. This links the LIGHT-LTβR pathway to intestinal inflammation
and the development of IgA nephropathy, which can occur as a secondary disease in
inflammatory bowel disease (IBD), coeliac disease and other chronic inflammatory
diseases (Wang, 2005).

1.1.5

Decoy Receptor 3

Decoy receptor 3 (DcR3, TR6, TNFRSF6B, M68) a third receptor for LIGHT was
identified by searching expressed sequence tag (EST) databases for sequences that showed
homology to members of the TNFR superfamily (Pitti, 1998). Through linkage analysis the
gene was located to Chr 20q13 (Pitti, 1998). Northern blotting showed that DcR3 mRNA
(1.2Kb) is expressed at high levels in several normal human tissues such as the stomach,
spleen, spinal cord, lymph node, lung and colon (Pitti, 1998; Bai, 2000). Its expression was
reported to be weak in the thymus and undetectable in PBMCs (Zhang, 2001), however,
other studies have shown that it is expressed in PBMCs (Otsuki, 2000; Wan, 2003).

The cDNA codes for a protein of 300 aa that is approximately 35 KDa in size and like other
members of the TNFR superfamily DcR3 forms a homotrimeric tertiary structure. The
amino terminus contains a 29-residue leader sequence, which is followed by four CRDs.
Unlike most other members of the TNFR superfamily, DcR3 lacks a transmembrane
domain and is therefore secreted rather than associated with the cell membrane (Pitti,
1998).
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1.1.5.1

Ligands for DcR3

The binding of DcR3 to LIGHT inhibits the interaction of LIGHT with both HVEM and
LTβR (Zhang, 2001; Yu, 1999).

This would suggest that DcR3 dampens down co-

stimulation of T cells by inhibiting LIGHT-HVEM signalling and prevents LIGHT induced
apoptosis of tumour cells via LTβR.

The Fas-FasL stimulated pathway is involved in apoptosis and is important in the
elimination of virus-infected cells and cancer cells by natural killer (NK) cells and CTLs.
DcR3 is known to bind to FasL where it interferes with the interaction between Fas and
FasL.

As a result, FasL induced apoptosis of lymphocytes and tumour cells can be

repressed by DcR3 (Pitti, 1998).

TL1A is the third member of the TNFSF that binds with DcR3. TL1A is mainly expressed
in endothelial cells (Migone, 2002). Zhai et. al., showed that recombinant TL1A could
inhibit the growth of colon carcinomas in mice, and they concluded that it functioned as an
angiogenesis inhibitor (Zhai, 1999).

Death receptor 3 (DR3) is expressed mainly on

lymphocytes, and its interaction with TL1A can provide a co-stimulatory signal for the
activation of T cells. TL1A has been shown to enhance the secretion of INF-γ and GMCSF from T cells without affecting the production of IL-2, IL-4, IL-10 or TNF (Migone,
2002). This indicates that TL1A can promote a Th1 response and it may play a role in
diseases mediated by a Th1 immune response. In fact, TL1A has been shown to be
upregulated in active Crohn’s disease, a Th1 mediated disease (Bamias, 2003). DcR3
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strongly inhibits TL1A responses in T cells and inhibits TL1A triggered apoptosis of
tumour cells (Migone, 2002).

1.1.5.2

Partial proteolytic cleavage of DcR3

There is evidence that DcR3 can be proteolytically cleaved between amino acids R218A219 to yield a smaller (1-218) circulating DcR3 fragment. This smaller 218 amino acid
fragment of DcR3 retains its ability to bind and inhibit LIGHT but loses its ability to bind
and modulate FasL mediated apoptosis (Wrobleski, 2003). This processing of DcR3 may
help to regulate the different co-stimulatory and apoptotic pathways induced by its ligands.

1.1.5.3

DcR3 expression in malignancy

The three ligands for DcR3, FasL (Pitti, 1998; Bai, 2000; Roth, 2001), LIGHT (Yu, 1999;
Zhang, 2001) and TL1A (Migone, 2002) can all function in the initiation of apoptosis or the
development of a Th1 mediated immune response. Therefore, overexpression of DcR3
could lead to gross inhibition of apoptosis and an ineffective CTL response. Pitti and
colleagues speculated that certain tumours could avoid detection by the immune system,
and thus Fas mediated apoptosis, by over-expressing DcR3 (Pitti, 1998).

Gene

amplification is a common occurrence in the development of tumours. It was shown by
quantitative PCR that in many tumour cell types that DcR3 gene amplification had occurred
(Pitti, 1998). Elevated levels of DcR3 mRNA and protein were also identified in these
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cells. DcR3 mRNA was localised to infiltrating malignant epithelium, but absent in the
surrounding stroma, indicating tumour specific expression (Pitti, 1998).

1.1.6

The immune system and human disease

The primary function of the immune system is to protect us from the constant barrage of
bacteria, viruses and other parasites that invade our bodies. For this the immune system
needs to be quite flexible so that it can recognise an almost endless array of foreign
invaders. However, on occasion the through a number of mechanisms it may turn its
powerful array of cells, cytokines and proteases against us leading to autoimmune diseases.

As described above LIGHT plays role in the activation of T cell and maturation of DC.
Over-expression of LIGHT in transgenic mice can cause severe intestinal inflammation
(see chapter 3) and symptoms of systemic autoimmunity (Wang, 2001; Shaikh, 2001). One
of the aims of this thesis is to analyse the gene expression of LIGHT and associated
receptors in human immune-mediated disease using Real-time PCR. The diseases chosen
for this study include coeliac disease, systemic lupus erythematosus and Wegener’s
granulomatosis, a brief description of each disease follows in sections 1.17, 1.18 and 1.1.9
respectively.

26

1.1.7

Coeliac disease (CD)

Coeliac disease (CD) is a chronic inflammatory disease of the upper small intestine that is
the result of gluten ingestion by genetically susceptible individuals. The disease was once
thought to be quite rare, but in recent years, it has been reported to have a prevalence of 1
in 120 to 300 individuals in both Europe and North America (Farrel, 2003). However, the
true prevalence of CD is difficult to determine. Some patients may have atypical symptoms
and be incorrectly diagnosed or have silent CD, which can remain undiagnosed, as the
patients show no symptoms (Visakorpi, 1997). CD is more often associated with a female
population (2:1 ratio) and presentation with the disease may occur at all ages (Oxentenko,
2003).

1.1.7.1

Diagnosis of CD

Patients with CD present with a wide range of symptoms including diarrhoea,
malabsorption (anaemia, osteoporosis) abdominal distension, failure to thrive (children),
weight loss and neuropsychiatric symptoms (anxiety, depression) among many others
(Collin, 2005; Duggan, 2003) and it is this broad range of symptoms that can make CD
difficult to diagnose.
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1.1.7.1.1 Duodenal biopsy

The gold standard for CD diagnosis is a duodenal biopsy, which is used to look for the
characteristic lesion in the gut including: villous atrophy, crypt hyperplasia and elevated
levels of intraepithelial lymphocytes (IELs) and lamina propria lymphocytes (LPLs). The
lesion is graded according to the Marsh classification system (Fig 1.04) (Marsh, 1992).
Type 0 is not seen that often in CD but more so in the related gluten induced condition
called dermatitis herpetiformis (DH). It has been demonstrated that these patients have IgA
and IgM anti-gliadin antibodies in their intestinal secretions (O’Mahony, 1990). A Marsh
Type I (infiltrative) lesion shows normal villous structure with lymphocyte infiltration into
the villous epithelial layer. It is generally accepted that more than 30-40 lymphocytes per
100 enterocytes is a significant increase (Marsh, 1992). A Marsh II (hyperplastic) lesion in
conjunction to lymphocyte infiltration there is also evidence of crypt hyperplasia. The
villous height /crypt depth ratio is generally below the normal value of 3-5. Villous
atrophy is the hallmark of Marsh class III (destructive) lesions. This class is further
subdivided based on the level to which the villous is damaged. Class IIIA show partial
villous atrophy with villous height /crypt depth ratio of less than one. Class IIIB describes
subtotal villous destruction where individual villi are still recognisable. Marsh Class IIIC
biopsies show total destruction of the villi. Type IV (hypoplastic) lesions are rare and
specific to CD. These are characterised by chronic unresponsiveness to the removal of
gluten from the diet, resulting in irreversible destruction of the mucosal surface.
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Fig 1.04 Marsh classification of the coeliac lesion (Adapted from Marsh, 1992). Villous
epithelial layer (VEL); Lamina propria (LP); Intraepithelial lymphocyte (IEL).

1.1.7.1.2 Serological testing in CD

Serological tests for CD are now commonly used to assist in diagnosis and monitoring the
adherence to a gluten free diet (GFD) by the patient. These serological assays include
testing for endomysial antibodies (EMA), anti-gliadin antibodies (AGA) and anti-tissue
transglutaminase (tTG) antibodies. The presence of antibodies against endomysium is
nearly 100% specific in the diagnosis of CD (Hill, 2005; Farrel, 2002; Feighery, 1998).
Detection of anti-tTG autoantibodies in CD stems from the discovery that tTG is the main
antigen to which anti-EMA are directed (Dieterich, 1997). These serology tests usually
detect IgA autoantibodies. As selective IgA deficiency occurs in 1.7 – 2.6 % of CD
patients (Cataldo, 1998) serology results may be falsely negative; therefore, a total serum
IgA test is also performed in conjunction with the other Ab tests. In cases where IgA
deficiency is diagnosed it is necessary to test for IgG antibodies to EMA, AGA and tTG.
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1.1.7.2

Treatment for CD

The treatment for CD is the life-long removal of gluten from the diet including all sources
of wheat, barley and rye. This can be a challenge for the patient, as many processed foods
contain gluten, so close consultation with a dietician is important in the management of the
disease.

Oats have been reported to be non-toxic to CD patients (Janatuinen, 2002;

Kilmartin, 2003). Patients may also require replenishment of vitamins and minerals with
supplements as deficiencies in iron, folate, calcium and vitamin D are found in untreated
CD patients (Farrel, 2002). Once gluten is removed from the diet, the majority of patients
show a clinical improvement within a few weeks. Histological improvement in the small
intestine can take longer, from months to years (Feighery, 1999). Some patients fail to
respond to a GFD or initially respond and then relapse again; these patients can be
diagnosed

with

refractory

CD.

Patients

with

refractory

CD

may

require

immunosuppressive treatments with corticosteroids azathioprine or cyclosporine (Rolny,
1999; Vaidya, 1999).

1.1.7.3

Conditions associated with CD

Many conditions have been associated with the presence of CD (Collin, 1994). It is likely
that some of these associations are due to the malnourished status endemic in the CD
population and should improve with a GFD. However, more complex disease associations
such as malignancy and autoimmunity could be due to dysregulation of common immune
effector pathways. Nevertheless, as the true prevalence of CD is not known, there is also
the possibility that some of these associations are coincidental (Feighery, 1999).
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1.1.7.3.1 Dermatitis herpetiformis (DH)

DH affects 10-20% of CD patients (Reunula, 2001; Fry, 2002) and presents as a pruritic
bullous rash, classically on the extensor surfaces of the body, which may leave
pigmentation and scarring (Oxentenko, 2003). As in CD, DH patients suffer from gluten
sensitivity and are seropositive for AGA and anti-tTG antibodies, although at lower levels
(Porter, 1999). Gastrointestinal symptoms are usually absent and this may be explained by
the fact that there are generally only mild histological changes in the small intestine.
Diagnosis is normally made by finding granular deposits of IgA in the papillary dermis,
with increased numbers of activated T cells. The disease may occur due to molecular
mimicry between tissue transglutaminase found in the gut and epidermal transglutaminase
(TG3) found in the skin (Sardy, 2002). Treatment for the disease includes adherence to a
GFD and the rash can be treated with a suppressive medication such as dapsone
(diaminodiphenylsulfone). Dapsone suppresses the inflammation in the skin but has no
effect on the intestinal abnormality (Zone, 2005).

As there are usually no severe

gastrointestinal symptoms associated with DH, many patients neglect a GFD choosing to
contain the rash with medication instead.

1.1.7.3.2 Malignancy and CD

CD has been linked to development of malignancies such as small bowel adenocarcinoma,
oesophageal and oropharyngeal squamous carcinoma and non-Hodgkin lymphoma (NHL)
(Catassi, 2002). The incidence of small bowel adenocarcinoma in CD is ~80 fold higher
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than in the general population (Green, 2001). Enteropathy associated T cell lymphoma
(EATL), a rare high grade T cell NHL of the upper small intestine, is specific to CD
(O’Farrelly, 1986). Some investigators have suggested that EATL is the last stage of
refractory CD (Catassi, 2005). EATL does not respond well to chemotherapy and the
patients health often rapidly declines (Green, 2005).

1.1.7.3.3 Autoimmune diseases and CD

Autoimmune disorders are ten times more frequent in CD patients than the general
population (Green, 2003). Associated autoimmune conditions include type 1 diabetes
(Cronin, 1997; Lampasona, 1999), autoimmune thyroid disorders (Mainardi, 2002),
autoimmune myocarditis (Frustaci, 2002), autoimmune hepatitis (Volta, 1998), rheumatoid
arthritis, systemic lupus erythematosus (Collin, 1994) and Sjogren’s syndrome (Iltanen,
1999). Some reports indicate that autoimmune disease association with CD is dependent
on the length of gluten exposure, as children diagnosed under the age of two have no
increased risk of developing a secondary autoimmune disease (Ventura, 1999). There is
also a strong association with both IgA nephropathy (Farrel, 2002) and IgA deficiency
(Duggan, 2004) and CD.

1.1.7.3.4 Osteoporosis and CD

Osteoporosis is another associated complication with CD (Walters, 1995), probably
because of malabsorption of minerals, circulating inflammatory cytokines and failure to
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attain maximum bone density during childhood (Green, 2003). Adherence to a GFD results
in mineral bone density improving but it may not return to within a normal range (Meyer,
2001).

1.1.7.3.5 Other conditions associated with CD

CD has also been statistically associated with many other medical conditions such as
Down’s syndrome (Gale, 1997), cystic fibrosis (Farrel, 2002), male/female infertility (Sher,
1994) and depression (Holmes, 1996). Very little is known about how these conditions are
associated with CD.

1.1.7.4

Intraepithelial lymphocytes (IELs) in CD

Two distinct populations of IELs are expanded in CD, TCRαβ+CD8+ and TCRγδ+CD8CD4- (Cerf-Bensussan, 1997). It has been shown that when patients are put on a GFD the
TCRαβ+ CD8+ cells return to normal levels but the TCRγδ+CD8–CD4– population remains
expanded (Spencer, 1991; Kutlu, 1993).

Activated IELs produce several cytokines

including INF-γ, IL-2, IL-8 and TNF-α (Lundqvist, 1996). A percentage of IELs are also
positive for granzyme B and TiA indicating that they have a cytotoxic T cell phenotype
(Oberhuber, 1996).
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Refractory CD patients have a large proportion of IELs with an abnormal phenotype of
TCR–, CD4–, CD8– and CD3– (Patey-Mariaud, 2000; De Serre, 2000). These IELs have
also been demonstrated to have a monoclonal TCRγ gene rearrangement (Cellier, 1998).

1.1.7.5

Lamina propria lymphocytes (LPLs) in CD

There is a significant infiltration of CD4+TCRαβ+ T cells in to the lamina propria during
active disease (Sollid, 2000).

Most of these T cells have a memory phenotype as

characterised by the expression of CD45RO+ (Halastensen, 1990).

There is also a

significant percentage of T cells positive for CD25 (IL-2Rα), indicating that they have an
activated phenotype. These cells however fail to express the proliferation marker Ki-67
(Halastensen, 1993), indicating gluten induces non-proliferative activation of CD4+ lamina
propria T cells. Studies examining mRNA levels of cytokines expressed by active CD4+ T
cells show that there is a significant increase in INF-γ in untreated CD (Nilsen, 1998).
There is also a smaller increase in the levels of IL-2, IL-4, IL-6 and TNF-α (Nilsen, 1998).

Plasma cells also increased in number during active CD and these cells decline in number
when the patient undertakes a GFD (Scott, 1984). These plasma cells produce IgA, IgM
and IgG antibodies that are directed towards gliadin (Falchuk, 1974) and endomysium
(Picarelli, 1996).
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1.1.7.6

Genetics of CD

There is a strong genetic association with CD with the risk of disease occurrence in firstdegree relatives 20-30 times higher than the general population and the concordance rate
between monozygotic twins is 75% (Greco, 2002).

1.1.7.6.1 HLA genes in CD

CD is primarily associated with specific HLA class II molecules, DQ (α1*0501, β*02)
known as DQ2 and DQ (α1*03, β*0302) which can be abbreviated to DQ8. HLA DQ2 is
found in the majority of CD patients (95%) and DQ8 in the remainder (Alaedini, 2005).
DQ2 is present in the general population at approximately 20-30% (Sollid, 1993). The
genetic contribution of HLA genes in CD has been estimated at approximately 40%,
(Bevan, 1999) indicating that non-HLA genes have a major role in determining
susceptibility to CD.

1.1.7.6.2 Non-HLA genes in CD

A non-HLA locus that has been reproducibly shown to be associated with CD is the CTLA4/CD28 gene region on chr 2q33, which has been separately demonstrated in Swedish
(Naluai, 2000), Finnish (Holopainen, 1999), French (Dijilali-Saiah, 1998) and UK (King,
2002) populations. CTLA-4 has an important role in maintaining tolerance to self-antigens;
studies have shown that CTLA-4 knockout mice develop severe autoimmune disease
(Waterhouse, 1995).
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Several genome wide studies have been performed using CD patients in order to identify
non-HLA risk factors. There is however very little consensus between these studies which
may indicate that each non-HLA gene has only a small impact on the disease (Sollid,
2002). Some of the chromosomal regions where there is evidence of association with CD
include 5q (Greco, 2001; Naluai, 2001), 11q (Holopainen, 2001; Naluai, 2001), 6q21-23
and 19p13.1 (Van Belzen, 2003). These regions contain many possible candidate genes
some of which have been implicated in other immune-mediated diseases. Interestingly, the
19p13.1-19p13.3 region is a paralog of the MHC found on Chr 6, and is one of four
locations thought to have arisen by chromosomal duplication, along with Chr 1q21q25/p11-p32 and Chr 9q33-q34 (Kasahara, 1999; Abi Rached, 1999). The LIGHT gene is
situated in this region along with CD27L and 4-1BBL within a T cell co-stimulatory locus
(Granger, 2001).

1.1.7.7

Pathogenesis of CD

The mechanisms behind the development of CD have not been fully elucidated. However,
the most popular hypothesis is based on a T cell driven intolerance to gluten in genetically
susceptible individuals.

1.1.7.7.1 The environmental trigger

Wheat gluten is a mixture of a number of different proteins that have been grouped into the
gliadin and glutenin fractions according to their solubility. Gliadins are alcohol soluble and
have unusually high content of proline (15%) and glutamine (35%) residues (Dewar, 2003).
Based on their amino acid sequence gliadins can be subdivided into α, γ and ω gliadins. Of
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these, the subtypes α and γ-gliadins are partially resistant to digestion by pancreatic and
brush-border proteases (Hausch, 2002; Shan, 2002).

This gives rise to a number of

antigenic peptides that may cross into the lamina propria via the paracellular or
transcellular routes. Movement by the paracellular route is facilitated by the increased
permeability of tight junctions within the epithelial layer. This is the result of an elevation
in zonulin (controls tight junctions in the small intestine) expression within the coeliac
lesion in response to gliadin (Fasano, 2000; Clemente, 2003). The gliadin peptides can
move via the transcellular route using enterocytic vesicles where they can then gain access
to the lamina propria (Zimmer, 1998). These antigenic peptides have been proposed to
activate both an innate (Schuppan, 2003) and the adaptive immune response (Schuppan,
2000).

1.1.7.7.2 Innate Immune response

Little is known about how gliadin derived peptides initiate a response from the innate arm
of the immune system. Interleukin-15 (IL-15) a cytokine typical of the innate immune
system (Fehniger, 2001) has been proposed to play a major role in causing damage to the
intestinal mucosa in CD (Maiuri, 2001; Maiuri, 2000). Specific toxic gliadin peptides have
been shown to induce the expression of IL-15, cyclo-oxygenase-2 (COX-2) and activation
markers (CD25 and CD83) by lamina propria mononuclear cells (LPMCs) whilst, not
causing activation of CD4+ T cells (Maiuri, 2003). Intestinal epithelial cells can also
produce IL-15 (Reinecker, 1996), which is a potent stimulator of IELs (Ebert, 1998).
Epithelial cells in conditions of stress or inflammation increase their expression of
molecules such as MICA and the MHC class I molecule HLA-E. Gliadin can directly
cause overexpression of MICA on enterocytes in CD (Martin-Pagola, 2004). Both MICA
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and HLA-E are recognised by natural killer (NK) receptors, NKGD2 and CD94, present on
IELs (Braud, 1998; Jabri, 2000). The expression of these NK receptors can be regulated by
IL-15 (Robert, 2001). Enterocytes that express MICA and HLA-E can be targeted by NK
receptor expressing IELs, whereupon the enterocyte is killed by apoptosis. Therefore,
gliadin peptides can directly (MICA upregulation) and indirectly (IL-15 upregulation)
cause IELs to induce the apoptosis of enterocytes.

Uncontrolled activation of these

pathways could lead to extensive enterocyte damage and villous atrophy.

1.1.7.7.3 Adaptive Immune response

Tissue transglutaminase (tTG) is a Ca++ dependent enzyme that can perform two types of
reactions in vivo, transamidation and deamidation. The transamidation reaction facilitates
the cross-linking of proteins through the amino acids glutamine and lysine. Deamidation
involves the conversion of glutamine to glutamic acid in the presence of H2O. At pH 7.3,
the transamidation reaction takes preference, however a drop in pH switches the balance in
favour of the deamidation reaction. The enzyme is ubiquitously expressed in the body; in
the small intestine, it is expressed just below the epithelial layer (Molberg, 1998). The
enzyme can be present intracellularly or extracellularly. As an extracellular enzyme it
functions in extracellular matrix assembly, cell adhesion and wound healing (Aeschlimann,
1994).
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The deamidation activity of tTG is significant in the development of an adaptive immune
response in CD. The peptide-binding grooves of the MHC class II molecules DQ2 and
DQ8 prefer negatively charged amino acids at key anchor positions (Sollid, 2000). Optimal
binding of gliadin-derived peptides to these MHC molecules is facilitated by tTG
converting key glutamine residues within the peptides to glutamic acid (negative charge)
(Quarsten, 1999; Molberg, 2001). The binding affinity of deamidated gliadin peptides to
DQ2 is 25 times higher than the native gliadin peptide (Kim, 2004).

Once the toxic peptides gain entry into the lamina propria, they can be deamidated by tTG,
taken up by APC and when presented in the context of DQ2/DQ8 to CD4+ T cells it
initiates their activation. Gluten specific CD4+ T cells isolated from the small intestine of
patients with active CD produce large quantities of INF-γ (Nilsen, 1995; Nilsen, 1998).
INF-γ can have a wide range of potent effects on various cells within the lamina propria
and on the enterocytes themselves. INF-γ can induce macrophages to produce TNF-α.
These two cytokines can work synergistically to have a direct cytotoxic effect on intestinal
epithelial cells (Deem, 1991).

IFN-γ sensitises enterocytes to apoptosis via FAS by

upregulating its expression on these cells (Martin, 2002; Ruemmele, 1999). INF-γ can also
induce fibroblasts and other cells in the lamina propria to release matrix metalloproteinases
(MMPs) which when not controlled can cause death to surrounding cells and destruction of
the mucosal matrix (Pender, 1997). In particular, MMP1 and MMP3 are overexpressed in
the coeliac lesion (Daum, 1999).
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Fig 1.05 The role of the adaptive immune response in the pathogenesis of CD (adapted
from Ciccocioppo, 2005; Kagnoff, 2005). tTG, tissue transglutaminase; APC, antigen
presenting cell; Ab, antibody; MMP, matrix metalloproteinases; IEL, intraepithelial
lymphocyte, EMA endomysial antibody; INF, interferon; G, granzyme.
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The expression of tTG is also elevated in the small intestine of active CD patients
(Molberg, 1998; Bruce, 1985), which would serve to deamidate further gliadin molecules
and thus sustain the inflammatory process (Fig 1.05). The situation is made more complex
by the fact that CD patients have autoantibodies to tTG, which is now recognised as the
major autoantigen for the disease (Dieterich, 1997). How these antibodies occur may be
explained by the fact that as part of its normal function tTG can cross-link proteins through
its transamidation reaction. It is thought that it may be possible for tTG to cross-link itself
to gliadin-derived peptides by autocatalysis (Molberg, 1998).

This new tTG-gliadin

complex could then be internalised by B cells via specific surface immunoglobulins.
Portions of the gliadin fragments may then be presented by DQ2 or DQ8 to gliadin-specific
T cells, which would in turn then provide help for B cell maturation, isotype switching and
antibody production.

This model is supported by the fact that anti-tTG antibodies

disappear once a patient complies with a GFD, as the T cell help needed for antibody
production is eliminated (Sulkanen, 1998).

It is not known to date whether the tTG-autoantibodies contribute to the development of gut
lesion. However, anti-tTG antibodies have also been characterised from patients, which
inhibit the bioactivity of tTG in the coeliac intestine (Esposito, 2002). One of the many
functions that tTG can perform is the activation of transforming growth factor (TGF) –β
(Nunes, 1997). TGF-β can effect the differentiation of intestinal epithelium, stimulate
extracellular matrix formation and regulate many immune cells within the gut (Halttunen,
1996; Dignass, 1996). Therefore, anti-tTG antibodies could have an indirect effect on
TGF-β activation and in doing so contribute to the formation of the lesion.
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1.1.8

Systemic Lupus Erythematosus (SLE)

SLE is an autoimmune disease of unknown aetiology, which is characterised by the
production of various autoantibodies, directed against several cytoplasmic, nuclear and cell
surface molecules and immune complex (IC) formation. Deposition of ICs in tissues can
lead to inflammation and cause damage to multiple organs. SLE patients can suffer from a
wide range of symptoms including glomerulonephritis, dermatitis, thrombosis, vasculitis,
seizures and arthritis (Hochberg, 1997). The prevalence rate has been reported to be 40 and
200 per 100000 in Caucasian and Afro-Caribbean populations respectively (Johnson,
1995). The disease predominantly affects women, with a female to male ratio of 8:1 (Tsao,
2003).

1.1.8.1

Diagnosis of SLE

Diagnosis of SLE is made when a patient fulfils at least four of the eleven, American
college of rheumatology (ACR) criteria, which were revised in 1997 (Table 1.01) (Tan,
1982; Hochberg, 1997).
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Symptoms leading to positive diagnosis of SLE
1
2
3
4
5
6
7
8
9
10
11

Malar rash
Discoid rash
Photosensitivity
Oral ulcers
Arthritis: (non-erosive)
Serositis: Pleurisy/pericarditis
Renal: proteinuria >0.5g/24 hours
Neurological: seizures or psychosis
Haematological: haemolysis/leucopenia/lymphopenia/thrombocytopenia
Immunological: anti-DNA/anti-Sm/antiphopholipid antibodies
Positive ANA
Four or more criteria: 96% sensitive; 96% specific for SLE

Table 1.01 American college of Rheumatology (ACR) classification criteria for SLE.
(Modified from Maddison, 2002).

1.1.8.2

Treatment

Treatment of SLE

for

SLE

involves

the

use

of

immunosuppressive

drugs

such

as

cyclophosphamide and corticosteroids, these cause non-specific immune suppression and
are used in high doses during acute phases of the disease. Due to cyclophosphamide’s
many side effects such as cytopenia, infections and the possibility of malignancy (Eiser,
1994), new therapies are being investigated including mycophenolate mofetil (T and B cell
suppressor) (Karim, 2002), B cell depletion using Rituximab, (monoclonal CD20 antibody)
(Anolik, 2003), autologous stem cell transplantation (Jayne, 2004) and blocking costimulatory molecules such as CD40-CD40L (Quezada, 2003). With effective intervention,
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the prognosis for patients with SLE has significantly improved, with a ten-year survival rate
of approximately 90% (Goldblatt, 2005).

1.1.8.3

Autoantibodies in SLE

SLE patients have a set of characteristic antibodies directed against several components of
cells. Recently it has been shown that these autoantibodies may be present for several years
preceding the onset of clinical symptoms (Arbuckle, 2003). Antinuclear antibodies (ANA)
are present in 98% of SLE patients (Maddison, 2003). Nonetheless, ANA antibodies are
not specific for SLE as they are found in a wide range of systemic rheumatic diseases such
as 80% of Sjogren’s syndrome patients, and organ specific autoimmune diseases including
70% of autoimmune hepatitis cases (Maddison, 2003).

Anti-double stranded DNA

(dsDNA) antibodies are present in 70% of SLE patients (Mok, 2003). Anti-DNA antibody
titres tend to fluctuate over time and with disease activity and are associated with the
development of glomerulonephritis in SLE (Mok, 2003). Antibodies against four groups of
RNA-binding proteins (Sm, UIRNP, Ro and La) are also commonly found in SLE
(Reichlin, 1988). Anti-Sm antibodies are the most specific to SLE and they react to the
core protein group of small nuclear ribonucleoproteins (snRNPs). There is however a wide
ethnic variation in the presence of anti-Sm antibodies, they are found more commonly in
Afro-American and Afro-Caribbean than Caucasian populations (Arnett, 1988)
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1.1.8.4

Hormonal factor involved in SLE

The strong association of the disease with the female population would suggest that there is
a hormonal influence on the development of SLE. In animal model studies, using lupus
prone mice (MLR-lpr/lpr mice) oestrogen can act to accelerate disease progression
(Carlsten, 1990). There is also evidence from mouse models that androgens may have a
protective role and this hypothesis has been tested in human trials for the treatment of SLE
(Chang, 2002).

1.1.8.5

Genetics factors involved in SLE

SLE shows a strong familial association and the concordance rate between monozygotic
twins is approximately 25-58% and drops to 5% for dizygotic twins (Piesesky, 1997). SLE
is seen as a polygenetic disease with many genetic loci identified as being associated with
disease susceptibility. Murine studies have shown that more than 40 genes can induce
lupus-like syndrome (Raman, 2003). Despite this rather large number of genes most can be
classified into one of three functional groups: molecules that effect the clearance of
apoptotic cells, molecules involved in the apoptosis of lymphocytes and molecules that can
amplify or modulate lymphocyte signalling and expansion (Raman, 2003).
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1.1.8.5.1 Complement deficiency in SLE

In the majority of SLE patients, multiple susceptibility genes are required with estimates of
up to four susceptibility genes required for the development of this complex disease (Schur,
1995). However, in a small proportion of SLE patients (<5%) a single gene may be
involved (Mok, 2003). These include homozygous deficiency in the early complement
proteins C1 (C1q, C1r and C1s), C2 and C4 (Carrol, 2004; Nath, 2004). Deficiency in C1q
is a particularly strong susceptibility gene as greater than 90% of these patients develop
SLE (Tsao, 2003). The complement system has an important role to play in the uptake and
clearance of apoptotic blebs. It has been proposed that defects in this pathway could lead to
open presentation of self-antigens, which subsequently leads to the development of high
affinity IgG autoantibodies (Botto, 1998). However, there is a concern with this hypothesis
as individuals deficient in the complement protein C3 have a reduced risk of developing
SLE (Carrol, 2004). Another hypothesis suggests that the early complement proteins have
a role in inducing B cell tolerance.

Complement coated self-antigens are bound to

developing B cells through the complement receptor 1 (CR1) and CR2 and this enhances
negative selection. The loss of early complement components would result in defective
elimination of autoreactive B cells (Carrol, 2004).
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1.1.8.5.2 HLA genes
Population studies have extensively looked at the contribution of major histocompatibility
complex (MHC) genes to human autoimmune disease. The HLA-DR2 and HLA-DR3 class
II genes have been consistently associated with SLE in several studies using Caucasian
populations with a two-fold relative risk conferred by each allele (Tsao, 2002). Conversely,
there is less consistent evidence for HLA association in non-Caucasian populations.

1.1.8.5.3 Non-HLA genes

Linkage analysis studies using SLE families have also located several other susceptibility
regions outside of the MHC region. Chromosomal regions that show significant linkage to
SLE include 1q23 (Moser, 1998; Edberg, 2002), 1q41-42 (Edberg, 2002; Shai, 1999; Tsao,
1997), 2q35-37 (Lindqvist, 2000), 4p16-15.2 (Gray-Mcguire, 2000) and 16q12 (Gaffney,
2000; Nath, 2004).

Each of these chromosome regions contains many possible SLE

susceptibility genes (Table 1.02).

A study involving just Caucasian subjects showed linkage between Chr 19p13.2 (Lindqvist,
2000) and SLE.

In a separate study, stratification of patients based on their major

manifestations of SLE showed that the development of anti-DNA antibodies was linked to
this chromosomal region (Namjou, 2002). This region is in close proximity to the LIGHT
co-stimulation locus (Granger, 2001).
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Candidate genes for SLE

Gene

Chromosome region

Associated allele

Reference

FCγRIIa
FCγRIIIa
IL-10
CTLA-4
PDCD-1
TNF-α
LTα
MBL
FasL
Fas
Bcl-2

1q22-23
1q22-23
1q31-32
2q33
2q37
6p21
6p21
10q11.2-q21
1q23
10q24
18q21

R131
F176
Multiple alleles
+49G
PD-1.3A
TNF2
-----230A
-844C
297C/416G
Multiple alleles

Salmon, 1996
Wu, 1997
Mehrain, 1998
Ahmed, 2001
Prokunia, 2002
Wilson, 1994
Kim, 1996
Davies, 1995
Wu, 2003
Horiuchi, 1999
Mehrain, 1998

Table 1.02 SLE candidate genes (Adapted from Nath, 2004).

1.1.8.6

Environmental factors in SLE

The concordance rate between monozygotic twins would indicate that environmental
factors might play an important role in the development of SLE. UV light, particularly
UVB, has been shown to be an important trigger for the disease (Mok, 2003). UV light can
induce apoptosis in keratinocytes, resulting in the formation of apoptotic blebs on the
surface of the dying cell that contain nuclear and cytoplasmic antigens (Casciola-Rosen,
1996), thus exposing them to the immune system which can provoke autoimmunity.
Exposure to environmental oestrogens such as those used in hormone replacement therapy
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(HRT) (Sanchez-Guerrero, 1995; Meier, 1998) and oral contraception (Sanchez-Guerrero,
1997) also have been shown to cause a small increase in the risk of SLE development.
Dietary factors such as the ingestion of L-canavanine, found in alfalfa sprouts, has been
reported to cause lupus-like symptoms in some individuals (Prete, 1985).

1.1.8.7

Pathogenesis of SLE

SLE is seen predominantly as an overactive B cell disorder due to the presence of
pathogenic antibodies (Lipsky, 2001). Nonetheless, the development and survival of these
pathogenic B cells is dependent upon T cell help (Manson, 2003). ANA producing B cells
show evidence of having undergone T cell driven Ig class switching and affinity
maturation, as the autoantibodies are of the IgG isotype (Hoffman, 2004).

1.1.8.7.1 Defects in apoptosis

Central tolerance removes self-reactive lymphocytes from the immune repertoire, however,
this process is incomplete and low affinity self-reactive B and T cells can escape and
become part of the normal peripheral immune system (Shlomchik, 2001). Autoantigens
may be presented to low affinity self-reactive T cells in the periphery.

In normal

individuals, tolerance to these self-antigens is induced or the T cell is eliminated via
activation induced cell death (AICD). AICD is a process whereby lymphocytes are deleted
after encountering soluble antigen or after persistent activation and proliferation (von
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Herrath, 2003). T cells from SLE patients show defects in AICD, these cells resist anergy
or AICD by upregulating and sustaining cyclooxygenase-2 (COX-2) expression (Lu, 2004).
In SLE, excessive self-antigens are made available due to abnormal apoptosis of cells and
the subsequent failure to remove these apoptotic bodies by phagocytosis.

Prolonged

exposure to apoptotic cells could be an important factor for breaking T cell tolerance in
genetically susceptible individuals. All autoantigen targets in SLE can be identified within
apoptotic blebs found on the surface of dying cells (Cascicola-Rosen, 1994). Clearance of
apoptotic cells by macrophages is facilitated by several receptors including complement
receptors, scavenger receptors and LPS receptors (CD14) (Berden, 2003). As mentioned
earlier, defects in complement receptors or early complement proteins C1, C2 and C4 are
particularly strong SLE susceptibility genes.

1.1.8.7.2 T cell activation responses in SLE

T cells isolated from SLE patients have an elevated and greatly extended intracellular Ca++
flux compared to control T cells when stimulated in vitro (Vassilopoulos, 1995). The
sustained increase in intracellular Ca++ maintains enzymes such as calcineurin and protein
kinase C (PKC) in an activated state and they in turn can activate a wide range of
transcription factors such as NFAT, AP1 and NF-κB. As mentioned previously, activation
of these transcription factors promotes cell survival and upregulation of proinflammatory
cytokines. It has also been reported that there is a reduction in the level of mRNA and
enzyme activity of PKA isoenzymes in SLE T cells (Laxminarayana, 1999).

PKA

isoenzymes mediate negative regulatory effects on signalling events and defects within this
pathway could lead to abnormally high T cell responses (Tsokos, 2000).
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Regulatory T cells (CD4+CD25+) are reduced in the periphery of SLE patients during times
of disease activity and during remission the numbers of these cells return to that of normal
individuals (Crispin, 2004; Liu, 2004). There is also impairment in CD8+ suppressor
function in human SLE, which can strongly inhibit B cell maturation (Filaci, 2001).
Natural killer T (NKT) cells, which express the NK receptor and invariant TCR, are also
reduced in number in active SLE patients (Oishi, 2001). NK T cells have been reported to
inhibit autoreactive B cells (Singh, 2004).

Activation of NK T cells using α-

galactosylceramide in murine models of SLE, suppresses lupus dermatitis (Yang, 2003) and
lupus nephritis (Singh, 2004), whereas the loss of NK T cells exacerbates the symptoms of
lupus in these animal models.
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Fig 1.06 Development of autoimmunity in SLE. (Adapted from Shlomchik, 2001). In
normal individuals, tolerance is induced in T cell when presented with self-antigen. Due to
many genetic and environmental factors, peripheral tolerance is lost in SLE patients, which
subsequently leads to the development of pathogenic antibodies and organ damage.

1.1.8.7.3

B cell tolerance and maturation

The early complement proteins such as C1q are speculated to have a role in the generation
of B cell tolerance (Carrol, 2004). Failure to induce tolerance in these low affinity selfreactive B cells, in SLE patients, means that they are now available to mature in a T cell
dependent manner. Elevated levels of B lymphocyte stimulator (BlyS) a member of the
TNFSF has been reported in active human lupus (Zhang, 2001). Continued stimulation of
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B cells by BlyS leads to the generation of plasma cells in a T cell dependent manner
(Schiemann, 2001), which can then produce large quantities of autoantibodies. Animal
studies have also shown that there is excessive co-stimulation between T cell-B cell-APC
via the CD40-CD40L and CD28-B7 pathways in SLE (Hoffman, 2004).

The maturation process leads to the generation of high affinity B cells from the low affinity
precursors (Sholmchik, 2001). The resulting pathogenic autoantibodies can form ICs with
soluble antigen. Links between polymorphisms in the FCγRIIa (CD32) and FCγRIIIa
(CD16) genes and increased risk of developing SLE have also been made (Salmon, 1996;
Edberg, 2002). These receptors are involved in the phagocytosis of IgG2 and IgG3, the
main IgG isotypes found in IC deposits. The FCγRIIa allele R131 (Salmon, 1996) and
FCγRIIIa allele (F176) (Wu, 1997) can cause a decrease in the receptors binding affinity for
IgG2 or IgG3 antibodies. The defective clearance of ICs, allows them to deposit within
various organs such as the kidneys where they can induce local inflammation and tissue
damage. This organ damage results in further self-antigens being released to the immune
system, thereby sustaining the inflammatory process. T cells themselves may also cause
tissue damage due to the release of potent cytokines such as TNF-α and INF-γ (Hoffman,
2004).

1.1.8.7.4

Glomerulonephritis in SLE

The kidney is particularly at risk of being damaged in SLE as the autoantibody-antigen ICs
are targeted to the glomerular basement membrane (GBM). The GBM is naturally anionic,
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due to the presence of large amounts of heparan sulphate and components of the major
autoantigens in SLE are strongly cationic, this combination facilitates their attachment to
the GBM (Berden, 2003). The IC deposition triggers the infiltration of immune cells
resulting in local inflammation (Ravetch, 2001). Th1-type cytokines, including INF-γ, play
a pivotal role in the resulting glomerular inflammation (Calvani, 2005). Sustained lupus
nephritis can result in glomerulosclerosis or renal fibrosis followed by end-stage renal
disease and death (Singh, 2005).
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1.1.9

Wegener’s granulomatosis (WG)

Wegener’s granulomatosis (WG) is a systemic autoimmune disease that is characterised by
necrotising granulomatous inflammation of the upper and lower respiratory tract and
vasculitis of small and medium sized blood vessels (Langford, 1999). The disease is also
associated with the presence of anti-neutrophil cytoplasmic antibodies (ANCAs) in patient
sera and the development of glomerulonephritis (van der Woude, 1985; Fauci, 1983). WG
is a rare disease, 2-3 cases per 100000 (Mahr, 2004), that has a higher prevalence in
Caucasian populations, with a male to female ratio of 1:1 (Cotch, 1996). As a disease, WG
can be divided into two categories: localised disease and generalised/systemic disease.
Localised WG starts in the upper respiratory tract with granuloma formation. This can
precede generalised WG, characterised by the presence of systemic vasculitis, for a long
period of time (Mueller, 2000).

1.1.9.1

Treatment of WG

The prognosis for WG is quite poor, with a median survival time of five months if left
untreated

(Langford,

1999).

Combination

immunosuppressive

therapy

using

cyclophosphamide and glucocorticoid is the most effective treatment for active disease.
With this treatment, 75% of patients achieve remission (Yi, 2001) and the 5-year survival
rate is 80% (Savage, 1997). However, the use of this aggressive immunotherapy can lead
to other complications such as malignancy (carcinoma of the bladder) and infection (TalarWilliams, 1996).
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1.1.9.2

Anti-neutrophil cytoplasm antibodies (ANCAs)

ANCAs are circulating antibodies directed mainly towards components of neutrophil
granules and monocyte lysosomes (van der Woude, 1985). ANCAs are associated with a
heterogeneous group of diseases called the primary systemic vasculitides (PSV) (Falk,
1988). WG, microscopic polyangiitis (MPA) and Churg-Strauss syndrome (CSS) are the
most common ANCA-associated PSV. ANCAs are pathogenic and correlate well with
disease activity (Pall, 1994).

ANCAs are divided into two groups based on their

immunofluorescent staining pattern. Cytoplasmic staining patterns are designated c-ANCA
and peri-nuclear staining patterns are named p-ANCA. The major antigens of p-ANCA and
c-ANCA are myeloperoxidase (MPO) (Falk, 1988) and proteinase-3 (PR3, PRTN3) (Jenne,
1990) respectively. MPO is located exclusively in the azuorophil granules, but PR3 is
located in the secretory vesicles as well as the granules. PR3 is a member of the serine
protease family and is an antibiotic protein. The presence of c-ANCA is associated with
WG and is found in ~80% of patients with active disease, p-ANCA antibodies are found in
a minority (~15%) of WG patients (Wiik, 2000).

1.1.9.3

Development of ANCA

Although the development of ANCA antibodies in WG is not completely understood, two
main hypotheses have emerged: the microbial superantigen hypothesis and the defective
apoptosis regulation hypothesis (Reumaux, 2004).
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1.1.9.3.1 Microbial Superantigens

Superantigens (SAgs) are components of bacteria, viruses etc. that can act as powerful
stimulators of the immune system. T cell SAgs bind to MHC class II molecules outside of
the peptide-binding groove and to conserved regions of specific families of T cell receptor
V-beta chains (TCR Vβ), regardless of the Ag specificity of the T cell. This allows SAgs
to stimulate the non-specific proliferation of all T cells that express TCR Vβ.
Staphylococcal protein A (SpA), a cell wall component found in most clinical strains of
Staphylococcus aureus, has been identified as a B cell SAg (Sasso, 1989). SpA can bind to
membrane immunoglobulin heavy chains encoded by the VH3 family genes and induce a
polyclonal antibody response (Popa, 2002). Therefore, SAgs have the potential to activate
autoreactive B cells in a T cell dependent and independent manner.

Evidence to support the possible role of SAgs in ANCA development in WG patients
comes from the finding that 60-70% are chronic nasal carriers of Staphylococcus aureus
(Reumaux, 2004) and carriers experience relapse nearly 8 times more frequently than noncarriers (Stegeman, 1994). A higher risk of relapse was associated with the staphylococcal
SAg, toxic-shock-syndrome toxin 1 (TSST-1) (Popa, 2002). It has also been reported that
in WG there is a skewing of the TCR Vβ repertoire in peripheral T cells (Giscombe, 1995).
It has also been reported that WG patients have ANCA antibodies with a VH3 encoded
heavy chain, which indicates that they have a potential to bind SpA (Sibilia, 1997).
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1.1.9.3.2 Defective apoptosis regulation

Defects in apoptosis or the clearance of apoptotic cells may lead to the exposure of selfantigens that are normally sequestered from the immune system leading to a response.
Apoptosis of neutrophils is an important mechanism in maintaining control of the early
inflammatory response and limits tissue damage (Reumaux, 2003). Furthermore, ANCA
have been identified to interact with components on the surface of apoptotic neutrophils
(Gilligan, 1996). The proteolytic events that take place during apoptosis may modify selfantigens to reveal novel epitopes that by-pass normal tolerance, or they could become
complexed to macromolecules from infectious agents to produce novel epitopes that elicit a
sustained immune response (Utz, 1998).

1.1.9.4

Genetic factors in WG

There have been reports of WG developing in members of the same family (Harper, 2000;
Huang, 2001) and there seems to be a Caucasian population bias for development of the
disease (Hoffman, 1992). This would indicate that there are genetic factors that predispose
to the development of WG. WG is likely to be a complex genetic disease with many loci
involved to give rise to disease susceptibility.
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1.1.9.4.1 HLA genes

In a recent study using 202 microsatellite markers in more than 150 WG patients, a
significant increase was seen in the frequency of the HLA DPB1*0401 allele and a
decrease in DPB1*0301 allele (Jagiello, 2004). Other studies have shown associations with
other HLA alleles such as DR1-DQw1 (Papiha, 1992), DR2 (Elkon, 1983) and B50 (Cotch,
1995). Nevertheless, there is no consistent associations identified with particular HLA
alleles and this may indicate that they make only a small contribution to the development of
WG.

1.1.9.4.2 Non-HLA genes

The constitutive expression of PR3 on resting neutrophils in circulation is genetically
determined (Schreiber, 2003). Higher constitutive expression of PR3 on neutrophils is a
risk factor for WG (Witko-Sarsat, 1999).

The (A-564G) polymorphism in the PR3

promoter region that is located within a putative Sp-1 transcription-factor binding site
shows association with WG (Gencik, 2000).
increased PR3 expression (Jagiello, 2005).

This polymorphism potentially leads to
Alpha 1-antitrypsin (α1-AT) is a natural

inhibitor of PR3, and decreased levels of functional α1-AT have been found in WG patients
(Esnault, 1997). A deficiency in α1-AT in WG has been associated with a poor prognosis,
greater organ involvement and increased mortality (Spegalmark, 1995).

Polymorphisms within Fc receptor (FcγR) genes also seem to play a role in the
manifestation of WG (Dijstelbloem, 1999). There are three subgroups of these receptors:
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FcγRI (CD64), FcγRII (CD32) and FcγRIII (CD16). Neutrophils typically express FcγRIIa
and FcγRIIIb whereas monocytes/macrophages express FcγRIa, FcγRII and FcγRIIIa.
These receptors bind the Fc portion of antibodies. They have a wide range of functions and
are involved in leukocyte degranulation, cytokine and chemokine production, generation of
oxidative burst, activation of complement receptor-mediated phagocytosis and antibodydependent cellular cytotoxicity (ADCC) (Huang, 2001). One particular polymorphism in
the FcγRIIa gene, R131H, alters the ability of the receptor to bind IgG2 (Salmon, 1992;
Parren, 1992). Analysis of WG patients showed that those homozygous for the R131H
polymorphism had a greater incidence of disease relapse (Edberg, 1997). Two common
allelic forms of FcγRIIIb exist, NA1 and NA2. It has been reported that these have quite
different effects on cell activation; NA1 induces a greater FcγR-mediated phagocytic
response (Salmon, 1995). The NA1 allele has been found at a higher frequency in WG
patients that also suffered from kidney disease.

TNF-α, LT-α, IL1-α, IL1-β and INF-γ are well-characterised proinflammatory cytokines
and have been demonstrated to be critical in granuloma formation (Huang, 2001).
Polymorphism within the TNF-α promoter region (-238G/A allele) and the INF-γ intron 1
polymorphism (+874 T/T allele) have also been linked with susceptibility to WG
(Spriewald, 2005). The -238G/A allele in the TNF-α promoter has been associated with
the production of higher levels of the cytokine (Reich, 2002). The INF-γ T/T allele is
linked with a high expressor phenotype (Pravica, 2000).

Other genes that have polymorphisms associated with WG are IL-10 (Zhou, 2000), CTLA4 (Giscombe, 2002) and IL-1β (Huang, 2000).
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1.1.9.5

Pathogenesis of WG

WG is a complex disease requiring environmental factors as well as a genetically
susceptible background for it to develop.

Many cell types from both the innate and

adaptive immune response are involved in the development of WG.

1.1.9.5.1 The role of T cells in WG
Infiltrates of activated CD4+ and CD8+ T cells are found in granulomatous lesions and the
periphery of WG patients (Schlesier, 1995; Mueller, 2000). T cells (CD4+, HLA DR+)
isolated from active WG patients show increase proliferation, TNF-α and INF-γ production
in response to non-specific stimulation (anti-CD3) when compared with healthy controls
(Ludviksson, 1998). This and other studies (Mueller, 2000) support the fact that Th1
cytokines are dominant in WG. INF-γ causes endothelial cells (EC) to increase expression
of MHC class II molecules and causes the upregulation of adhesion molecules such as
ICAM-1 and VCAM-1 (Huang, 2001). This upregulation of adhesion molecules allows for
further accumulation of immune cells within vasculitic lesions.

T cells isolated from the peripheral blood of WG patients show responsiveness to isolated
PR3 (Van der Woude, 1990; Brouwer, 1994). Antigen-specific T cells can provide help to
B cells and induce affinity maturation and the production of high affinity antibodies. In
WG, there is evidence that ANCAs are high affinity antibodies of the IgG subclass
indicating that both affinity maturation and Ig class switching have taken place (Jayne,
1991; Mulder, 1994). Antigen-specific T cells have also been found to remain present in
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the periphery of patients during remission (King, 1998). These T cells may have an
important role in the tendency of patients to suffer from disease relapse.

1.1.9.5.2

Neutrophil activation

TNF-α released from activated T cells and macrophages can stimulate the translocation of
PR3 from the cytosol to the surface of neutrophils (Fig 1.07). Subsequently, ANCA-IgG
binds with the Fab regions to PR3 and the Fc region can bind with FcγR either on the same
cell, known as the Kurlander phenomenon, or on neighbouring neutrophils (Reumaux,
2004). This in turn, enhances the activation of the neutrophil and causes the release of
reactive oxygen species (ROS) such as hydrogen peroxide (H2O2), hypochlorous acid
(HOCl) and hydroxyl radicals (OH). PR3, MPO and elastase are also released. All of these
molecules are capable of causing apoptosis in endothelial cells (Varani, 1989; Yang, 1996).
In addition, due to PR3 and MPO cationic nature these enzymes can non-covalently bind to
the anionic surface of endothelial cells (EC). This facilitates the binding of ANCA and the
triggering of EC damage through ADCC (Savage, 1993; Varagunam, 1992). Activated
neutrophils also release cytokines and chemokines that attract more cells to infiltrate the
site of inflammation, thereby sustaining the disease process.

In normal circumstances following activation of neutrophils, they undergo apoptosis and
are cleared by macrophages (Zimmerman, 1992; Savill, 1992). In WG, there is evidence of
dysregulated and accelerated apoptosis of neutrophils that are initially primed with TNF-α
and then incubated with ANCAs (Harper, 2000). These apoptotic neutrophils show no
expression of surface phosphatidylserine, an important ‘eat-me’ signal to scavenging
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phagocytes. Failure to clear these apoptotic neutrophils may lead to secondary necrosis and
further tissue damage. Apoptotic neutrophils that are opsonised by IgG stimulate the
production of TNF-α by phagocytosing macrophages (Manfredi, 1998).

As PR3 is

expressed on the surface of neutrophils (Csernok, 1994), the opsonisation of these cells by
ANCA may increase the production of proinflammatory cytokines to be released from
macrophages, thus producing further tissue damage.
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Fig 1.07 The role of ANCA in the pathogenesis of WG (Adapted from Reumaux, 2004;
Langford, 1999). (1) Local infection can cause the release of cytokines from T cells
allowing activation of endothelial cells (EC) and priming of circulating neutrophils. (2)
TNF-α has a potent effect on neutrophils causing relocalisation of MPO and PR3 from
intracellular stores to the cell surface and the upregulation of integrins. (3) Individuals who
may have a polyclonal T and B cell response to SAgs or defects in apoptotic cell clearance
may be susceptible to the production of ANCA. (4) Binding of ANCAs to neutrophils
causes further activation and results in degranulation and the release of PR3, MPO and
ROS. Following release PR3 may bind to the surface of EC, causing ANCA to also bind to
the surface of ECs leading to enhanced adhesion molecule and cytokine expression
resulting in increased neutrophil recruitment. The culmination of these processes is the
development of a self-propagating immune response that damages to the ECs.
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Chapter 1.2

REAL-TIME PCR

1.2.1

Polymerase chain reaction (PCR)

The idea of producing millions of copies of a specific DNA sequence was first proposed in
1971 (Kleppe, 1971). However, it took until 1985 (Saiki, 1985) for the first polymerase
chain reaction (PCR) to be developed for β-globin.

At this time, there were no

thermostable DNA polymerases available; therefore, fresh enzyme needed to be added
before each extension step. Water baths were used to cycle through the different reaction
temperatures, as automated thermocyclers were not available. In 1988, the first use of a
thermostable DNA polymerase in PCR was reported (Saiki, 1988), and soon thereafter
automated thermocyclers were developed. Both of these innovations had a major impact on
the practicality and cost of performing PCR

The most recent advance in PCR technology was the development of Real-time PCR or
kinetic PCR (Higuchi, 1992; Higuchi, 1993). Work carried out by Higuchi et al laid the
foundations for Real-time PCR, however it is only in recent years that this technology has
become mainstream. Real-time PCR is the monitoring of amplicon accumulation during
the exponential phase of PCR using a fluorescent reporter. Detection of a fluorescent
signal, the point at which fluorescence starts to rise above the background noise is called
the crossing point (Cp) and can often be referred to as the cycle threshold (Ct). The Cp is
proportional to the initial starting copy number of the target sequence (Higuchi, 1993). Due
to this relationship between the Cp and initial starting concentration Real-time PCR can be
used to accurately quantify target sequences, which has a wide range of applications.
Advantages of using Real-time PCR include rapid cycling times (~30 mins for 35 cycles),
low risk of cross-contamination because of a closed tube system, no post-PCR
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manipulation, high sensitivity (~3 pg genomic DNA (gDNA)), amplicon detection across a
wide range (10-1010 copies) and accurate quantification (Logan, 2004).

Some of the

current disadvantages are the high cost of equipment, a high level of technical skill is
necessary and there is limited capacity for performing multiplex PCR (Logan, 2004).

1.2.2

Real-time PCR platforms

In the late 1990’s, the first commercial Real-time PCR machines became available. The
first of these was the ABI Prism 7700 sequence detection system (Applied Biosystems),
which was closely followed by the LightCycler (Roche Diagnostics) (Wittwer, 1997). Both
companies have released newer, improved versions of these machines and several other
companies have entered into the Real-time PCR market with their own instruments such as
the Mx4000 (Stratagene), iCycler (BioRad) and the DNA engine opticon2 (MJ Research)
among others. While there are some major differences in how each machine operates, they
all consist of a thermocycler, optics for fluorescence excitation and emission acquisition
and a computer with software for data analysis.

1.2.2.1

The LightCycler

The LightCycler instrument was the first machine to allow ultra-rapid thermocycling
(Wittwer, 1997). This was achieved through two methods. Firstly, the LightCycler system
dispensed with the use of a thermal heating block to cycle through temperatures during
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PCR, instead the machine uses air to heat and cool the PCR reaction components. The air
is warmed by passing it through a heating coil in a thermal chamber, which allows for very
rapid temperature transitions rates of up to 20oC/second (Fig 1.08). Secondly, the PCR
occurs in a specially designed borosilicate glass capillary that has a maximum volume of 20
µl. The capillaries provide a large surface-to-volume ratio that allows rapid equilibrium
between the air in the thermal chamber and the PCR components. The combination of
these two innovations allows for a 30-40 cycle PCR to be performed in 20-30 mins. The
LightCycler also has an inbuilt optical unit comprising of a light emitting diode (LED) and
3 photodetection diodes. The photodetection diodes are set to 3 different wavelengths: 530
nm (F1 channel), 640 nm (F2 channel) and 710 nm (F3 channel).

These different

wavelength channels can be used to detect fluorescence from different fluorescent dyes
used during Real-time PCR. The LightCycler is compatible with all the major fluorescent
chemistries used to detect amplicon accumulation during Real-time PCR as discussed
below.
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Fig 1.08 Schematic diagram of the LightCycler Real-time PCR thermocycler
(LightCycler brochure, 2001).
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1.2.3

Amplicon detection

As mentioned previously Real-time PCR is based on the ability to monitor the
amplification of PCR product as it is being generated by the polymerase enzyme. To do
this a fluorescent reporter system is incorporated into the PCR reaction. There are many
different reporter systems on the market, nonetheless they all fall into one of two
categories, non-specific double stranded (ds) DNA binding dyes or fluorescent-labelled
sequence specific probes (Lee, 2004).

1.2.3.1

Non-specific dsDNA binding dyes

Ethidium bromide (EtBr) is the most common nucleic acid binding dye used in molecular
biology, with its conventional use being to stain agarose gels used during traditional PCR
product analysis.

In 1992, Higuchi et al reported the use of EtBr to monitor the

amplification of PCR product in a closed tube format (Higuchi, 1992). In 1993, Higuchi et
al coined the term “kinetic PCR” after they demonstrated that fluorescence intensity during
thermocycling was proportional to the starting copy numbers of the target sequence
(Higuchi, 1993). In recent years, the minor groove binding dye SYBR Green 1 (Morrison,
1997) has clearly become the favourite of the non-specific dsDNA binding dyes with many
publications reporting its use (Vandenbroucke, 2001; Gundry, 2002). The SYBR dyes
typically increase in fluorescence by 20 to 100 fold when bound to dsDNA and have a
similar emission spectrum to that of fluorescein (approx 520 nm) (Lee, 2004).
Fluorescence is usually monitored at the end of the extension phase in a typical SYBR
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Green 1 Real-time PCR experiment, as it is at this point that there is the maximum amount
of dsDNA present for that cycle number (Fig 1.09).

The use of non-specific binding dyes can be favoured by many researchers as they are
widely available, cheap and very little optimisation is required to transfer an efficient
traditional PCR over to a Real-time format.

Whilst generic dyes can be used for

quantitative Real-time PCR, there are some limitations due to their non-specific DNA
binding action. Any PCR artefact formed, such as primer-dimers, when performing Sybr
Green 1 quantitative Real-time PCR will also be detected due to the non-specific nature of
the dye. This could lead to misinterpretation of the data. However, there are further
optimisation strategies that can be employed to help avoid this, such as performing a
touchdown PCR, which will help reduce the production of non-specific amplicons in the
early stages of the PCR. Another method to improve the use of SYBR Green 1 for
quantification is to establish the Tm of both the specific amplicon and PCR artefacts using
melting-curve analysis. If the Tm of the artefact is significantly lower than that of the
specific amplicon then fluorescence readings can be acquired at a temperature above that of
the Tm for the artefact. Therefore, any increase in fluorescence is now specific to the
amplicon of interest (Ball, 2003; Morrison, 1998).

Multiplexed quantification is not

possible as there is no way to differentiate the two products from each other, as
fluorescence from both will be detected in the same channel.

70

Fig 1.09 SYBR Green 1 detection. SYBR Green 1 cannot bind to ssDNA (A) but as Taq
polymerase extends the primer, SYBR Green 1 can bind to the minor groove of the duplex
and its fluorescence emission is enhanced (B).

1.2.3.2 Specific DNA binding probes

There are many different probe chemistries available on the market today, each with a
slight variation of a common theme: an oligo-nucleotide that is coupled to a fluorophore.
When the probe/probes bind to their complementary target sequence a fluorescent event can
be monitored which is directly related to the amount of amplicon present at that cycle.
There are three commonly used probe types; hydrolysis probes (Fig1.10), molecular
beacons (Fig 1.11) and dual hybridisation probes (Fig1.12).

As probes are sequence

specific they avoid the problems of non-specific detection of PCR artefacts associated with

71

the use of Sybr Green 1. Nevertheless, the use of probes increases the cost of each test and
each probe must be carefully designed otherwise it may not work efficiently.

1.2.3.3

Fluorescence Resonance Energy Transfer (FRET)

Fluorescence resonance energy transfer (FRET) is a spectroscopic process where energy is
passed between two molecules up to 10-100 Å apart which have overlapping emission and
absorption spectra (Clegg, 1992). The mode of action of the commonly used probes is
based on the principles of FRET. For some probe types such as the 5’ hydrolysis probes
and molecular beacons, FRET occurs between a fluorogenic label and a dark or ‘blackhole’ non-fluorescent quencher, which dissipates the energy as heat rather than
fluorescence (Ginzinger, 2002). Other probes, such as hybridisation probes, use FRET to
transfer the energy from one fluorogenic dye to another which then releases a longer
wavelength of light that is then detected by the instrument (Wittwer, 1997).

1.2.3.4

Hydrolysis probes

The hydrolysis probes are often more commonly named TaqMan probes, and while they
work with many Real-time platforms, these probes seem to have found their home on the
ABI Prism 7700 sequence detection system (Applied Biosystems). These probes utilise the
fact that Taq (or several other polymerase enzymes) have 5’ 3’ exonuclease activity
(Gelfand, 1989). The 5’ end of the probe is labelled with a reporter dye (FAM, TET, JOE,
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HEX or VIC) and the 3’ end has a covalently linked quencher (TAMRA, DABCYL). The
proximity of both molecules to each other when attached to the probe allows FRET to
occur, however the energy is dissipated as heat rather than fluorescence by the quencher.
When the probe binds to the target sequence at the annealing phase, Taq can now cleave the
5’ reporter dye from the probe, which now releases it from the effects of the quencher and
fluorescence, can be emitted and recorded by the instrument (Fig 1.10). A drawback when
using this type of probe is that in order for the probe to remain annealed to its specific
sequence the extension temperature must be adjusted. Therefore it is common to have a
combined annealing and extension step at 60-62°C, this ensures that the probe remains
hybridised so it can be cleaved by the 5’-3’ exonuclease activity of Taq and Tth
polymerases.

However, the sub-optimal extension temperature affects the enzymes

processivity and is therefore not suitable for longer amplicons (Bustin, 2000). These
probes have been used for a wide range of applications such as gene copy number
quantification (Aarskog, 2000), virus quantification (Quinlivan, 2005; Kawai, 1999),
quantification of cytokine mRNA expressed in Hodgkin’s lymphoma (Malec, 2004) and
analysis of DNA and RNA extracted from archival material (Lehmann, 2001; Godfrey
2000) to name but a few.
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Fig 1.10 Hydrolysis probe detection. When the probe is intact the fluorphore is quenched
(A), the 5’-3’ exonuclease activity of Taq cleaves the probe releasing the reporter dye into
solution where it is no longer quenched (B).

1.2.3.5

Molecular beacons

The molecular beacons (Livak, 1995) mode of action is based on a conformational change,
from hairpin loop to linear structure, when it is bound to its specific sequence. The
linearisation of the probe causes a reporter and quencher dye to be separated from each
other so that fluorescence can be emitted from the reporter (Tyagi, 1996) (Fig 1.11). The
major drawback in using molecular beacons is that the probes are complex to design. If the
stem region is not optimal, the probe may form alternative conformations, which may not
place the fluorophore and quencher in close proximity to each other. This can result in a
proportion of the free probe not being quenched, which leads to a high background signal
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(Bustin, 2000). If the stem region has too high of a binding affinity then this may interfere
with hybridisation of the probe to its target sequence resulting in inefficient detection of the
amplicon.

Fig 1.11 Molecular beacon detection. When the probe is not hybridised to its specific
sequence it forms a stem-loop conformation that causes the fluorophore to be quenched
(A), binding of the probe causes a conformational change that separates the fluorophore and
quencher and allows emission of fluorescence (B).
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1.2.3.6

Dual hybridisation probes

This method utilises two independent probes, which maximises the assays specificity
(Wittwer, 1997). One probe is labelled on its 3’ end with a donor dye (anchor probe), and
the second probe is labelled with an acceptor dye at its 5’ end (detector probe) (Fig 1.12).
Using this arrangement, as the anchor and detector probes anneal to their specific sequence
the two dyes are brought into close proximity to each other allowing FRET to occur. The
detector probes 3’ end is usually blocked with a phosphate group to prevent it from being
extended by Taq polymerase (Landt, 2001). These probes have few draw backs as they are
easy to design, relatively easy to multiplex and as the probe is not hydrolysed they can be
used for melt curve analysis, which is particularly applicable to mutation detection.
However, one of the drawbacks of using these probes is that amplicons must be bigger than
if only a single probe system is used. This can limit their use in applications that involves
fragmented nucleic acids, such as that which has been extracted from archival tissue
samples, as shorter amplicons work much more efficiently in these circumstances
(Lehmann, 2001).
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Fig 1.12 Hybridisation probe detection. When both probes are free in solution FRET
cannot occur as the two dyes are apart (A), when both probes hybridise to there target
sequence the dyes are brought into close proximity that allows FRET to occur (B).

1.2.4

Mutation detection by Real-Time PCR

Mutations can be large rearrangements of genetic material such as gene insertions/deletions
or small variations such as small insertions/deletions (a couple of base pairs (bp) or point
mutations.

Small genetic variations are usually referred to as single nucleotide

polymorphisms (SNPs) and are the most common type of mutation, occurring
approximately every 1000 nucleotides (Sachidanandam, 2001; Venter, 2001). The majority
of these are found in the non-coding regions of the genome and are thought to be of no
significance, but can be used as genomic markers in population genetics. A SNP in the
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coding region of a gene may results in an altered protein and detection of these is important
in many monogenetic diseases such as cystic fibrosis (Kerem, 1989).

DNA sequencing will remain the gold standard for characterisation of unknown
sequences/mutations however its use for rapid mutation detection is quite poor. Since the
development of PCR (Mullis, 1987; Saiki, 1985), many variations such as restriction
fragment length polymorphism (RFLP) PCR and amplification refractory mutation system
(ARMS) PCR (Newton, 1989) have been developed for use in mutation detection. The
majority of these techniques are laborious, slow and expensive. Real-time PCR provides an
improvement on all of the conventional techniques in terms of throughput, flexibility and
ease of analysis.

The LightCycler when used in conjunction with hybridisation probes allows for mutation
detection by performing melting curve analysis directly after the amplification step
(Wittwer, 1997). During melting curve analysis fluorescence is continuously monitored as
the temperature is slowly increased (0.1 ºC/sec). At a specific temperature, the detector
probe will begin to dissociate (“melt”) from its target sequence. The melt temperature
(Tm) is the temperature at which 50% of the probe is dissociated from the target sequence.
As the temperature approaches the Tm of the detector probe a decrease in the level of
FRET will be observed as a melting curve. When a mutation occurs in the target sequence,
this has a destabilising effect on the detector probe and it has a lower Tm than that of the
perfectly matched probe (Fig 1.13 A, B). The LightCycler software displays the melting
curves as melting peaks by plotting the negative derivative of fluorescence (-dF) against the
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negative derivative of temperature (-dT) (Fig 1.13 C) and this allows easy discrimination of
wildtype, mutant and heterozygote genotypes (Lay, 1997).

1.2.4.1

Dual hybridisation probe design

The detector probe is designed to span the site of the possible mutation and is typically 1530 bases in length. The anchor probe should have a Tm 5-10oC higher than the detector
probe this ensures that the detector probe “melts” first (Landt, 2001). Consequently, the
drop in FRET is due to the detector probe, which allows the presence or absence of a
mutation to be determined. If the detector probe is designed so that the mutation is
approximately at the centre of the probe this has the greatest destabilising effect on the
probe than if it is at either end (Landt, 2001). A larger destabilising effect on the probes
Tm means the melting curve peaks are further apart, allowing the identification of wildtype
and mutant genotypes to be made easier (Bernard, 2001).
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Fig 1.13 Mutation detection using dual hybridisation probes.

Absence of a point

mutation allows for perfect hybridisation of the detector probe (A), presence of a mutation
causes incomplete hybridisation of the detector probe (B). The matched probe (A:T)
requires a higher melting temperature than mismatched (A:G) probe (C). Negative
derivative of fluorescence (-dF), Negative derivative of temperature (-dT).
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1.2.4.2

Multiplex mutation detection on the LightCycler

Multiplex PCR is the process of generating more than one amplicon at a time. This
increases the information obtained from a single PCR and helps to reduce the cost of
analysis. Multiplex mutation detection can be performed on the LightCycler by using two
of the instruments detection channels. The F2 and F3 channels can be used to detect
fluorescence from the LCRed640 and LCRed705 dyes respectively. Using two different set
of hybridisation probes each specific for a single mutation and labelled with one of the two
LightCycler dyes it is possible to type at least two different mutations per sample
(Aslanidis, 1999; Bernard, 1998).

1.2.4.3

Other detection formats for mutation detection

The other common detection systems can all be used for mutation analysis. Mutation
detection can be performed using Sybr Green 1 (Wittwer, 1997; Ririe, 1997). However the
use of Sybr green 1 is a low-resolution method, as a single bp change will have only a small
impact on the Tm of amplicon that maybe a couple of hundred bp in length. A newer dye
called LCGreen 1 has been specifically developed for use in mutation detection (Wittwer,
2003). The one advantage of using the intercalating dyes is that any mutation within the
amplicon can be detected and therefore used for mutation scanning (Wittwer, 2003). By
using high-resolution melting techniques with customised equipment, it is possible to detect
single-base heterozygotes in products up to 1000 base pairs in length (Wittwer, 2004).
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Hydrolysis probes, because of their mode of action, cannot be used to perform melting
curve analysis as the probe is consumed during the amplification stages. Therefore, to use
this system for mutation detection it is necessary to design two probes, one that will bind to
the wildtype and another for the mutated sequence, each of which is labelled with a
different reporter dye (Edwards, 2004). Mismatches between the probe and target sequence
reduce the efficiency of binding and as a result Taq does not cleave the probe and no
reporter dye is released. Genotypes can be assessed based on which reporter dye is released
during amplification. Molecular beacons have also been adapted to SNP detection assays
(Tyagi, 1998).

1.2.5

Quantitative Real-Time PCR

Quantification of nucleic acids has many applications such as in monitoring gene
amplification in tumours, viral quantification and gene expression analysis between normal
and disease states. Since its inception PCR would seem to have been the best method for
quantitative analysis as it has a sensitivity 5 orders of magnitude greater than the best
blotting techniques (Rasmussen, 2001). However, the exponential amplification of the
target sequence is not ideally suited to quantification, as small differences in amplification
efficiency from sample to sample can result in huge differences after 35-40 PCR cycles.
Additionally, reagent limitations or the production of pyrophosphate molecules leads to a
decrease in amplicon synthesis and the PCR enters the “plateau phase” (Fig 1.14). In the
plateau phase, the PCR is no longer generating product at an exponential rate, and some
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reactions will enter this stage earlier than others and therefore generate less amplicon. It is
this reason, which makes end-point quantification so unreliable (Ginzinger, 2002).

Since Higuchi et al (1992) showed that it was possible to measure the kinetics of a PCR by
monitoring product accumulation from cycle to cycle in Real-time, allowing truly
quantitative PCR to be performed. From the simple addition of ethidium bromide to a PCR
mix to the use of more complex and specific probe technologies Real-time quantitative
PCR has become a fast growing field with many applications in biotechnology and
molecular medicine.

Fig 1.14 Quantitative Real-time PCR amplification curve. During amplification there is
an initial lag phase (A) followed by the exponential phase (B) and lastly the plateau phase
(C).
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1.2.5.1

Dynamic range of Real-time PCR

The dynamic range of a Real-time quantitative PCR is between 10 and 1010 copies of initial
template (Saunders, 2004). The upper limit is set by the need to establish a base-line level
of fluorescence before amplicon accumulation is detected, since after this point it is not
possible to accurately determine the Cp (Saunders, 2004). The lower limit for accurate
quantification is determined by the sensitivity of the PCR, which is often influenced by the
reaction components, so careful optimisation can enhance the sensitivity of the PCR. Preamplification of the target sequence using external primers, nested PCR, has been used by
some investigators to enhance the sensitivity of the assay (Brechtbuehl, 2001). However,
the use of nested PCR cancels out many of the benefits of Real-time particularly the
avoidance of possible cross-contamination, as PCR tubes must be opened.

1.2.5.2

Real-time PCR efficiency

One of the most crucial factors in carrying out quantification is that the efficiency of the
reaction is similar between control/standards and the actual test samples. The efficiency of
PCR can be estimated from the slope of the Cp plotted against log of concentration. The
slope reflects the number of cycles it takes to increase the amplicon number by 1 log value
(Saunders, 2004). This relationship should be linear with a slope of approximately -3.33.
Efficiency can be calculated from the following equation: E = 10-1/slope (Rasmussen, 2001).
A reaction that is 100% efficient (perfect doubling of amplicon per cycle) will give a value
of 2 from this equation (Bernard, 2002). Therefore, values less than 2 indicate that the
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reaction is not operating at 100% efficiency.

Efficiency can be improved by careful

optimisation of the PCR parameters such as primer concentration, annealing temperature,
amplicon length and so on.

PCRs with low efficiency (E = 1.5) can be used for

quantification, however, this can have an effect on the dynamic range of detection and
samples with low copy numbers may be missed (Saunders, 2004).

1.2.5.3

Gene expression analysis by Real-time PCR

The messenger RNA (mRNA) content of a cell is a good indicator of the genes that a cell is
expressing at that particular time. In response to environmental changes, a cell may adjust
the mRNA copy numbers as part of a complex regulation mechanism. This has particular
significance with many different diseases, as they are often associated with changes at the
mRNA level. There are five common methods for detecting and quantifying mRNA
transcripts: northern blotting, in situ hybridisation, RNAse protection assay (Hod, 1992),
micro-array analysis and reverse transcription (RT) PCR (Simpson, 1988; Vrieling, 1988).
The first three methods are quite labour intensive and have a comparatively low sensitivity.
Micro-array analysis is still prohibitively expensive for routine gene expression analysis
such as in monitoring a patient’s response to chemotherapy. RT-PCR is the most sensitive
and flexible of the quantification methods (Wang, 1999) and is suitable for routine analysis.
As RNA cannot directly act as a template for PCR, it is first necessary to generate a cDNA
copy of the RNA that can then be amplified using PCR. Until the arrival of Real-time
PCR, there has been a problem with the quantification of mRNA transcripts, as end-point
PCR does not reflect the initial starting copy number of the target sequence. A real-time
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approach to RT-PCR avoids many of the problems associated with conventional
quantitative protocols and its sensitivity, specificity and wide dynamic range has made it
the method of choice when quantifying steady-state mRNA levels (Bustin, 2000).

1.2.5.4

Relative quantification

Relative quantification determines the changes in steady-state mRNA levels of a gene in
comparison to an internal control/reference RNA (Fink, 1998). The reference is usually
described to as a housekeeping gene. Housekeeping genes are genes that should remain at
a constant level within a cell regardless of environmental/experimental factors.
Amplification of the housekeeping gene can occur in the same reaction as the target
sequence (multiplex) or in a separate tube, either way all samples are expressed as an Xfold difference relative to the housekeeping gene.

This form of quantification is

independent of RNA/DNA concentration added to the RT-PCR/PCR. Nonetheless, there
are some problems associated with this type of quantification. The major problem is due to
the difficulty in finding a suitable reference gene whose expression remains constant under
experimental conditions (Bustin, 2004). It has been recommended that the expression of at
least 10 reference genes should be analysed along with target gene mRNA in order to get
accurate relative quantification data (Vandesompele, 2002). If cohort samples sizes are
even of a modest size this then becomes quite a large and demanding task. Some common
reference genes are glyceraldehyde 3-phosphate dehydrogenase (GAPDH), TATA-box
binding protein (TBP), hypoxyxanthine-guanine phosphoribosyltransferase (HPRT), β-2
microglobulin (β2M), phorphobilogen deaminase (PBGD), and 18S/28S ribosomal RNAs
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to name but a few. Incidentally, while GAPDH has been a widely used reference gene for
many years, its suitability as a reference gene is questionable. There is an overwhelming
amount of evidence indicating that GAPDH is an unsuitable reference gene. GAPDH
mRNA concentrations can vary, between individuals (up to 5 orders of magnitude) (Bustin,
1999), during pregnancy (Cale, 1997), during the cell cycle (Mansur, 1993) and it is
upregulated in certain cancers (Ripple, 1995). GAPDH transcription can also be induced
by hypoxia (Zhong, 1999), calcium ionophore A23187 (Chao, 1990), insulin (Barroso,
1999) and apoptosis (Ishitani, 1997). Therefore the use of GAPDH as an internal control
for Real-time quantitative should be discouraged (Bustin, 2000).

1.2.5.5

Absolute quantification

The other option for Real-time quantification is absolute quantification, which involves the
determination of the exact copy number of target sequences within a quantity of sample. It
provides a more accurate and reliable, albeit more labour intensive method for
quantification of nucleic acids (Ke, 2000). A series of standards are generated and a plot of
Cp verses log concentration allows the Cp of the unknown samples to be compared to the
standards. Standard curves can be generated in a number of ways. Purified PCR product or
synthetic oligonucleotides can be used to generate standard curves. Sometimes there can be
problems with reamplification and this approach may only be suitable for the quantification
of short amplicons (Pfaffl, 2005). Recombinant DNA can also be used to generate standard
curves; these are very stable and produce very reproducible results (Pfaffl, 2001). The one
drawback is, when used for mRNA quantification this type of standard is not subjected to
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the RT phase of the assay, therefore differences in RT efficiency will not be reflected in the
standard curve. A third method for generating standards is to use recombinant RNA; these
standards will reflect all stages of an RT-PCR reaction. Nevertheless they are difficult to
produce and purify, are very labile and the resulting PCR is less efficient (Pfaffl, 2001).
The results are usually then expressed as copy number per denominator, which could be per
mg tissue or per µg total RNA and so on.

Real-time PCR is an adaptable, sensitive and rapid technique for the quantification of
nucleic acids. It also provides a platform for rapid SNP detection using post-PCR melting
curve analysis. In the last couple of years the technology has become an integral part of
many diagnostic and research laboratories, which should serve to drive the technology
forward, by improving the instruments, the detection chemistries and reduce the cost of
analysis.

88

Chapter 2

CHALLENGES TO REAL-TIME PCR

Chapter 2.1

DETECTION OF FIVE COMMON CFTR
MUTATIONS BY REAL-TIME ARMS PCR

2.1.1

INTRODUCTION

2.1.1.1

Cystic Fibrosis (CF)

Cystic fibrosis (CF) is the most common recessively inherited lethal genetic disease of
Caucasians, with a prevalence of 1 in 2500 (Collins, 1992; Mateu, 2002). The disease also
has an astounding carrier frequency of 1 in 25 (worldwide) (Hutchison, 2001) and in
Ireland, the carrier frequency has been reported to be as high as 1 in 19 (McQuaid, 2000).

2.1.1.2

Diagnosis of CF

In 1953, it was demonstrated that children with CF had excessive salt in their sweat
(DiSant’Agnese, 1953). This led to the measuring of sodium (Na+) and chloride (Cl-) levels
in the sweat as a diagnostic standard for the disease (Gibson, 1959). The normal levels of
NaCl in sweat is approximately 15-40 mM, people with CF may have NaCl levels >100
mM (Wine, 2001). With the advent of molecular techniques and the identification of the
gene (CFTR) involved in CF, the combination of two CFTR mutations and an abnormal
concentration of sweat electrolytes is generally accepted as sufficient for diagnosis (Stern,
1997)
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2.1.1.3

Clinical features of CF

The main pathological hallmark of CF is the build up of thick viscous mucus in the airways
(Wine, 1995), which is very significant, as the usual cause (>90%) of death in CF is
respiratory failure (Davies, 1998). The build up of the mucus in the lungs helps to initiate a
cycle of chronic infection and inflammation. The lungs become infected in early childhood
and eventually become damaged and scarred. Colonisation of the lungs generally follows a
similar pattern, beginning with Staphylococcus aureus and Haemophilus influenzae in early
childhood and ends with Pseudomonas aeruginosa in adolescence (Hutchison, 1999).
Pseudomonas aeroginosa can be isolated from 80-90% of adult CF lungs (Hutchison,
1999). Individuals that have avoided colonisation, with the opportunistic pathogen, have
survival rate twice that of patients who have been colonised (Hutchison, 1999). The main
cause of damage occurs when recruited neutrophils, whose number may be a million fold
higher than in normal lungs, die and release a protease called elastase (Bradbury, 2001).
The elastase destroys elastic fibres in the lung, which over time reduces the lungs air
capacity ultimately leading to respiratory failure.

The gastrointestinal tract is also involved in most patients; approximately 85% (Collins,
1992) show pancreatic insufficiency caused by obstructed pancreatic ducts resulting in
destruction of the pancreas.

Nearly 10% of newborns with CF suffer with intestinal

obstruction (meconium ileus), which can be fatal if left untreated (Rowe, 2005). Men with
CF are often infertile due to obstruction of the vas deferens in utero leading to a condition
known as congenital bilateral absence of the vas deferens (CBAVD). There is also a
significant increase in the incidence of liver disease and overt cirrhosis in patients with CF
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who also carry a homozygous or compound heterozygous mutation in the protein mannosebinding lectin (Gabolde, 2001). An increased risk of digestive tract cancers has also been
reported in CF patients (Neglia, 1995).

2.1.1.4

Treatment of CF

The treatment of CF includes chest percussion to help clear mucus build-up in the lungs,
antibiotics to control bacterial infection, pancreatic enzyme supplements to compensate for
the damage caused to the pancreas and dietary supplements to help patients meet their
nutritional requirements.

This combination of therapy has greatly improved the life

expectancy of an individual diagnosed with CF from approximately 1 year in 1930 to 30-32
years today (Geddes, 1998; Bradbury, 2001). Lung transplantation is also now becoming a
common treatment for suitable patients with severe damage to the airways.

Other

experimental treatments include delivery of elastase inhibitors (either recombinant or
synthetic forms) to the lungs, which may help to reduce damage caused to the lungs during
inflammation (Bradbury, 2001).

2.1.1.5

Cystic fibrosis transmembrane conductance regulator (CFTR)

In 1989 the CF gene was identified, it was first mapped to chromosome 7q31 using linkage
analysis (Riordan, 1989). Then by using chromosome-walking techniques, a candidate
gene was identified (Rommens, 1989). The CF gene itself is quite large at 250,000 bp
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(Kerem, 1989) and contains 27 exons. The CF gene’s protein product was named the cystic
fibrosis transmembrane conductance regulator (CFTR) (Riordan, 1989). The CFTR is an
integral membrane protein, 1480 amino acids in length that contains a glycosylation site.
The CFTR is a member of the ABC (ATP-Binding Cassette) superfamily of transporters
that transports chloride ions (Cl-) across the plasma membrane (Riordan, 1989). As the
movement of water is linked osmotically to the transport of ions, Cl- secretions maybe one
method of hydrating the mucosal surface of the respiratory and intestinal tracts (Geddes,
1998).

The CFTR protein has two hydrophobic domains that incorporate themselves into the
plasma membrane. Each of the domains has six loops that span the plasma membrane.
There are also two nucleotide-binding domains called NBD1 and NBD2. The regulatory
domain controls the status of the channel. The CFTR is regulated by protein kinase A
(PKA) and ATP (Collins, 1992). Activation of the channel first involves a rise in the cells
cyclic AMP (adenosine 3’5’-monophosphate) concentration, which in turn activates protein
kinase A (PKA).

Once activated, PKA phosphorylates four serine residues in the

regulatory domain (Collins, 1992). This causes a conformational change in the CFTR
structure and ATP can now bind to the two NBDs. Cleavage of the ATP at NBD1 causes
the channel to open and Cl- ions can pass through. Binding of ATP to NBF2 is thought to
stabilise the open conformation of the protein. When NBD2 hydrolyses the ATP the
channel closes and requires another ATP to bind to open again (Jenstch, 1996).
Deactivation of the channel is carried out by protein phosphatases (Akabas, 2000), mainly
protein phosphatase 2C, which has been shown to be closely associated with CFTR through
immunoprecipitation studies (Zhu, 1999).
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Fig 2.1 Structure of the CFTR. The protein has 5 distinct domains consisting of: 2
membrane spanning domains which form the channel across the plasma membrane, 2
nucleotide binding domains (NBD) and a regulatory domain (Adapted from Riordan, 1989;
Rowe, 2005).

2.1.1.6

Mutations in the CFTR

To date more than 1000 mutations have been described in this gene, however the majority
of these are rare (Tsui, 2003). CFTR mutations can be classified into groups (I-VI) based
on how they are believed to cause CF. Class I mutations result in no protein being
synthesised, class II mutations block correct processing of the protein, class III mutations
result in disordered regulation of the protein, class IV mutations result in altered
conductance through the channel, class V mutations cause a reduced number of CFTR
transcripts due to promoter or splicing abnormalities and class VI mutation result in an
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accelerated turnover of the protein from the cell surface (Rowe, 2005). Classes I-III tend to
cause a severe CF phenotype and classes IV-VI resulting in a milder phenotype.

By focusing on five common mutations it is possible to detect the disease causing mutation
in approximately 90% of Irish patients (Scotet, 2003) and ~71% in the worldwide
population (Tsui, 2003). The five mutations are delF508 (77.4%, 66.0%), G551D (7.1%,
1.6%), R117H (2.7%, 0.3%), 621+1 G>T (1.4%, 0.7%) and G542X (0.5%, 2.4%) figures
are for the Irish population (Scotet, 2003) and worldwide (Tsui, 2003) respectively.

The delF508 mutation is a class II mutation, which is found in exon 10 of the CF gene that
codes for the NBD1 domain (Naruse, 1999). It involves a 3 bp (CTT) deletion, which
results in the loss of a phenylalanine (F) at codon 508. The delF508 mutation results in a
protein-processing defect, which traps the delF508 CFTR in the endoplasmic reticulum
(Devidas, 1997) and prevents it from being transported to the apical plasma membrane. Of
the other mutations G542X is a class I mutation (Rowe, 2005) it is found in exon 11
(Karem, 1990) and results in the introduction of a premature stop codon. G551D is a class
3 mutation (Rowe, 2005) also found in exon 11 (Cutting, 1990). The protein is processed
and targeted correctly to the plasma membrane but lack responsiveness to stimulation by
cAMP. The 621+1GT is a class V mutation is located in intron 4 and results in the
mRNA being incorrectly spliced.

R117H is class IV mutation and results in altered

conductance through the CFTR channel (Sheppard, 1993).
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2.1.1.7

Pathogenesis of CF

How lung disease develops in the CF lung has been a difficult problem to explain. Healthy
lungs are sterile below the first bronchial division (Wine, 1999) despite a constant influx of
bacteria and viruses from the air we breathe. Lung sterility is maintained by a wide range
of methods, such as mucocillary clearance, which cleans the airways mechanically. The
airway surface liquid (ASL), which is thin film of liquid that coats the surface of the lungs,
contains a wide range of proteases, antimicrobial peptides and antibodies that inactivate or
destroy pathogens without causing collateral damage to the cells of the lungs.

There are currently two proposed hypotheses of how disease is initiated. These are the high
salt hypothesis (Smith, 1996; Zabner, 1998) and the low volume hypothesis (Matsui, 1998).
The high salt model is based mainly on the CFTR function as an anion channel. Nonfunctional CFTR results in reduced transepithelial Cl- transport, the resulting elevated
levels of NaCl in the ASL would be enough to inactivate antimicrobial peptides an
therefore predispose patients to colonisation by opportunistic pathogens such as
Pseudomonas aeruginosa.

The low volume model is based on CFTR ability to regulate other channels particularly
epithelium sodium channels (ENaC) (Reddy, 1999). The absence of CFTR leads to over
activity of Na+ absorption through the ENaC, it is thought then that the transepithelial
imbalance in Na+ and Cl- ions leads to the absorption of Cl- via other non-CFTR channels.
The result of this is there is an increase in absorption of Na+, Cl- and water causing the
dehydration of the airway surfaces and defective mucocillary clearance.
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Explanations for the cause of pulmonary defects in CF are unlikely to explain the damage
sustained to other organs.

In the pancreas there is no evidence of overactive Na+

absorption, also in the intestine there is no evidence of increased susceptibility to infection
by altered immune responses as occurs in the lung (Rowe, 2005). However, in glandular
tissues of CF patients there is a defect in Cl- and fluid secretions. When secretin binds its
receptor on pancreatic duct cells, resulting in elevated intracellular levels of cAMP normal
CFTR function is initiated. In the pancreas, this results in the efflux of Cl-, Na+ and water
into the lumen of the pancreatic ducts (Naruse, 1999). In the absence of functional CFTR,
the deficiencies in fluid secretions results in the blockage of ducts leading to organ damage.
Similar mechanisms are proposed to cause damage to the vas deferens, liver and other
glands in cystic fibrosis.

2.1.1.8

Detection of CF mutations

Many mutation detection systems have been utilised to detect common CF mutations,
including single stranded conformation polymorphism (SSCP) (Ravik-Glavac, 1994),
restriction fragment length polymorphism (RFLP) (Shrimpton, 1991), Amplification
Refractory Mutation System (ARMS) PCR (Ferrie, 1992) and reverse dot-blot (Cuppens,
1992). These techniques rely on PCR amplification of the target region, which is then
followed by extensive post-amplification analysis.

In recent years improvements in

technologies has led emergence of homogeneous methods, where both the amplification
and detection occur in a single “closed-tube” reaction (Foy, 2001). Current homogeneous
techniques include Real-time PCR (Wittwer, 1997), ligase chain reaction (LCR) (Austina,
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1997) and strand displacement amplification (Little, 1999). The advantage of closed-tube
systems is the reduced risk of cross contamination and improved speed with no postamplification processing.

2.1.1.9

Amplification Refractory Mutation System (ARMS) PCR

ARMS PCR is a technique that allows a specific allele to be PCR amplified (Newton, 1989;
Wu, 1989; Sommer, 1989; Okayama, 1989).

It is also referred to as allele specific

amplification (ASA). The technique makes use of the fact that DNA polymerase enzymes
such as Taq polymerase require the ultimate 3’ end base of the primer to be complementary
to the template sequence for amplification to occur. If the 3’ end base matches with the
base on the target DNA, then amplification takes place. However, if a mismatch occurs,
the 3’ end will not be fully hybridised and Taq polymerase will be unable to initiate
amplification (Fig 2.2). Thus, by designing primers complementary to the wildtype and
mutant sequences and using them in two separate PCRs, both homozygous and
heterozygous samples can be genotyped. For ARMS to work it is important that a DNA
polymerase without proof-reading capabilities is used, as a proof-reading enzyme could
correct the mismatch and discrimination between alleles would be lost (McPherson, 2000).
The amplicons are separated on agarose gels, and presence or absence of a particular band
implies the genotype of the sample. Extensive optimisation of the amplification conditions
is generally essential for proper ARMS analysis (Kwok, 1990; Sommer, 1992).
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Fig 2.2 Amplification refractory mutation system (ARMS) PCR. The normal ARMS
primer (3’ A) will successfully bind to the normal allele and allow the initiation of PCR
amplification. The normal ARMS primer will not allow amplification of the mutant allele
due to the 3’ mismatch. The mutant ARMS primer (3’ C) will only match with the mutant
allele and will not amplify the normal allele.
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2.1.1.10 Aim of this chapter

The aim of this chapter is examine the use of Real-time PCR for mutation detection in
cystic fibrosis. Current methods for carrying out mutation detection do not make full use of
melting curve analysis, meaning that at most two mutations can be looked at in a single
PCR (1 per colour channel). The work outlined here seeks to make an improvement on this
by combining ARMS and Real-time PCR for use in the diagnosis of cystic fibrosis with
particular emphasis put on mutations pertinent to the Irish population.
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2.1.2

MATERIALS AND METHODS

2.1.2.1

Patient DNA samples

Both control DNA samples for protocol optimisation and 21 test DNA samples used in the
blinded study were obtained from Dr David Barton at the National Centre for Medical
Genetics, Our Lady's Hospital for Sick Children, Crumlin, Dublin 12.

2.1.2.2

DNA isolation

Where DNA needed to be extracted, EDTA blood was used with the following protocol:
firstly red blood cells (RBCs) were lysed by incubating 3 ml of whole blood in 9 ml of
RBC lysis solution (155 mM Ammonium chloride, 10 mM Potassium hydrogen carbonate,
1 mM EDTA) at room temperature for 10 mins. Followed by a centrifugation step at 3000
rpm for 10 mins. After decanting the supernatant the resulting white blood cell (WBC)
pellet was suspended in 3 ml of WBC lysis solution (25 mM EDTA, 2% SDS). Then 1 ml
of protein precipitation solution (10 M ammonium acetate) was added, followed by a 10
second vortex. The resulting solution was centrifuged at 3000 rpm for 10 mins. The
supernatant was then subjected to an isopropanol (0.5 ml) precipitation step, followed by
centrifugation at 3000 rpm for 5 mins the resulting DNA pellet was washed in 1ml of ice
cold 70% ethanol and then resupended in Tris-EDTA at pH 8.0.
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2.1.2.3

Primers

The sizing primers for detection of the delF508 mutation are CF10-B (GTTTTCCTGGAT
TATGCCTGGGCAC) and CF10-D (GTTGGCATGCTTTGATGACGCTTC).

The ARMS PCR primers used in this study were previously published primer sets (Ferrie,
1992), the name and sequence of each primer and the concentration used in the final
reaction is outlined in Table 2.1. All primers were synthesised by Proligo, France.

2.1.2.4

Preparation of 10% Acrylamide gel for analysis of the sizing

PCR products
See appendix 1

2.1.2.5

Real-time PCR detection of the delF508 mutation

Real-time PCR detection of the delF508 mutation was performed using previously
published primer and hybridisation probes (Gundry, 2001). Primers used were CF-245F
(GGAGGCAAGTGAATCCTGAG) and CF-500R
The

hybridisation

probe

sequences

were

(TTTTCCTGGATTATGCCTGGCACCTTAA-F)
GAAAATATCATCTTTGGTGTTTC-P).
synthesised by Proligo, France.

(CCTCTTCTAGTTGGCATGCT).
as

follows

delF508

ANCHOR

and

delF508

DETECTOR

(705-

Primers and hybridisation probes were

Real-time PCR was performed on a LightCycler

instrument (Roche Diagnostics). The total reaction volume was 10µL, containing: 1µL of
10X LightCycler DNA Master Hybridisation enzyme mix (Roche Diagnostics), 4 mM
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MgCl2, 0.1µM hybridisation probes and 0.5 µM primers. PCR conditions were 95ºC for 6
mins, followed by 40 cycles at 95ºC for 0 secs, 60ºC for 10 secs and 72ºC for 10 secs.
Melting curve analysis was performed directly post PCR and the condition were 95ºC for 0
secs, 40ºC for 10 secs followed by heating back to 70ºC while continuously monitoring the
fluorescence in each capillary.

2.1.2.6

Hybridisation probe design for Real-time ARMS PCR

Using sequences downloaded from the National Centre of Biotechnology Information
(NCBI) website hybridisation probes were design as per the usual guidelines for primer
design. The sequences used were CFTR exon 4 (Genbank accession no.M55109.1), CFTR
exon 10 (Genbank accession no.M55115.1) and CFTR exon 11 (Genbank accession no.
M55116.1).

Once suitable locations were identified for the probe sets within these

sequences the predicted melt-temperatures of the detector probes were calculated using
MeltCalc software (www.meltcalc.com).

The probes were modified to give the most

suitable Tm to give the best melt-curve profile. The name, sequence, concentration used in
the final reaction and Tm of the probes as well as the mutation they can be used to detect is
outline in Table 2.2. All probes were synthesised by Proligo, France.
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2.1.2.7

Multiplex set-up

Two multiplex PCR reactions were optimised using previously published ARMS primers
(Ferrie, 1992). The first reaction detects the G551D, R117H and F508del mutations. The
F508del ARMS primers (CF-DFjN and CF-DFwM) are specific for this mutation and are
not influenced by the benign I506V and F508C.

As the CF-DFwM primer is

complementary to the sequence distal to the delF508, the presence of the delI507 mutation
is not recognised (Ferrie, 1992). The second reaction detects the 621+1 GT and G542X
mutations. A PCR product should be formed in both the A and B ARMS reactions
regardless of the sample genotype.

2.1.2.8

Real-time PCR

Real-time ARMS PCR was carried out on a LightCycler (Roche Diagnostics). The total
reaction volume was 10µL, containing: 1µL of 10X LightCycler DNA Master
Hybridisation enzyme mix (Roche Diagnostics), 3 mM MgCl2, 0.1µM hybridisation probes
and ARMS primers concentrations as outlined in Table 2.1. ARMS PCR and subsequent
melting curve analysis was carried out as follows: Initial denaturation was 7.5 min at 95°C
followed by 40 cycles of 95°C for 1s, 64°C for 20s and 72°C for 20s. A touchdown PCR
was carried out with the annealing temperature starting at 70°C and dropping to 64°C at
1°C/cycle. Fluorescence was measured at the end of the annealing step. The PCR stage
was followed by a melting curve analysis, 95°C for 10s, 40°C for 30s and heating back up
to 70°C at 0.1°C/sec with continuous monitoring of fluorescence. The touchdown PCR
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conditions used allowed specific amplification of wildtype or mutated sequences as
detected by standard agarose electrophoresis and melting curve analysis.

2.1.2.9 Agarose Gel electrophoresis

Agarose gel electrophoresis was carried on samples tested using the Real-time ARMS PCR
to confirm the presence of the bands. In order to retrieve the PCR mix back from the
LightCycler capillary the cap was removed and inverted into a 0.5 ml eppendorf and
centrifuged at 3000 rpm for 5-10 secs. ARMS PCR products where then separated on a
2.5% agarose gel run at 100 V for 1 hour.
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ARMS primer name and seq (5’ to 3’)*

Multiplex
rxn

Primer
conc

delF508
DF-C: ACTTCACTTCTAATGATGATTATGGGAGA

1A/B

100 ng

DF-j-N: TATCTATATTCATCATAGGAAACACCACA

1A

100 ng

DF-w-M: TATCTATATTCATCATAGGAAACACCATT

1B

100 ng

11-C: TAAAATCAGCAATGTTGTTTTTGACCT

1A/B

150 ng

GD-j-N: GCTAAAGAAATTCTTGCTCGTTGCC

1B

150 ng

GD-j-M: AGCTAAAGAAATTCTTGCTCGTTGCT

1A

150 ng

RH-C: CACATATGGTATGACCCTCTACATAAACTC

1A/B

120 ng

RH-d-N: CCTCTGCCTAGATAAATCGCGATAGAAC

1A

120 ng

RH-d-M: CCTCTGCCTAGATAAATCGCGATAGAAT

1B

120 ng

621-C: TCACATATGGTATGACCCTCTATATAAACT

2A/B

200 ng

621-j-N: TGCCATGGGGCCTGTGCAAGGAAGTATTCC

2A

200 ng

621-j-M: TGCCATGGGGCCTGTGCAAGGAAGTATTCC

2B

200 ng

11-C: TAAAATCAGCAATGTTGTTTTTGACCT

2A/B

40 ng

GX-e-N: ACTCAGTGTGATTCCACCTTCTAC

2B

40 ng

GX-e-M: CACTCAGTGTGATTCCACCTTCTCA

2A

40 ng

G551D

R117H

621+1 G
T

G542X

Table 2.01 Sequence and concentrations of CF ARMS primers. Primer with a “C” in
their name indicates that it is a common primer and is present in both the wildtype and
mutant reactions. The names of the wildtype specific primers end in a “N” and mutant
specific primer names end in a “M”. *ARMS primer sequence taken from Ferrie, 1992.
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Real-time PCR probe seq (5’ to 3’)

Conc

Tm

Detection of wildtype and mutant R117H and 621+1 G>T
CF4ARMS-A: CCTTTTGTAGGAAGTCACCAAAGCAGTAC-f
CF4ARMS-D: 640-GCCTCTCTTACTGGGAAGAATCA-p

0.1µM
0.1µM

62°C

0.1µM
0.1µM

51°C

0.1µM
0.1µM

55°C

Detection of wildtype and mutant delF508
CF10ARMS-A: GCACAGTGGAAGAATTTCATTCTGTTCTCAG–f
CF10ARMS-D: 640-TTCCTTGGATTATGCCT-p

Detection of wildtype and mutant G542X and G551D
CF11ARMSA: TATGATTACATTAGAAGGAAGATGTGCCTTT-f
CF11ARMS-D: 705-AATTCAGATTGAGCATACT-p

Table 2.02 Sequence of Real-time PCR probes sets used to detect ARMS products in a
melt-curve analysis. Anchor probe (A), Detector probe (D), (Fluorescein (f), Phosphate
(p), LC Red 640 dye (640, detected in the F2 channel), LC Red 705 dye (705, detected in
the F3 channel).
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2.1.3

RESULTS

2.1.3.1

Comparison of Real-time and traditional PCR for the detection
of delF508 mutation

In the first part of this study, we compared the detection of the delF508 mutation in CF by
Real-time PCR and two other traditional PCR based methods.

The two traditional

approaches were a sizing PCR and ARMS PCR. The sizing PCR is based on the fact the
delF508 mutation is the result of a 3 bp deletion. Primers amplify a region, which includes
the possible mutation site, the PCR products are then analysed using a 10% acrylamide gel.
In a wildtype sample the resultant PCR product will be 97 base pairs (bp) in length, an
individual who is homozygous mutant will have a PCR amplicon of 94 bp and a
heterozygote will display a band at the two different product sizes (Fig 2.3, Panel A). The
ARMS PCR analysis for the delF508 was performed using the ARMS primers detailed in
Table 2.1. In ARMS PCR each sample is tested in two separate PCRs, one specific for the
wildtype allele and the other for the mutant allele. An internal control set of primers was
also included in both PCR to ensure that a PCR product is formed in each reaction as a
quality control step. The PCR products were then separated on a 2% agarose gel and
diagnosis can be made on the resulting band patterns observed (Fig 2.3, Panel B). These
two techniques were compared to a set of published primers and hybridisation probes,
which were used to perform Real-time melting curve analysis for the detection of the
delF508 mutation. During melting curve analysis, a temperature will be reached which
causes FRET activity to decrease as the detector probe is disassociated from its
complementary sequence adjacent to the anchor probe. The first derivative of the melting
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curve is determined by the LightCycler analysis software (Roche) that allows the drop in
fluorescence to be seen as a peak. If there is no mutation present, the probe requires more
energy (higher temperature) to destabilise it, in this case resulting in a melt curve peak at
61oC (Fig 2.3, Panel C, blue line). If the mutation is present then the detector probe will
become destabilised at a lower temperature, in this case 51oC (Fig 2.3, Panel C, red line).
A heterozygote will show a peak at both temperatures (Fig 2.3, Panel C, green line). When
all three protocols were successfully optimised in our hands, we performed a small, blinded
study using a mix of samples that were wildtype, heterozygous and homozygous mutant for
the delF508 mutation using each of the three methods.

All samples were correctly

identified using the three different PCR based methods. However, the time required to
perform the Real-time PCR based method was considerably shorter (35 mins) than the
other two techniques (ARMS, 5 hrs; sizing PCR, 6 hrs).
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Fig 2.3 Three methods for detection of the delF508 mutation. Panel A: Standard sizing
PCR; Lane 197 bp band (normal), Lane 2 97 and 94 bp band (heterozygote) Lane 3 94 bp
band (homozygous mutant). Panel B: ARMS PCR; 100 bp sizing ladder (L), normal
ARMS (N), mutant ARMS (M). An internal control is present in each reaction to ensure
that the PCR is working.

Sample 1 Wildtype, Sample 2 heterozygote, Sample 3

homozygous mutant. Panel C: Real-time PCR melting curve analysis; Blue curve (normal),
Green curve (heterozygote), Red curve (homozygous mutant).
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2.1.3.2

Real-time multiplex PCR for detection of delF508 and R117H
mutations

After we had shown that Real-time PCR was a suitable method for mutation detection, we
set about designing a multiplex PCR to detect more than one mutation at a time. This
would have the advantage of saving time and cutting cost of performing the test. The
LightCycler has two colour channels that can be used to detect fluorescence from two
different reporter dyes (LCRed640, F2 channel; LCRed705, F3 channel). We aimed to
develop a multiplex Real-time PCR that would allow two mutations to be detected per
colour channel ie four mutations in total.

We firstly designed a set of primers and

hybridisation probes that would be detected in the same channel as the delF508
hybridisation probes from the previous experiment. However, despite careful design of the
R117H hybridisation probes, under melting curve analysis the R117H and delF508
wildtype peaks merged with each other (Fig 2.4) not allowing the genotype to be clearly
identified. Therefore, we realised that if we were to detect more than one mutation per
colour channel on the LightCycler, we would need to take a novel approach to designing
hybridisation probes for mutation detection on the LightCycler instrument.
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Fig 2.4 Multiplex melting curve analysis for delF508 and R117H mutations. Green and
red melting curves are of wildtype samples for both mutations. The delF508 peak is at
61oC and the R117H peak is at 65oC, however peaks are not clearly distinguishable from
each other.
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2.1.3.3

Real-time ARMS PCR

Traditionally during the design of hybridisation probes for mutation detection, the detector
probe is positioned over the site of the mutation (Fig 2.5, Panel A). Preferably, with the
possible mutation site as close to the centre of the probe to cause the biggest destabilisation
effect when a mutant allele is present. However, we showed in the previous experiment
that even with careful design of the detector probe, it is difficult to be sure of the Tm at
which it will disassociate during melting curve analysis. Hence we took an approach that
allowed us to design hybridisation probes that would melt at the temperature which we
desired, and which could be positioned anywhere along the length to the amplicon. For this
we combined traditional ARMS PCR with Real-time PCR. The ARMS primers will detect
the genotype of the sample and a set of hybridisation probes that will have a predefined Tm
will be used to detect the presence or absence of a PCR product. With this approach the
hybridisation probes can be placed anywhere along the length of the amplicon (Fig 2.5,
Panel B).

One of the advantages of this is it allows us to design better working

hybridisation probes. The ARMS primers used were previously published primer sets
(Ferrie, 1992) and are outlined in Table 2.1 (Methods). Using a combination of the
LightCycler hybridisation probe design software version 1.1 (Roche) and the melt-calc
software package (Schütz, 1999), hybridisation probes were designed to detect the PCR
amplicons produced by the ARMS primers (Table 2.2, Methods)
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The CF4ARMS-A/D probes detect both the R117H and 621+1 GT mutations and
produce a peak at 62°C during a melting curve analysis. CF10ARMS-A/D probes detect
the delF508 mutation and melt at 51°C. CF11ARMS-A/D produces a Tm peak at 55°C and
detects both the G551D and G542X mutations.

Fig 2.5 Orientation of hybridisation probes for Real-time ARMS PCR. Panel A: shows
the traditional position that Hybridisation would be located with respect to the possible site
of the mutation. Panel B: shows the position of the hybridisation probes in our system with
respect to the mutation site. AP, Anchor probe (AP), Detector probe (DP), Forward primer
(FP), Reverse primer (RP), Common primer (CP), Normal ARMS primer (N), Mutant
ARMS primer (M).
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The optimisation of the ARMS Real-time PCR reactions was performed in the usually
manner, magnesium ions were titrated, primer concentrations varied and adjustment of the
annealing temperature were all carried out until a reproducible assay was developed.
Following the optimisation procedure, samples with a variety of mutation combinations
were tested with the assay, some examples of the resulting melting curve profiles are
outlined in Fig 2.06, Fig 2.07 and Fig 2.08.

As can be seen peaks are now clearly

distinguishable from each other and the genotype of each sample can be clearly identified.
This protocol was very rapid taking approximately 45 mins.
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Fig 2.06 Melting curve profiles of a delF508 heterozygote. The A reaction (red line)
detects wildtype delF508 and R117H (F2 channel) and mutant G551D (F3 channel), the B
reaction (grey line) detects mutant delF508 and R117H and wildtype G551D. As can be
seen from the upper graph a product is detected in both the wildtype and mutant reactions
for the delF508 indicating the carrier status of this sample. The agarose gel (inset) also
shows the presence of two bands for delF508 in this sample.
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Fig 2.07 Melting curve profiles of a R117H/G551D compound heterozygote. The A
reaction (red line) detects wildtype delF508 and R117H (F2 channel) and mutant G551D
(F3 channel), the B reaction (black line) detects mutant delF508 and R117H and wildtype
G551D. As can be seen from the upper graph (F2) a product is detected in both the
wildtype and mutant reactions for the R117H. The lower graph (F3) also shows 2 peaks for
G551D indicating that the sample is a compound heterozygote and would be affected with
CF. The agarose gel (inset) confirms the genotype of the sample.
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Fig 2.08 Melting curve profiles of a G542X heterozygote. The A reaction (red line)
detects wildtype 621+1 G>T (F2 channel) and mutant G542X (F3 channel), the B reaction
(black line) detects mutant 621+1 G>T and wildtype G542X. As can be seen from the
lower graph (F3) a product is detected in both the wildtype and mutant reactions for the
G542X indicating the carrier status of this sample. The agarose gel (inset) confirms the
presence of two bands for G542X in this sample.
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2.1.3.4

Blinded Trial

Using the optimised protocol as outlined in the methods, a panel of patient samples
containing combinations of the five mutations (delF508, G551D, R117H, G542X and
621+1GT) were tested blind.

All of the patient samples provided were correctly

identified and correlated with previous genotyping carried out in the National Centre for
Medical Genetics, Our Lady's Hospital for Sick Children, Crumlin, Dublin 12. The results
are presented in Table 2.3.
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Sample No delF508 R117H G551D 621+1 G542X

Genotype

Sample 1

W

C

C

W

W

R117H/G551D

Sample 2

C

W

W

C

W

delF508/621+1

Sample 3

C

W

C

W

W

delF508/G551D

Sample 4

C

W

C

W

W

delF508/G551D

Sample 5

C

W

W

W

W

delF508/N

Sample 6

C

W

W

W

W

delF508/N

Sample 7

C

W

W

C

W

delF508/621+1

Sample 8

C

W

W

W

W

delF508/N

Sample 9

W

W

C

W

W

G551D/N

Sample 10

W

W

W

W

W

N/N

Sample 11

M

W

W

W

W

delF508/delF508

Sample 12

W

W

W

W

W

N/N

Sample 13

W

W

W

W

W

N/N

Sample 14

C

W

W

W

W

delF508/N

Sample 15

C

W

W

W

W

delF508/N

Sample 16

W

M

W

W

W

R117H/R117H

Sample 17

M

W

W

W

W

delF508/delF508

Sample 18

W

W

W

W

W

N/N

Sample 19

C

W

W

W

W

delF508/N

Sample 20

W

W

W

C

W

621+1/N

Sample 21

C

W

C

W

W

delF508/G551D

Table 2.03 Blinded trial results using optimised Real-time ARMS multiplex PCR.
Wildtype, W; Heterozygote, C; homozygous mutant, M.
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2.1.4

DISCUSSION

Cystic fibrosis is the most common genetic disease in people of a European descent
(Mateu, 2002). The disease is monogenic disorder caused by insufficiencies in the CFTR
protein. In the last 10-20 years, a better understanding of the mechanisms behind the
development of CF has led to better clinical management of the disease and ultimately
improved the life span of patients. However, the first step in treatment of a disease is a
definitive diagnosis.

Real-time PCR has provided a dynamic platform for the molecular diagnosis of hereditary
diseases. Many of the detection chemistries used for Real-time PCR and melting curve
analysis have already been applied to the diagnosis of CF, such as Sybr Green 1, (Kleinle,
2002; Wittwer, 2003) scorpion probe (Thelwell, 2000) and dual hybridisation probe
(Burggraf, 2002; Gundry, 1999) based detection systems. Each detection system has its
advantages and disadvantages. Sybr Green 1 is a non-specific dye and by this very fact, it
is cheap and quick to develop a real-time PCR assay. However, it has the downfall of
detecting non-specific products making it difficult to perform multiplex PCR. Scorpion
probes have the benefit of incorporating a forward primer and detector probe in one
oligonucleotide, but are expensive and complex to design. Hybridisation probes offer the
highest specificity of all the detection chemistries (Wittwer, 1997). Nevertheless, due to
their dual probe system, they are required to be longer than the other probe types and the
design of an efficient probe pair can be limited by the nature of the sequence around the site
of a mutation.
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The work in this chapter aimed to improve multiplexing capabilities of Real-time PCR in
its use for mutation detection. In the first part of the study, we demonstrated that Real-time
PCR was a feasible approach to mutation detection in CF by comparing it to two other
traditional methods for detecting the delF508 mutation (Fig 2.3). The Real-time PCR
technique proved to be as accurate in genotyping the patient samples as the two traditional
methods (sizing PCR and ARMS PCR). Melting curve peaks for wildtype and mutant
alleles were clearly distinguishable from each other (Fig 2.3, Panel C) and the test was very
rapid (~ 35 mins).

The next stage was to start multiplexing the most common mutations in Ireland (Scotet,
2003) into one Real-time PCR assay. To begin with, a set of primers and probes were
designed for the R117H mutation, and would be detected in the same colour channel as the
delF508 primers and probes. However, it was soon realised that this approach would prove
to be very difficult. When the hybridisation probes were designed for the R117H mutation
we tried to generate a detector probe that would have a Tm above that of the delF508
detector probe ie greater than 61oC (Fig 2.3C). This was to ensure that melting curve
analysis peaks would be distinguishable from each other therefore making genotyping of
the sample a straightforward process. Despite trying to keep the peaks separated from one
another, during melting curve analysis the wildtype peaks for both delF508 and R117H
merged with each other, not allowing a clear genotype to be identified (Fig 2.4). The
problem arose from the use of a traditional approach to hybridisation probe design, where
the detector probe is positioned over the site of the mutation (Bernard, 1998; Bernard,
2001). This places limits on designing effective hybridisation probe pairs. The DNA
sequence around the mutation site may not always be the best suited for the task. The DNA
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sequence may have a very high G:C content, which would result in a very stable detector
probe even when a mutation is present. This would cause the wildtype peak and mutant
peak to be poorly differentiated from each other. Another problem with this approach is
that it is very difficult to determine how much a particular mutation will destabilise the
detector probe during a melting curve analysis. In the case of the delF508 mutation, 3 bp
are deleted which has a large destabilisation effect on the detector probe, hence the 10oC
different between the Tm of the wildtype peak and mutant peak (Fig 2.3). However, with
single bp substitutions as in the case of the R117H mutation the destabilisation effect will
be much smaller.

Therefore, it was decided to take a novel approach to performing

multiplex mutation detection on the LightCycler instrument. We would need a technique
that would allow us more freedom to design effective hybridisation probes by not being
restricted to placing the hybridisation probe over the mutation site.

To this end, Amplification Refractory Mutation System (ARMS) PCR primers were used to
selectively amplify the wildtype or mutant alleles in separate reactions.

Subsequent

detection of PCR products is carried out using a common set of hybridisation probes. The
advantage of this system is it increases the flexibility of the hybridisation probe design
allowing probes with precise Tms to be generated. In this way, melting curve peaks can be
at a predetermined Tm for a particular PCR product, which allows for easier multiplexing
of Real-time PCR. Similar ARMS based techniques have been developed for the ABI
prism 7700 sequence detector from PE Applied Biosystems using TaqMan® probes (Glaab,
1999). These protocols depend on the detection of an amplification curve and are limited to
the detection of one mutation per colour channel. Our protocol detects melting curve
peaks, post amplification and allows multiple mutations to be detected per colour channel.
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Optimisation of the annealing temperature was particularly crucial, as at the incorrect
annealing temperature a certain amount of mispriming occurred, the mutant primers were
producing a product in a wildtype sample. This problem occurred mainly due to the
sensitivity of the LightCycler instrument, often when a misprimed peak occurred the band
was very faint on the corresponding agarose gel. The problem of the mispriming was
solved by careful optimisation of the annealing conditions, primer concentrations and the
addition of a “touch-down” segment to the start of the amplification stage. The “touchdown” PCR provides more stringent annealing conditions in the initial cycles of the
amplification process and in doing so eliminated the mispriming event.

The main advantage of the LightCycler system is its speed; the optimised protocol takes
approximately 45 minutes to complete, which is a significant improvement over standard
ARMS followed by gel electrophoresis, which can take approximately 5 hours to perform.
Genotyping on the LightCycler system, using standard multiplex hybridisation probes that
overlie the mutation site can be technically challenging and have some limitations. Even
with careful design of the hybridisation probes, wildtype and mutant alleles may not
necessarily be discriminated from each other (Bernard, 1998).

Our system allows

hybridisation probes to bind to any region of the amplicon therefore providing scope for
better probe design. The number of mutations that can be detected in a single reaction is
dependent on the number of melting peaks that can be clearly differentiated from each other
(Von Ahsen, 1999). This usually leads to development of multiplex reactions where a
single mutation is detected per colour channel (Gundry, 2001, Bestmann, 2002). Here we
have demonstrated a method, which makes it quite possible to detect more than one
mutation in a single channel.

Using the nearest neighbour formula in the MeltCalc
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software package (Schütz, 1999), detector probes can be carefully designed that produce a
peak within 1-2°C of the predicted Tm. This allows Tm peaks, which indicate the presence
or absence of a PCR product, to be strategically placed within the normal melting curve
range of 45-70°C for hybridisation probes. Over this melting curve range, we feel it should
be possible to clearly distinguish three peaks in a single channel. This potentially makes it
possible to multiplex six mutations into two capillaries when using both fluorescent
channels. This enhances the capabilities of the LightCycler for mutation detection; similar
strategies could also be employed for other Real-time systems.

To conclude, the results presented here demonstrate the ability to carry out multiplex
mutation detection using a combination of ARMS PCR and Real-time melting curve
analysis. This method provides an improvement over current techniques for performing
multiplex mutation detection on the LightCycler instrument. Any laboratory currently
using ARMS PCR in a diagnostic setting can quite easily convert their standard ARMS
PCR to a Real-time ARMS PCR. This will have a significant advantage in time saving,
prevent any possible of cross contamination and reduce the handling of the potential
carcinogen ethidium bromide.
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Chapter 2.2

QUANTIFICATION OF THE DOSAGE
SENSITIVE PMP22 GENE IN HEREDITARY
PERIPHERAL NEUROPATHIES

2.2.1

INTRODUCTION

2.2.1.1

Charcot-Marie-Tooth (CMT) disease

In 1886 Drs Charcot and Marie in France and Dr Tooth in England separately described
patients suffering from an inherited form of peroneal muscular atrophy (Charcot and Marie,
1886; Tooth, 1886).

Charcot-Marie-Tooth (CMT) disease is now used to describe a

clinically and genetically heterogeneous group of disorders that can be characterised by a
chronic motor and sensory polyneuropathy. CMT is the most common inherited disease of
the peripheral nervous system (PNS) with a prevalence rate of 1 in 2500 (Boerkoel, 2002).

2.2.1.2

CMT classification

CMT can be subdivided into five major groups: CMT1, CMT2, CMT3 (usually referred to
as Dejerine-Sottas syndrome, DSS), CMT4 and CMTX and there are several subtypes
within each group (Vance, 2000). Groupings are based on mode of inheritance (autosomal
dominant (CMT1 and CMT2), autosomal recessive (CMT4), X-linked (CMTX)) and the
chromosomal locus involved. The autosomal dominant forms are divided based on nerve
conduction velocities (NCVs). Normal NCVs are typically >40-45 meters/second (m/s),
and patients with CMT1 have significantly reduced NCVs usually between 10-30 m/s
(Hoogendijk, 1994; Birouk, 1997; Thomas, 1997; Krawjewski, 2000). In CMT2 NCVs are
usually within the normal range though they can fall within the low normal or mildly
abnormal range (35-50 m/s) (Dyck, 1993; Saito, 1997). CMT1 is the most common type
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(Kamholz, 2000) and has been further divided into 4 subtypes (Table 2.04).

CMT1

subtypes are clinically indistinguishable from each other and identification is based on the
chromosomal locus involved (Bird, 2004).

CMT1 subtype

Genetic mechanism

Locus

% of cases

CMT 1A

Duplication of PMP22
Point mutations in PMP22

17p11

70-80%

CMT 1B

Point mutations in MPZ (P0)

1q22-q23

5-15%

CMT 1C

?

16q*

10-15%

CMT 1D

Point mutation in EGR2

10q21

<5%

Table 2.04 Breakdown of CMT 1 subtypes. PMP22, peripheral myelin protein 22; MPZ,
myelin protein zero (P0); EGR2, early growth response 2. * No gene has been identified
for CMT1C however using linkage analysis it has been mapped to Chr 16q (Street, 2002).
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2.2.1.3

Clinical features of CMT1

The clinical symptoms of CMT1 usually appear in patients during the first or second
decades of life (Carter, 1995; Garcia, 1999).

The disease is characterised by slowly

progressive atrophy of the distal muscles, predominantly those innervated by the peroneal
nerve (Dyck, 1992; Lupski, 1991). Patients usually present with muscle weakness in the
legs and feet, 20-30% of these experience pain particularly in the feet (Carter, 1998). Pes
cavus (highly arched foot) is not seen during the early stages of disease but generally
develops as the patient gets older, and results from imbalances between the extrinsic and
intrinsic muscles of the feet (Garcia, 1999). Other symptoms that develop with age are
claw-hands, stork-leg appearance (due to atrophy of the leg muscles), enlarged nerves (the
greater auricular nerve may be visible at the surface of the neck) and 40% of patients
develop hand tremor by their mid-30s (Caradoso, 1993). Histological findings in CMT1
are segmental demyelination and Schwann cell proliferation forming concentric arrays,
often referred to as “onion bulb” formations, around demyelinated or partially
remyelinating axons (Dyck, 1993; Ionasescu, 1995).

2.2.1.4

CMT type 1A

CMT1A accounts for 70-80% of CMT1 patients and has an estimated prevalence of
1:10000 (Nelis, 1996). In 1989, CMT1A was linked to the short arm of chromosome 17
(Raeymaekers, 1989; Vance, 1989). During 1991, two independent reports described a
large segmental duplication (~ 1.5 Mb of DNA) to associate with CMT1A patients within
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band 17p11.2 (Lupski, 1991; Raeymaekers, 1991).

This duplicated region was

subsequently shown to contain the gene for peripheral myelin protein 22 (PMP22)
(Matsunami, 1992; Patel, 1992; Timmerman, 1992; Valentijn, 1992a). A gene dosage
effect was hypothesised to be the molecular pathogenic cause of the disease; further
evidence to support this was shown when a patient who had 4 copies of the PMP22 gene
had a more severe phenotype (Lupski, 1992). The dosage hypothesis was given even more
strength by the generation of transgenic mice and rats that carried additional copies of the
PMP22 gene (Huxley, 1996; Huxley, 1998; Magyar, 1996; Sereda, 1996; Vallat, 1996;
Perea, 2001). Point mutations within the PMP22 gene have also been identified in CMT1A
patients where a duplication could not be found (Fabrizi, 1999; Roa, 1993; Valentijn,
1992b). CMT1A due to point mutations in the PMP22 gene often presents as a more severe
disease phenotype than duplication positive patients (Tyson, 1997).

2.2.1.5

Hereditary neuropathy with liability to pressure palsies (HNPP)

Hereditary neuropathy with liability to pressure palsies (HNPP) is an autosomal dominant
disorder, that is characterised by recurrent peripheral motor/sensory nerve palsies which
occur due to minor compression trauma (Verhagen, 1993). NCVs are significantly reduced
at compression sites within the peripheral nerves (Verhagen, 1993).

The disease is

sometimes referred to as “tomaculous neuropathy” due to the presence of sausage shaped
swellings in the myelin sheath (Latin: sausage = tomaculum). These tomaculum can occur
in both the sensory and motor neurons (Oda, 1990). Patients also have variable degrees of
segmental demyelination and axonal loss (Lenssen, 1998).
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The underlying genetic defect in 84% (Sutton, 2004) of HNPP families is a 1.5-Mb deletion
on chromosome 17p11.2, which contains the gene for PMP22 (Chance, 1993). However,
in a minority of HNPP families no deletion could be detected (Marimam, 1994; Harding,
1995). Point mutations within the PMP22 gene have also been associated with HNPP
(Lenssen, 1998; Bort, 1997; Young, 1997).

2.2.1.5

Peripheral myelin protein 22 (PMP22)

PMP22 is an 18 KDa polypeptide that undergoes post-translational modification to form a
mature 22 KDa glycoprotein.

The protein is 160 aa in length and has 4 distinct

hydrophobic domains and 2 extracellular domains (D’Urso, 1997) that are highly conserved
among different species (Agostoni, 1999; Wulf, 1999). The cDNA for PMP22 was first
identified by screening for genes that were repressed in peripheral nerves following nerve
damage (Welcher, 1991).

The gene for PMP22 was mapped to 17p11.2-p12 using

Southern analysis of somatic cell hybrids (Patel, 1992) and by fluorescent in situ
hybridisation (FISH) (Takahashi, 1992). Cloned Human PMP22 was shown to have 87%
and 86% homology to rat and mouse PMP22 respectively (Patel, 1992). The PMP22 gene
has 2 promoter regions that regulate the expression of 2 alternatively utilised 5’ noncoding
exons, termed exons 1a and 1b (Suter, 1994).

The protein is highly expressed in myelinating Schwann cells, mRNA transcripts where
found to be upregulated 200-fold during myelination (Snipes, 1992) and at lower levels in
several non-neural tissues (Spreyer, 1991; Welcher, 1991; Baechner, 1995). PMP22 is
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mainly localised within the compact portion of the myelin sheath it is not found in noncompact myelin (Snipes, 1992; Haney 1996) and is estimated to comprise 2-5% of total
myelin protein (Pareek, 1993).

PMP22 like any other integral membrane protein is processed through the secretory
pathway, involving synthesis in the rough endoplasmic reticulum (RER), maturation in the
Golgi and targeting to the plasma membrane. It has been shown that the majority of newly
synthesised PMP22 is retained in the ER and degraded (Pareek, 1993; Pareek 1997;
Notterpek, 1999). The small percentage of PMP22 that leaves the ER for the Golgi and
undergoes glycosylation making it more stable (Pareek, 1997).

The function of PMP22 is not fully characterised but seems to have an important role in the
formation and maintenance of myelin (Snipes, 1992; Li, 2004). PMP22 has also been
implicated in the formation of the intracellular junction of epithelial cells (Notterpek, 2001)
as well as the regulation of cell proliferation and apoptosis (Fabbretti, 1995; Karlsson,
1999; Zoidl, 1995; Zoidl, 1997).
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2.2.1.6

Schwann cell maturation

During development of the PNS, Schwann cell precursors arise from the neural crest; these
precursors then migrate and make contact with developing peripheral axons (Le Douarin,
1993). These immature Schwann cells then invade and ensheath bundles of axons, where
they then differentiate further into non-myelinating or pro-myelinating Schwann cells
(Webster, 1993). Pro-myelinating cells develop a one to one association with an axon;
these cells can then differentiate into mature myelinating Schwann cells.

Mature

myelinating Schwann cells turn on genes that code for the major myelin proteins and turn
off previously expressed genes (Scherer, 1997). The mRNA for PMP22, MPZ, myelin
basic protein (MBP), and myelin-associated glycoprotein (MAG) are rapidly upregulated.
Once myelination of the axon is complete, maintenance of the sheath depends on continued
Schwann cell-axon interactions (Kamholtz, 2000).

2.2.1.7

Unequal recombination at chromosome 17p11.2-12

The CMT1A and HNPP disease phenotypes seem to result from gene dosage sensitivity
(Lupski, 1992; Chance, 1993), which Gabriel and colleagues provided more evidence for,
through immunohistochemistry on CMT1A and HNPP nerve biopsy samples (Gabriel,
1997). Mapping of the 1.5 Mb segment that can be duplicated or deleted showed that
located on either side of the region are two almost identical (>98%) 24 Kb repeats, that
have been termed CMT1A-REPs (Pentao, 1992; Chance, 1994; Kiyosawa, 1995). The
unequal recombination event occurs between a flanking proximal CMT1A-REP on one
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homolog and a misaligned distal CMT1A-REP on the other homolog (Han, 2000). It has
been shown that recombination events do not happen equally across the entire 24 Kbs of
the repeats. There is a 3.2 Kb “hot-spot” region most (75-80%) recombination events can
be located to (Lopes, 1998; Reiter, 1997) and a further 9.2 Kb region that contains the
majority of the remaining rearrangements (Kiyosawa, 1995; Lopes, 1998). Most de novo
cases of CMT1A and HNPP are of paternal origin (Bort, 1997; Palau, 1993; Lopes, 1997)
arising from interchromosomal recombination during spermatogenesis. Duplication and
deletions that are of maternal origin seem to be the result of an intrachromosomal process,
either unequal sister chromatid exchange (Lopes, 1998) or, in the case of deletions, by
excision of an intrachromatidial loop (LeGuern, 1996).

Fig 2.9 Unequal crossing over between distal and proximal CMT1A repeats (adapted
from Lopes, 1999).

132

2.2.1.8

Aim of the chapter

The aim of this study is to successfully develop a quantitative Real-time multiplex PCR
that will be capable of detecting changes in PMP22 gene copy number. This will push
Real-time PCR to the limits of it capabilities, as any changes in PMP22 gene copy number
will be very subtle. Multiplexing both the reference and target gene into the same reaction
and detecting them using different coloured hybridisation probes is an important aspect of
this study. By having both amplicons form in the same PCR, under the same conditions,
this should help to reduce variability in the assay. β-globin will be used as a reference
gene and the final results will be presented as a relative ratio of PMP22 to β-globin gene
copy numbers.
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2.2.2

MATERIALS AND METHODS

2.2.2.1

Patient samples

CMT1A and HNPP samples used in this study were kindly provided by Dr David Barton,
from the National Centre for Medical Genetics. Normal control samples were obtained
from within the Department of Biological Sciences, Dublin Institute of Technology, these
samples would have consisted of staff and student volunteers who had given informed
consent.

2.2.2.2

DNA isolation

DNA was isolated as previously described (Materials and methods chapter 2.1.2.2).

2.2.2.3

Primer and hybridisation probe design

Primers and hybridisation probes were designed for β-globin (NCBI accession no:
NG_000007.3) and the exon 1a portion of the PMP22 gene (NCBI accession no: U08049)
with the aid of the LightCycler probe design software version 1.0. The name and sequence
of each primer and hybridisation probe is outlined in Table 2.05 as well as the
concentration used in the final reaction.
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2.2.2.4

DNA quantification

DNA was quantified using Hoechst quantification reagent (Molecular probes). The assay
was carried out as per the manufacturer’s instructions and measurements were taken on a
VersaFluor™ Fluorimeter (BioRad).

The DNA concentration of each sample was

quantified in this manner and then samples were diluted in nuclease free water to a working
concentration of 25 ng/µl, which was determined to be sufficient for Real-time PCR
analysis.

2.2.2.5

Real-time PCR

Real-time quantitative PCR was carried out on a LightCycler instrument (Roche
Diagnostics). The total reaction volume was 10 µl, containing: 1 µl of 10X LightCycler
DNA master hybridisation enzyme mix (Roche Diagnostics), 4 mM MgCl2, 0.1 µM
hybridisation probes and primer concentrations were at 1 µM. PCR conditions were carried
out as follows: initial denaturation was 5 min at 95°C followed by 40 cycles of 95°C for 0s,
55°C for 20s and 72°C for 20s. A touchdown PCR was carried out with the annealing
temperature starting at 55°C and dropping to 50°C at 1°C/cycle.

Fluorescence was

measured at the end of each annealing step. Data analysis was carried out using the second
derivative maximum analysis method in the LightCycler software version 3.5.
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2.2.2.6

Relative quantification

Relative quantification was performed with the aid of the LightCycler relative
quantification software version 1.1 (Roche). To carry out relative quantification, efficiency
correction files were generated by analysing a dilution series of control DNA with the
optimised β-globin/PMP22 multiplex.

Standard curve files were exported from the

LightCycler software into the relative quantification software so that an efficiency
correction file could be generated. This is an important step as it compensates for any
difference in the amplification efficiency between β-globin and PMP22 amplicons. Not
correcting for efficiency could result in an over/under-estimation of PMP22 copies relative
to β-globin copies and thus giving a false positive or negative result. Sample data was then
analysed using the relative quantification (Roche) software as per the manufacturers
instructions.
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Primer/hybridisation probe seq (5’ to 3’)

Conc

β-globin primer
bGCMTF: CATTTGCTTCTGACACAACT
bGCMTR: CTGGGTCCAAGGGTAG

1.0 µM
1.0 µM

β-Globin hybridisation probes
bGCMT-p1: GAAGTCTGCCGTTACTGCCC-f
bGCMT-p2: 640-TGGGGCAAGGTGAACGT-p

0.2 µM
0.2 µM

PMP22Ex1a primers
PMP22Ex1aF: GGGCCTCTTGGGATTAT
PMP22Ex1aR: GCTCCCCGAGATGTTC

1.0 µM
1.0 µM

PMP22Ex1a hybridisation probes
PMP22-p1: CCAGCATTGGACCAGCCC-f
PMP22-p2: 705-GAATAAACTGGAAAGACGCCTGG-p

0.2 µM
0.2 µM

Table 2.05 Sequence of primers and hybridisation probes used for PMP22 dosage
analysis.

Fluorescein (f), Phosphate (p), LC Red 640 dye (640, detected in the F2

channel), LC Red 705 dye (705, detected in the F3 channel). The final concentration (conc)
of each primer/probe in the multiplex PCR is also indicated.
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2.2.3

RESULTS

2.2.3.1

Standard curve reproducibility and PCR efficiency

The exponential nature of PCR amplification and the small quantities of target molecules
used at the start, mean that even small variations in the reaction component can affect the
reproducibility of PCR (Wu, 1991). The first part of this study involved careful design of
both PCR primers and hybridisation probes for both PMP22 and β-globin. β-globin will
act as a reference gene to which PMP22 gene copy numbers will be represented as a ratio
of. Extensive optimisation was then required to ensure the multiplex was reproducible and
that each amplicon had a similar efficiency.

When we had successfully optimised the multiplex PCR, we tested both genomic DNA
standards and patient samples to show that the results were reproducible from assay to
assay. The Cps were reproducible for the quantitative multiplex when using the same set
of prepared genomic DNA standards in consecutive PCRs (Fig 2.10) as indicated by the
low coefficient of variation (CV) (Table 2.06). Crossing points for test samples were also
reproducible, 3 samples tested over 4 separate PCRs and showed very little variation in Cp
values (Fig 2.11) the CV was also low (Table 2.07).

It is also important that the efficiency of each amplicon in the multiplex is similar. If the
efficiency for one amplicon varied much from the other amplicon within the multiplex
PCR this could lead to over/under estimation of the copy number, potentially leading to
misdiagnosis of the sample. The efficiency is calculated from the slope of Cp against log
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concentration using the following equation: Efficiency (E) = 10-1/slope (Rasmussen, 2001).
As mentioned previously a slope of –3.33, indicates that the PCR is 100% efficient. When
we calculated the efficiency for amplification of both PMP22 and β-globin amplicons were
109% and 108% respectively (Table 2.08). This shows that there is only a marginal
difference in efficiency between amplification of PMP22 and β-globin in our optimised
multiplex PCR.

Fig 2.10 Standard curves for PMP22 and β-globin quantification for 3 consecutive
PCRs.
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Cp reproducibility for genomic DNA standards

Genomic DNA standards

40 ng/ul

20 ng/ul

10 ng/ul

Mean Cp

22.09

22.93

23.94

Range

(22.01-22.22)

(22.80-23.02)

(23.84-24.01)

Std dev

0.112

0.114

0.142

CV %

0.50

0.49

0.59

Mean Cp

22.17

23.05

23.91

Range

(22.13-22.21)

(23.02-23.06)

(23.74-24.01)

Std dev

0.04

0.023

0.146

CV %

0.18

0.10

0.60

PMP22

β-globin

Table 2.06 Reproducibility of PMP22/β
β-globin quantitative multiplex PCR using
genomic DNA standards.
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Fig 2.11 Crossing points for 3 samples in 4 consecutive PCRs. Sample 1 (S1) is a
CMT1A positive sample hence the lower Cps in the PMP22 graph when compared with
the β-globin graph.
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Cp reproducibility for patient samples

Sample 1

Sample 2

Sample 3

23.25

24.01

23.95

PMP22
Mean Cp
Range

(23.07-23.46) (23.87-24.12)

(23.65-24.07)

Std dev

0.163

0.134

0.198

CV %

0.70

0.56

0.83

Mean Cp

24.04

24.06

24.16

β-globin

Range

(23.92-24.19) (23.95-24.20)

(24.02-24.29)

Std dev

0.121

0.126

0.141

CV %

0.51

0.52

0.59

Table 2.07 Reproducibility of PMP22/β
β-globin quantitative multiplex PCR using
patient samples. Efficiency (E), Standard deviation (Std dev), coefficient of variation
(CV).
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PCR efficiency calculations

Slope

E = 10-1/slope

%E

Mean

-2.943

2.187

109.34

Std dev

0.171

0.11

5.25

CV %

5.8

4.8

4.8

Mean

-2.985

2.163

108.14

Std dev

0.135

0.07

3.93

CV %

4.5

3.6

3.6

PMP22

β-globin

Table 2.08 Efficiency of both PMP22 and β-globin amplification.
Standard deviation (Std dev), coefficient of variation (CV).
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Efficiency (E),

2.2.3.2

Relative quantification of PMP22 gene copy numbers

Relative quantification involves expressing the target amplicon as a ratio of a control
amplicon that should remain constant in a test sample. A separate relative quantification
software package is available for the LightCycler instrument that determines the relative
concentration of an unknown sample by normalising it to a calibrator sample. In this
study, the calibrator is a genomic DNA sample that is known to have neither a
duplication/deletion of the PMP22 gene. This calibrator sample is included in each run
and it is used by the software to establish a normal ratio. The software calculates a relative
ratio based on the comparative threshold cycle method (Livak, 1997).

Firstly, the

deltadeltaCp (∆∆Cp) is calculated as follow:

∆∆Cp = [∆
∆Cp β-globin (calibrator sample) - ∆Cp PMP22 (calibrator sample)] [∆
∆Cp β -globin (patient sample) - ∆Cp PMP22 (patient sample)].

After the ∆∆Cp is calculated the relative gene copy number of unknown to calibrator
sample can be calculated using the expression: 2-∆∆Cp. Using this method, the expected
results for a normal individual would be a ratio of ~ 1:1, 1.5:1 for CMT1A and 0.5:1 for
HNPP.

Use of the LightCycler relative quantification software avoids the need to

manually calculate ratio values. The software also allows efficiency correction files to be
generated, which can be used to normalise ratio values if there is a difference in efficiency
between the calibrator and target amplification.
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Following optimisation of the PMP22/β-globin quantitative multiplex, we tested a number
of samples for PMP22 duplication or deletions. A typical example of an amplification
curve for a normal sample is seen in Fig 2.12. As we can see, the difference between the
Cps for the calibrator and test sample is similar for both β-globin (Fig 2.12, Panel A) and
PMP22 (Fig 2.12, Panel B). A CMT1A sample shows a larger difference between the Cps
of the calibrator and test sample for β-globin than for PMP22 (Fig 2.13). This indicates
that in that sample there are more copies of the PMP22 gene than β-globin. The reverse is
seen when a HNPP sample is tested (Fig 2.14).

The relative ratios of PMP22 to β-globin gene copy numbers of all samples tested are
shown in Fig 2.15. The mean ratio of PMP22 to β-globin for the control, CMT1A and
HNPP groups were 1.03 (range: 0.83-1.2; standard deviation: 0.110; CV: 10.7%), 1.70
(range: 1.47-2.2; standard deviation: 0.281; CV: 16.5%) and 0.44 respectively. These
figures are within the expected theoretical values for the different relative ratios. From
these results we can see that a ratio of >1.4 is indicative of CMT1A. The diagnosis of
HNPP can be made with samples that have a relative ratio of <0.55. There was no overlap
of copy number between the CMT1A or HNPP patients and the controls.
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Fig 2.12 Relative quantification of PMP22 gene copy number in a normal sample. The
calibrator is labelled in green, the unknown sample in blue and the negative control in red.
As can be seen there is no major difference between the delta Cp for the calibrator and test
sample for either β-globin (panel A) or PMP22 (panel B).
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Fig 2.13 Relative quantification of PMP22 gene copy number in a CMT1A patient.
The calibrator is labelled in green, the sample is in blue and the negative control is in red.
As can be seen in this example the delta Cp between the calibrator and sample for β-globin
(panel A) is greater than the delta Cp between the calibrator and sample for PMP22 (panel
B) indicating that there is an increased amount of PMP22 genes in this sample.
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Fig 2.14 Relative quantification of PMP22 gene copy number in a HNPP sample. The
calibrator is labelled in green, the sample is in orange and the negative control is in red. As
can be seen in this example the delta Cp between the calibrator and sample for β-globin
(panel A) is smaller than the delta Cp between the calibrator and sample for PMP22 (panel
B) indicating that there is a decreased amount of PMP22 genes in this sample.
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Fig 2.15 Distribution of normal, CMT1A and HNPP samples. The number of samples
in each group is indicated in brackets. Samples falling on or between the green lines are
within the normal range (0.8-1.2). Samples above the blue line indicate that duplication is
present and are therefore CMT1A positive. A sample below the red line indicates that there
is a loss of a copy of the PMP22 gene and are therefore HNPP positive.
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2.2.4

DISCUSSION

The major cause of CMT1A is the duplication of a 1.5Mb region on chromosome 17p11.2
(Lpski, 1991; Raeymaekers; 1991), which was shown to contain the gene for peripheral
myelin protein 22 (PMP22) (Matsunami 1992; Patel, 1992; Timmerman, 1992; Valentijn,
1992).

Hereditary neuropathy with liability to pressure palsies (HNPP) has been

associated with a reciprocal deletion of the same 1.5 Mb region (Chance, 1993). A gene
dosage effect was hypothesised to be the molecular pathogenic cause of the diseases
(Lupski, 1992). Overexpression of PMP22 leads to the CMT1A disease phenotype and
underexpression of PMP22 leads to the HNPP phenotype. This hypothesis has been lent
more weight with the use of transgenic mouse models for both diseases (Huxley, 1996;
Huxley, 1998; Magyar, 1996; Sereda, 1996; Vallat, 1996; Perea, 2001).

Many molecular techniques have been applied to the diagnosis of these two neuropathies.
Southern blotting was used in conjunction with densitometric measurements to detect
differences in gene dosage (Lupski, 1991). Pulsed field gel electrophoresis (PFGE) has
been used to detect recombination specific junction fragments (Chance, 1994). Interphase
fluorescence in situ hybridisation (FISH) methodologies have also been developed to
detect the gain or loss of the PMP22 gene (Shaffer, 1997; Kaskork, 1999).

Other

techniques include repeat-PCR (REP-PCR) (Stronach, 1999), short tandem repeat (STR)
PCR (Haupt, 1997; Badano, 2001) and endpoint quantitative PCR (Poroppat, 1998; Young,
1998). However, many of these techniques have several drawbacks. The hybridisation
techniques are very time consuming and large amounts of high-grade DNA are required.
Endpoint PCR is only semi-quantitative at best due to PCR reaching a plateau in latter
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cycles and requires a considerable amount of post-PCR processing followed by
densitometric analysis.

Real-time PCR a recent advancement of the PCR technology has led to development of a
truly quantitative technique.

Quantification is based on the principle that the Cp is

proportional to the starting copy number of the target sequence (Higuchi, 1993). One of the
advantages of using Real-time PCR for the diagnosis of hereditary diseases is that the
detection systems used are very sensitive, requiring only small amounts of DNA making
them suitable for neo-natal screening.

In this chapter, we aimed to determine how sensitive Real-time PCR is for quantification of
subtle changes in gene copy number. It is clear that Real-time PCR can easily detect log
fold changes in the target amplicon but would it be able to measure changes as small as a
1.5 fold increase? To achieve this we developed a Real-time multiplex PCR to quantify the
duplication or deletion of the gene for PMP22. Recently other groups have taken Real-time
PCR approaches for gene dosage analysis in CMT1A. These have included a competitive
gene dosage assay, where the area under a melting curve peak for an intronic polymorphic
markers are compared between a PCR competitor and a test sample (Ruiz-Ponte, 2000).
Other approaches have included Sybr Green 1 based relative quantification of PMP22 gene
dosage using either β-globin (Choi, 2005) or albumin (Kim, 2003) as a reference gene. The
inability to perform multiplex PCR is a major disadvantage of using Sybr Green 1 for
quantification, this means both the target and the reference gene have to be amplified in
separate reactions. Any pipetting errors made when loading the test sample into 2 separate
PCRs could result in a false positive/negative result. The optimum approach is to develop a
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multiplex reaction whereby both the target and a reference gene are amplified in the same
reaction. In this system, any sample loading variations will not alter the result. Other
advantages include the saving of time and reagents, as only a single PCR is needed to
assess both amplicons. This approach to the quantification of PMP22 gene dosage was
taken by a group using TaqMan probes and albumin was used as a reference gene (Thiel,
2003).

We used the multiplex PCR approach to co-amplify portions of exon 1a of the PMP22 gene
and β-globin gene simultaneously. Using hybridisation probes labelled with different dyes
meant that each amplicon could be detected in a different colour channel on the
LightCycler. A relative quantification strategy was employed, meaning that PMP22 copy
number would be expressed as a ratio of β-globin copy number. Careful optimisation of
the PCR parameters was required, as the efficiency at which both amplicons were being
produced had to be similar. PCR efficiency calculations were made by running serial
dilutions of a standard, in this case a commercial preparation of gDNA at a known
concentration, in the multiplex. The slope of the resulting standard curves could then be
put into the following equation: E = 10-1/slope, the average efficiency of both reactions was
very similar differing by only 1% (Table 2.08). Calculation of the Cp values for both the
calibrator and test samples was performed using the second derivative maximum algorithm
in the LightCycler data analysis software. This approach was taken, as it is a more
automated way of obtaining Cp data. Cp values were reproducible from day to day for both
standards (Table 2.06 and Fig 2.10) and patient samples (Table 2.07 and Fig 2.11).
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Relative quantification was performed by exporting the Cp data for each sample into the
LightCycler relative quantification software. Use of this software serves two purposes,
firstly coefficiency files can be generated from the standards, this allows for correction of
efficiency if differences occur between the two amplicons.

Secondly, it is a more

automated way of obtaining ratio values. Automation of any aspect of a diagnostic test can
eliminate/reduce human error when interpreting the results.

The mean ratio of PMP22 to β-globin for the different groups, controls, CMT1A and HNPP
are 1.03, 1.70 and 0.44 respectively, which is similar to previously published data (Choi,
2005; Aarskog, 2001; Ruiz-Ponte, 2000; Thiel, 2003). There is a clear gap between the
gene copy number ratios between each group (Fig 2.15) with no overlapping results. The
control and CMT1A cohort numbers are similar or better than other studies. The single
HNPP sample is a limitation of this study, nonetheless, it is clearly discernible from the
normal cohort and falls within the ratio range of other studies (Choi, 2005; Aarskog, 2001).

To conclude, the Real-time multiplex PCR assay that we have developed allows the rapid
differentiation of gene deletions and duplications and allows for the diagnosis of CMT1A
and HNPP patients. The assay is quick (~ 45 mins), requires very little DNA (~25 ng/µl)
and data interpretation is automated which facilitates high-throughput. As this work has
also shown that Real-time PCR techniques are sensitive enough to detect subtle changes in
gene copy numbers, similar approaches could be employed for a wide range of genetic
diseases such as Down’s syndrome caused by trisomy 21 (Zimmermann, 2000). Many
cancer cells undergo amplification of certain genes that help them avoid the immune
system resulting in a more aggressive tumour such as decoy receptor 3 in gastrointestinal
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tumours (Pitti, 1998; Bai, 2000) and Her2/neu in breast cancer (Slamon, 1987). These
events could also be monitored with an approach similar to the one used in this study.
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CHAPTER 3

ANALYSIS OF LIGHT MESSENGER RNA
EXPRESSION BY QUANTITATIVE REALTIME RT-PCR IN HUMAN IMMUNEMEDIATED DISEASES

3.1

INTRODUCTION

3.1.1

Autoimmune diseases

Autoimmune diseases are individually rare but when taken together they affect
approximately 5 % of the population in the western world with a disproportionately skewed
effect on women (McKay, 2004; O’Shea, 2001). The consensus is that these diseases occur
due to abnormal lymphocyte activation, however, other cells types can make a significant
contribution to disease pathogenesis, particularly APCs such as DCs (Bayry, 2004). The
development of autoimmune conditions is a complex process involving genetic
predisposition as well as environmental triggers such as pathogen exposure and diet (Rioux,
2005).

Autoimmune diseases are often categorised into organ/tissue-specific as in the case of
insulin dependent diabetes mellitus (IDDM), multiple sclerosis (MS) and thyroiditis or
systemic diseases such as rheumatoid arthritis (RA) and SLE in which multiple organs can
be affected. Despite these differences, there are many common elements between the
various clinical diseases. Genome-wide linkage analysis shows that many autoimmune
diseases share common susceptibility loci (Maas, 2002). Different clinical diseases may
also over-lap within families or individuals. This would possibly indicate that common
groups of genes could contribute to the development of different autoimmune diseases.
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3.1.2

LIGHT and immune-mediated diseases

As mentioned previously, LIGHT plays important roles in a variety of different aspects of
the immune system including T cell co-stimulation (Harrop, 1998; Tamada, 2000), DC
maturation (Morel, 2001), mLN organogenesis (Wang, 2002) and negative selection of
thymocytes (Wang, 2002; Wang 2001). With such a diverse effect on the immune system,
LIGHT is a good candidate gene to have a role in the development of immune-mediated
diseases.

In 2001, two papers were published that identified the in vivo effects of T cells
overexpressing LIGHT using transgenic mice (Shiakh, 2001; Wang, 2001). Both groups
constitutively overexpressed LIGHT on T lymphocytes using lineage specific promoters.
These LIGHT-Tg mice developed a lymphoproliferative disorder with gross enlargement of
the spleen and LNs caused by the expansion of the T cell compartments. Haematoxylin and
Eosin (H&E) staining of the small intestine showed signs of chronic inflammation with
substantial infiltration of mononuclear cells, loss of goblet cells, distortion and hyperplasia
of the crypts and villus atrophy (Shiakh, 2001). Following in vitro activation of T cells
there was a significantly increased number of INF-γ, IL-4 and Granulocyte-monocyte
colony stimulating factor (GM-CSF) producing cells in LIGHT-Tg mice than in the WT
mice (Wang, 2001).
activation

of

GM-CSF leads to the preferential increase in GM lineages and

mature

macrophages

and

granulocytes.

Granulocytes

and

monocytes/macrophages are major effector cells of the immune response; elevated levels of
these cells in conjunction with high levels of activated T cells may cause the destruction of
peripheral tissue and ultimately lead to autoimmunity.
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In addition to severe intestinal inflammation, the LIGHT-Tg mice also developed
glomerulonephritis, involving 80% of the glomeruli and strong IgG deposits were observed
in the glomeruli of Tg mice (Wang, 2001). These manifestaions resemble those seen in
MRL-lpr/lpr mice, which is an established mouse model for SLE. The LIGHT-Tg mice
were also shown to have an 8-fold increase in anti-DNA autoantibodies, with there being
only a slight increase in total IgG levels when compared with WT mice (Wang, 2001).

These studies showed that while LIGHT could trigger symptoms of systemic
autoimmunity, overexpression of LIGHT had a particularly profound effect on the intestine.
Only memory and activated T cells have the ability to effectively migrate to peripheral
tissues (Masopust, 2001), while naïve T cells migrate to secondary lymphoid organs
(Butcher, 1999; von Andrian, 2001). Migration of T cells to effector sites such as the
lamina propria is facilitated by interaction with tissue-specific integrins and chemokine
gradients. Mucosal addressin cell adhesion molecule 1 (MAdCAM-1), which is expressed
at constitutively low levels in the intestine specifically promotes α4β7 integrin bearing T
cells to migrate to intestinal effector sites (Berlin, 1993).

LIGHT-Tg mice showed

increased in vivo expression of MAdCAM-1 on endothelial cells (Wang, 2004) and
recombinant LIGHT has been demonstrated to increase the expression of MAdCAM-1
(Wang, 2005). Peyer’s patches (PP) derived DC have the ability to induce high expression
of α4β7 integrin on T cells, as LIGHT plays a role in DC maturation, excessive LIGHT
could lead to increased PP DC maturation ultimately leading to increased numbers of T
cells with a predilection for the gut. Activation of LTβR on LP stromal cells by LIGHT
expressed on activated T cells leads to the creation of microenvironments that are
conducive to increased recruitment of cells to the LP (Fig 3.01) (Chin, 2003).
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To further prove that LIGHT-expressing T cells preferentially home to the gut an adoptive
transfer study was performed. The mLN cells were transferred from LIGHT-Tg mice into
recombination activating gene-1 knockout (RAG-1-/-) mice (Wang, 2005). The LIGHT-Tg
mLN cells caused severe intestinal inflammation in the recipient, whereas the transfer of
wildtype mLN cells into the RAG-1-/- model did not cause intestinal inflammation.

LIGHT knockout (LIGHT-/-) mice have also been generated, and their T cells show
decreased proliferation and release of cytokines in response to in vitro stimulation (Scheu,
2002).

This indicates the importance of LIGHT signalling via HVEM to allow full

activation of T cells. CD 8+ T cell responses in particular are sub-optimal in these LIGHT
knockout animals. Blocking LIGHT binding to its receptors using either HVEM-Ig or
LTβR-Ig recombinant fusion proteins has been shown to alleviate T cell-mediated
autoimmune diseases.

Insulin dependent diabetes mellitus (IDDM) is an autoimmune

disease caused by T cell-mediated destruction of insulin producing β cells of the pancreatic
islets of Langerhans (Bach, 1994).

The non-obese diabetic (NOD) mouse, a well-

established model for IDDM was used to test the role of LIGHT in T cell-mediated disease.
Treatment of the mice with HVEM-Ig significantly reduced the development of IDDM by
blocking LIGHT-signalling pathways (Wang, 2001).

LIGHT expression by T cells has been linked to a wide range of immune-mediated diseases
such as rheumatoid arthritis (Kim, 2005), Crohn’s disease (Wang, 2005; Cohavy, 2005),
ulcerative colitis (UC) (Mao-Mao, 2005) atherosclerosis (Lee, 2004) chronic heart disease
(Yndestad, 2002) autoimmune hepatitis (Anand, 2006) as well as graft verses host disease
(GVHD) (Tamada, 2000). The evidence overall, from both animal and human studies
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suggests that the overproliferation and hyperactivation of T cells caused by T cell derived
LIGHT can lead to the breakdown of self-tolerance. This implies that dysregulation of
LIGHT expression could be an important factor in the induction of both T and B cell
autoimmunity and in the pathogenesis of autoimmune diseases.

159

Fig 3.01 The role of LIGHT-LTβ
βR interactions in promoting chronic intestinal
inflammation (Adapted from Chin, 2003). Activated autoreactive T cells can migrate to
the lamina propria via upregulation of the integrin α4β7 which can bind to MAdCAM-1
which is constitutively expressed in the intestine. Activation of LTβR on LP stroma by
LIGHT on autoreactive T cells leads to increased expression of adhesion molecules,
chemokines and proinflammatory cytokines.

This leads to increased migration of

inflammatory cells to the LP in a positive feedback loop, leading to chronic inflammation
and tissue destruction. TCR, T cell receptor; MHC, major histocompatibility complex;
APC, antigen presenting cell.
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3.1.3

Mitogen activation of T cells

The first stage in the activation of T cells is the engagement of the T cell receptor (TCR)
with a MHC-peptide complex. Intracellular signalling through the TCR results in the
recruitment of a large number of proteins to its cytoplasmic domain and the activation of
enzymes such as phospholipase C (PLC).

PLC can convert phophatidyinositol 4, 5

phosphate (PIP2) to inositol 1, 4, 5 triphosphate (IP3) and diacylglycerol (DAG) two
important second messengers within cells. Increases in intracellular levels of IP3, result in
the generation of a Ca++ flux within cells and the activation of Ca++ dependent phosphatases
such as calcineurin. This in turn can cause the activation and translocation of transcription
factors such as NF-AT and AP-1 to the nucleus. DAG has a role in the activation of protein
kinase C (PKC). To date there have been nine isoenzymes of PKC identified, some are
ubiquitously expressed while others are tissue-specific. PKC isoenzymes generally require
both an increase in Ca++ and DAG to become activated.

However, PKCθ a T cell,

monocyte and platelet specific isoform can be activated by DAG alone (Newton, 1997).
PKCθ is rapidly recruited to the site of TCR clustering upon stimulation (Monks, 1997) and
deletion of the gene in knockout mice results in defective T cell activation (Sun, 2000).

Activation of T cells via the TCR can be mimicked in a number of ways; by using
monoclonal anti-CD3 antibodies, by the use of T cell specific lectins such as Concavalin A
(ConA) or Phytohaemaglutinin (PHA) or by using a combination of a phorbol ester such as
phorbol 12-myristate 13-acetate (PMA) and a calcium ionophore such as ionomycin. PMA
is an analog of DAG and thus it can directly bind and activate PKC isoenzymes.
Ionomycin is a polyether antibiotic produced by Streptomyces conglobatus (Liu, 1978).
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Ionomycin is capable of binding to divalent ions such as Ca++ and Mg++ in a 1:1
stoichiometry (Lui, 1978). The calcium salt of ionomycin is a very effective mobile carrier
of Ca++, leading to a flux of Ca++ within cells. In T cells, this results in the expression of
activation markers such as CD7 (Ware, 1991), or the hydrolysis of phosphoinositides and
the activation of PKC (Chatila, 1989). PMA and ionomycin can work in synergy to bypass
the TCR signalling and directly activate down-stream signal transduction pathways that
ultimately lead to activation of the T cell.

3.1.4

Jurkat T cells

The Jurkat T cell line was originally derived from peripheral blood of a 14-year-old boy
suffering from acute lymphoblastic leukaemia (ALL) (Schneider, 1977). The original line
was designated JM, but was heavily infected with mycoplasma. A bid to clear the cell line
of the infection yielded the Jurkat E6-1 clone, which has become the standard Jurkat cell
line used today (Abraham, 2004). The Jurkat cell has been used over the last 25 years by T
cell immunologists to identify many of the events following on from TCR simulation that
leads to activation of the cell and the initiation of an immune response (Abraham, 2004).
Incubation of Jurkat cells in the prescence of PMA and ionomycin induces a strong
activation response, as measured by the increased expression of IL-2 (Abraham, 2004).
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3.1.5

Interferon–gamma (INF-γγ)

The outcomes of an antigen driven T cell response is tightly regulated by cytokines, which
play a key role in dictating which T helper (Th) cell pathway is induced. The Th1 pathway
or cell-mediated immune response is characterised by the presence of IL-12, IL-2 and INFγ, whereas the Th2 pathway or humoral response is defined primarily by the production of
IL-4 and IL-10 (Mossman, 1989). These two pathways tend to be antagonistic of each
other, Th1 cytokines downregulate Th2 responses and vice versa.

The majority of

autoimmune diseases in both human and animal studies that are associated with specific
MHC class II allotypes have been characterised as being mediated by the Th1 pathway
(Rosloniec, 2002). INF-γ is the cytokine that defines Th1 differentiation (O’Shea, 2001)
and its role in autoimmunity has been extensively investigated. The INF-γ gene is located
on Chr 12q14 (Zimonjic, 1995) that codes for a mature protein of 146 amino acids. It is
expressed by activated Th1, NK and cytotoxic T cells and it has a wide range of
proinflammatory effects on various cells of the cell-mediated immune response. INF-γ has
been shown to enhance the activity of macrophages, induce proliferating B cells to switch
to IgG2a antibody production, increasing the expression of both MHC class I and II
molecules on various cells and inhibiting the proliferation of Th2 cells. SLE patients have
been shown to have elevated levels of both INF-γ mRNA and soluble protein in their
peripheral blood (Csiszár, 2000).

CD patients have also been demonstrated to show

increased expression of INF-γ in duodenal biopsies (Nilsen, 1998).
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3.1.6

Analysis of mRNA expression by Real-time PCR

Many cellular decisions such as differentiation, survival and growth are linked to altered
patterns of gene expression within the cell. The ability to quantify transcription levels of
specific genes has become a central part of research into their function and how they may
be altered during disease processes. Reverse transcription (RT) PCR remains the most
sensitive method for the detection of mRNA and coupled to a Real-time quantitative system
it has become the method of choice when assessing steady state mRNA levels (Bustin,
2000). The design of a quantitative RT-PCR has to take into consideration many factors
that may have an effect on the result.

The first decision is whether to use mRNA or total RNA as a target for the RT-PCR. The
use of mRNA has been reported to give better sensitivity (Burchill, 1999). However, extra
steps are needed to isolate it from the total RNA, which can result in loss of transcripts and
not all mRNA molecules have poly A tails (essential for enrichment of mRNA from total
RNA). Therefore, for most assays, the use of total RNA is advisable (Bustin, 2004).

The next decision to make is which type of primer will be used to generate cDNA from
mRNA during the RT phase.

The RT step can be primed using oligo-dT, random

hexamer/nonomers and target specific primers. Oligo-dT primers initiate RT by binding to
the poly A tail of mRNA molecules, therefore it cannot prime RNAs that lack a poly A tail
eg histone or viral RNAs (Bustin, 2004). Random primers initiate RT from multiple points
along the transcript. They yield the most amount of cDNA and can be useful for transcripts
that contain large amounts of secondary structure. Nonetheless, it has been reported that
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their use can lead to an overestimation of mRNA by ~19 fold when compared to targetspecific primers (Zhang, 1999). Target specific primers synthesize the most specific cDNA
and are probably the most sensitive option for quantification (Lekanne, 2002). A drawback
of using target specific primers is that separate priming reactions are necessary for each
individual target that is analysed, whereas the use of random/oligo-dT primers yields a
stock of cDNA which can be used to amplify multiple targets.

The last major factor to be considered is whether a one-step or two-step RT-PCR will be
required and the choice of RT enzyme. A one-step RT-PCR involves both the RT and PCR
phases being performed in the same reaction tube (Goblet, 1989; Mallet, 1995). In a twostep RT-PCR the RT step is performed in a separate reaction and then an aliquot of this is
added to the PCR for amplification of the specific target sequence. Each approach has its
advantages and disadvantages. The one-step is less time-consuming and the possibility of
cross-contamination is reduced. Nevertheless, this requires more RNA than a two-step RTPCR when analysing multiple mRNA targets, this only becomes a factor when samples are
very small and RNA is limited. The two-step allows multiple target mRNA to be PCRamplified from a single RT reaction.

There are several RNA dependent DNA polymerases on the market that can be used for
RT. The most common two are avian myeloblastosis virus reverse transcriptase (AMVRT) and Moloney murine leukaemia virus reverse transcriptase (MMLV-RT). AMV-RT is
a more robust enzyme and has a greater processivity than MMLV-RT (Brooks, 1995).
Both enzymes work optimally in the region of 37-42oC, which makes them susceptible to
problems during first strand synthesis if there is a high degree of secondary structure
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present. There are enzymes on the market, which to some extent can avoid problems with
RNA secondary structure such as Tth polymerase. Tth polymerase is derived from the
thermostable bacteria Thermus thermophilus (Myers, 1991). The enzyme in the presence of
Mn++ ions (Chiocchia, 1997) has both PCR and RT activities allowing a “single-enzyme”
one-step RT-PCR to be performed. Unlike AMV-RT and MMLV-RT, Tth polymerase is a
truly thermostable enzyme allowing the RT reaction to be carried out at a higher
temperature (61oC). Only the primer Tm limits the temperature at which the RT reaction
can be carried out. Carrying out RT reactions at a higher temperature (61oC instead of
45oC) has the advantage of relaxing secondary structure within the mRNA, which can
affect the ability of the RT enzyme to generate transcripts (Bustin, 2000).

The co-

purification of RT-PCR inhibitors during RNA extraction can present as a serious problem
to accurate and reproducible quantification of mRNA levels (Cone, 1992). Common PCR
inhibitors include heavy metals (Wilson, 1997), residual presence of heparin (anticoagulant) (Beutler, 1990) and haem compounds like haemoglobin (Akane, 1994) and
myoglobin (Belec, 1998). Tth polymerase has been shown to be very resistant to the
inhibitory effects of K+ and Na+ (Al Soud, 1998) and biological sample contaminants
(Poddar, 1998). The sensitivity of target mRNA detection using Tth polymerase has also
been reported to be very high, with detection of low abundance mRNA from a single cell
being possible (Chiocchia, 1997). Therefore, Tth polymerase displays many properties that
make it suitable for one-step, specifically primed, quantitative RT-PCR.
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3.1.7

Aim of this chapter

The TNF superfamily is an ever-growing group of powerful immunomodulatory molecules.
Each member has a complex role to play in the initiation or inhibition of an immune
response. As the family grows, the interactions of each of the members and their receptors
form an even more complex web of interacting effector pathways. Many lines of evidence
in both animal model and human studies indicate an association of aberrant LIGHT
expression with the development and maintenance of immune-mediated diseases. The aim
of this chapter is to examine the mRNA expression of LIGHT and its associated receptors
(HVEM, LTβR and DcR3) in CD and SLE. CD is characterised by profound inflammation
in the small intestine and SLE is associated with anti-DNA autoantibodies and
glomerulonephritis and these manifestations have been clearly identified in LIGHT-Tg
mice. We speculate that increase expression of LIGHT may contribute to the strong Th1
response associated with both conditions. A cohort of WG patients was also included in
the study, as the disease is characterised by the presence of autoantibodies and
glomerulonephritis.
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3.2

MATERIALS AND METHODS

3.2.1

Jurkat T cell stimulation

Jurkat cells were grown in RPMI 1640 (Sigma) supplemented with 10% fetal calf serum
(FCS) (Sigma), 2mM glutamine (Sigma) and penicillin/streptomycin solution (Sigma) and
incubated at 37°C in 5% CO2. For the stimulation time-course assay, cells were grown in 6
well tissue culture plates (Greiner) at 1x106 per ml. At time zero, cells were stimulated
using a combination of 10 ng/ml PMA (Sigma) and 1 µg/ml ionomycin (Sigma), unless
otherwise stated. Cells were harvested for RNA extraction over a period of 48 hrs.

3.2.2

Patient Samples

Whole blood samples (3 ml) were collected into sterile EDTA Vacutainer tubes from 35
healthy controls, 27 CD, 15 WG and 14 SLE patients. Consent was obtained from all
patients in accordance with both the Dublin Institute of Technology’s ethics review board
and St James’s hospital ethics review board.

As samples for medical based research are becoming more difficult to obtain, we decided to
use existing intestinal tissue that had been collected as part of a wider study investigating
the molecular mechanisms involved in the destruction of epithelial cells in CD patients.
For that study the epithelial layer was striped from the duodenal biopsy using an enzymatic
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digestion protocol, samples were then frozen and transported on dry ice before being
processed for RNA extraction. The samples collected included 9 patients with untreated or
active disease, 2 treated patients that were on a GFD and 4 disease controls. Intestinal
biopsies were collected from CD patients undergoing routine diagnosis at St James’s
hospital and all patients had given informed consent.

3.2.3

Total RNA isolation from cultured Jurkat T cell and peripheral
blood leukocytes

Erythrocytes were lysed in red blood cell (RBC) lysis solution (155mM ammonium acetate,
10mM Potassium Hydrogen Carbonate, 1mM EDTA). PBL were pelleted at 3000 rpm for
5 minutes at room temperature. The PBL pellet was then briefly washed in RBC lysis
solution, before being homogenised in 1 ml of Tri reagent (Invitrogen) using a sterile 23g
needle and syringe. Tri reagent combines phenol and guanidine thiocynate in a monophase solution to facilitate the immediate and most effective inhibition of RNase activity.
Total cellular RNA was extracted as per the manufacturer’s instructions; RNA pellets were
resuspended in RNase free water and samples were stored at –80°C pending further
analysis. Cell lines were spun at 3000 rpm for 5 mins to remove cell culture media, RNA
was then extracted from these in the same manner as WBCs.
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3.2.4

Total RNA isolation from duodenal biopsies

Biopsy material was transported on dry ice and stored at –80°C before processing for RNA
isolation. Three biopsies were used for each patient, firstly the biopsies were teased apart
in 100µl of Tri reagent (Invitrogen) on a sterile microscope slide which had been pretreated with RNAzap (Sigma). The crudely broken down sample was then transferred to a
1.5 ml eppendorf where and additional 100 µl of Tri-reagent was added, the sample was
then further broken down using a motorised pellet pestle (Sigma). Finally, a further 800 µl
of tri-reagent was added to the eppendorf and passed through a 23g needle several times.
This processing ensured full homogenisation of the sample. Total RNA was then isolated
as per the manufacturers instructions.

3.2.5

Isolation of peripheral blood mononuclear cells (PBMCs) and
granulocytes

PBMCs were isolated using Histopaque-1077 (Sigma). Histopaque-1077 is a solution of
polysucrose and sodiumdiatrizoate, adjusted to a density of 1.077 g/ml.

During

centrifugation, erythrocytes and granulocytes are aggregated by the polysucrose and rapidly
sediment. Lymphocytes and other mononuclear cells remain at the plasma/histopaque1077 interface. PBMC were isolated as per the manufacturer’s instructions. The resulting
PBMC pellet was processed for total RNA isolation using Tri-reagent. The granulocytes
were retrieved from the sedimented pellet following histopaque-1077 separation from the
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PBMCs. The pellet contains a mix of granulocytes and erythrocytes. Erythrocytes were
lysed using RBC lysis buffer and following centrifugation the resulting granulocyte pellet
was processed for total RNA isolation using Tri-reagent.

3.2.6

Total RNA quantification

Total RNA from the cell lines, peripheral blood and duodenal biopsies was quantified using
RiboGreen quantitation reagent (Molecular probes).

Ribogreen is an ultra sensitive

fluorescent stain for quantifying RNA in solution. The assay was carried out as per the
manufacturer’s instructions and measurements were taken on a VersaFluor™ Fluorimeter
(BioRad). The total RNA concentration of each sample was quantified in this manner and
then samples were diluted in nuclease-free water (Gibco) to a working concentration of 50
ng/µl, which was determined to be sufficient for Real-time PCR analysis.

3.2.7

Standard curve preparation for quantitative Real-time
PCR

In order to carry out absolute quantification a series of standards were produced. This was
done by cloning the PCR product of interest into the multiple cloning site of a pCR TOPO
2.1 vector (Invitrogen) as stated in the manufacturer’s instructions.

White positive

transformed bacterial colonies were selected and isolation of the recombinant plasmid was
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carried out using a Wizard® Plus SV miniprep DNA purification system (Promega).
Purified plasmid was quantified using a Fluorescent DNA quantitation kit (BioRad) and
fluorescent measurements were taken on a VersaFluor™ Fluorimeter (BioRad).

This

allowed the exact number of plasmid molecules per µl of plasmid miniprep to be calculated
as follows (Whelan, 2003):

Weight in Daltons (g/mol) = (bp size of ds product)(330 Daltons X 2nt/bp)
Hence: (g/mol)/Avogadro’s number = g/molecule = copy number

(Where: bp = base pair, ds = double stranded, nt = nucleotide, Avogadro’s number = 6.023
X 1023)

Each plasmid contains a single copy of our sequence of interest. These could then be used
to generate accurate standards for quantitative Real-time PCR over the range of 1x107 to
1x102 copies.

3.2.8

Real-time quantitative PCR

One-step quantitative RT-PCRs were performed on a LightCycler (Roche) using a
LightCycler RNA master hybridisation probes RT-PCR kit (Roche). This kit utilises the
ability of Tth polymerase to carry out both RT and PCR activities in the presence of Mn++
ions. Primers and hybridisation probes (Table 3.01) used in this study were designed using
the LightCycler probe design software (Roche). Primers were designed so they spanned
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exon-intron boundaries so that they would not amplify sequences from genomic DNA. In
the case of quantifying LIGHT and the splice variant deltaLIGHT the same primers are
used but the LIGHT hybridisation probes bind to the region that is spliced out in the
alternative transcript and therefore detect only the full-length message (Fig 3.02). The
deltaLIGHT hybridisation probes span across the splice site and can therefore only cause
fluorescent resonance energy transfer (FRET) when bound to the spliced message. In this
way, we can track changes in the levels of the two different spliced variants of LIGHT.
The one-step quantitative RT-PCR thermocycling conditions were as follows 61°C for 20
mins, 95°C for 2 mins followed by 45 cycles of 95°C for 0s, 55 °C for 12s and 72°C for
14s.

Fig 3.02

Placement of hybridisation probes to selectively detect different splice

variants of LIGHT.

The first set of hybridisation probes (set 1), bind to a sequence

within the spliced region, which is only present in the full-length mRNA transcript. The
second set of hybridisation probes (set2) span the splice junction site and are therefore
separated in the full-length transcript. In the alternative transcript, they can bind in close
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proximity to each other allowing FRET to occur. The advantage of this system is that only
one set of primers is used to amplify both transcripts, this will ensure that the efficiency of
both PCRs will be similar allowing levels to be directly compared.

3.2.9

Statistical analysis

A non-parametric Mann-Whitney U-test was performed to compare the median mRNA
expression of two sample populations for statistical differences. P values were two-sided
and statistical significance was considered when P ≤ 0.05.

Correlations between the

expression of different mRNAs within a sample group were measured using Spearman’s
rank order correlation coefficient. Results were deemed to be statistically significant when
P ≤ 0.05. A students T test was performed to compare the mean mRNA expression values
from the different cell populations in the control and SLE patients. P values were twosided and statistical significance was considered when P ≤ 0.05.
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Primer/hybridisation probe seq (5’ to 3’)

Conc (µM)

LIGHT
Forward
Reverse
Probe 1
Probe 2
deltaLIGHT
Probe 1
Probe 2

GACAGACCGACATCCCATT
TGCTGGGTTGACCTCGT
GCTGCACTGGCGTCTAGGAGAGA-f
x-CGTCACCCGCCTGCCTGACG-p
ACCGGAGACAGTGGTGCAGTGTGG-f
x-CCGGGACGGACCTGCAGG-p

1.0
1.0
0.2
0.2
1.0
1.0

HVEM
Forward
Reverse
Probe 1
Probe 2

ATGTAGTCAAGGTGATCGT

Forward
Reverse
Probe 1
Probe 2

TTTCTGCTTGGAGCAC

Forward
Reverse
Probe 1
Probe 2

GCAAAAATCCATTAGAGC

GTATCTCTGGCGTCGG
GGTGGCCGTGGAGGAGACAATACCCTCATTCACG-f
x-CGAGGAGCCCAAACCACTGACCCA CAGACTCT-p

0.2
0.2
0.2
0.2

DcR3
CCTCTTGATGGAGATGT
CACCTTCTCAGCCAGCAGCTCCAGCTCAG-f
x-CAGTGCCAGCCCCACCGCAACT-p

1.0
1.0
0.2
0.2

LTβR
GGAAGTATGGATGGGC
GAAACTGGGATCGCTGCTCAAGAGGC-f
x-CCGCAGGGAGAGGGACCC-p

1.0
1.0
0.2
0.2

INF-γ
Forward CAAAAGAGTGTGGAGACC
1.0
Reverse TCGACCTTGAAACAGCA
1.0
CCAACGCAAAGCAATACATGAACTCATCCAAGTGATG
Probe 1
0.2
Probe 2

GC-f
x-CAACTGTCGCCAGCAGCTAAAACAGGGAAGCG-p
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0.2

Table 3.01 Primers and hybridisation probes used for Real-time quantitative RT-PCR.
Fluorescein (f); phosphate (p); LCRed 640/705 dye (x).

3.3

RESULTS

3.3.1

Standard curve generation for absolute quantification

To perform absolute quantitative Real-time PCR a series of standards were produced for
each of the mRNAs being analysed in this study. To do this the PCR products generated
using the primers in Table 3.01 for each of the mRNA species and were cloned into a pCR
2.1 TOPO vector. Positive recombinant plasmids could then be grown in bacterial culture
from which stocks of the plasmids could be purified and the copy number calculated. Once
the copy number was calculated, standard curves could be generated by serially diluting the
recombinant plasmid over the range of 1 X 107 to 1 X 102, an example of a typical result is
seen in Fig 3.03. Using this method to generate standard curves, from which unknown
samples could be measured, proved to be very reproducible from assay to assay (Fig 3.04).
Using the slope of each standard curve the efficiency of each PCR could be established. As
can be seen from Table 3.02 each of the quantitative PCRs has a very high efficiency
(~100%) indicating that the RT-PCR protocols have been successfully optimised.
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Fig 3.03 Real-time standard curve for quantifying LIGHT mRNA copy numbers. This
curve has a wide dynamic range of 6 orders of magnitude.

Fig 3.04 Reproducibility of crossing point verses starting copy number of LIGHT
plasmid molecules.
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Real-time PCR efficiency calculations
Slope

E = 10-1/slope % E

LIGHT

-3.324

1.999

99.96

deltaLIGHT

-3.254

2.029

101.46

HVEM

-2.908

2.207

110.37

LTβ
βR

-3.503

1.930

96.48

INF-γγ

-3.063

2.121

106.03

DcR3

-3.808

1.831

91.53

Table 3.02 PCR efficiency for quantitative RT-PCR protocols.

Efficiency (E) is

calculated for the slope of the standard curve. E = 2 is equivalent to E = 100%, indicating
that there is optimal amplification of the amplicon during the PCR phase.
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3.3.2

Total RNA extraction

The extraction of high quality RNA is essential in any gene expression study. We used a
commercial RNA extraction solution called Tri-reagent to perform total RNA isolation
form the cells and tissue used in this study. This protocol is quick and allows the extraction
of high quantity RNA as indicated by a strong 28S and 18S ribosomal bands. Fig 3.05
shows 4 total RNA samples as a representative of the high quality RNA isolated using this
method, each lane contains approximately 1µg of total RNA.

Fig 3.05 Total RNA extracted using Tri-reagent.
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3.3.3

Effect of PMA concentration on the expression of LIGHT

In order to ensure that we could measure changes in mRNA expression using our RT-PCR
protocol we used the Jurkat T cell line as an in vitro model. In the first experiment using
Jurkat cells, we tested the effect that 24 hr stimulation using PMA and ionomycin (P/I)
would have on the expression of LIGHT mRNA. This demonstrated that the stimulation of
LIGHT message is dependent on PMA, (Fig.3.06) ionomycin alone is insufficient to induce
expression. From this experiment it was decided that 10ng/ml PMA and 1µg/ml ionomycin
was sufficient to induce an upregulation of LIGHT mRNA in Jurkat T cells and these
concentrations were used in further experiments.

Fig 3.06 LIGHT mRNA expression is dose dependent on PMA. 1: RPMI control; 2:
1µg/ml ionomycin; 3: 10ng/ml PMA; 4: 1ng/ml PMA and 1µg/ml ionomycin; 5: 10ng/ml
PMA and 1µg/ml ionomycin; 6: 100ng/ml PMA and 1µg/ml ionomycin
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3.3.4

Effect of stimulation on mRNA expression over 48hrs

While the kinetics of LIGHT and HVEM expression have been previously established
(Granger, 2001) the quantification of their mRNA changes over a 48 hr period would
provide a good test for our Real-time RT-PCR protocol. Jurkat cells were cultured for 48
hrs in the presence or absence of P/I, cells were harvested at various time-points and the
expression of LIGHT, deltaLIGHT and HVEM mRNA were analysed. Visible changes in
the levels of LIGHT mRNA expressed occur after ~ 8 hrs and steadily increased and by 24
hrs there was approximately an 8-fold increase in LIGHT expression (Fig 3.07) when
compared with the RPMI control. By 48 hrs the level of LIGHT mRNA has completely
diminished back to low basal levels. The expression of deltaLIGHT shows a similar
pattern of expression to LIGHT following stimulation, mRNA levels peak at 28 hrs with an
approximate 7 fold increase in message levels (Fig 3.07). At the 48 hr time point the
expression of deltaLIGHT mRNA remains ~ 2.5 fold higher than the RPMI control. In
contrast to LIGHT, HVEM mRNA levels undergo a rapid downregulation with changes
seen as early as 4 hrs. After 24 hrs there is approximately a 3.5 fold decrease in the total
amount of HVEM mRNA expressed, and by 48 hrs expression starts to return to normal
basal levels (Fig 3.08).
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Fig 3.07 48hr expression pattern of LIGHT and deltaLIGHT mRNA following
stimulation of Jurkat T cells. Stimulation was carried out using PMA (10ng/ml) and
ionomycin (1µg/ml). The results are expressed as fold change of the RPMI control at each
time point.

182

Fig 3.08 48hr expression pattern of HVEM mRNA following stimulation of Jurkat T
cells. P/I: PMA (10 ng/ml) and ionomycin (1 µg/ml). The results are expressed as fold
change of the RPMI control at each time point.
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3.3.5

Expression of mRNA in peripheral blood of test cohorts

Once we established that our Real-time PCR protocol was suitable for detecting changes in
the level of mRNA using the Jurkat T cells, we proceeded to quantify the levels of mRNA
expressed in the periphery of a normal control (NC) cohort (35 samples) and of patients
with CD (27 samples), WG (15 samples) and SLE (14 samples).

The expression of

LIGHT, deltaLIGHT, HVEM, DcR3, LTβR and INF-γ mRNA were analysed for all the
groups (Fig 3.09 – 3.14). When the CD cohort was compared to the control group, no
statistical differences were seen between the two groups for any of the mRNA species with
the exception of INF-γ (P = 0.008). The WG cohort showed lower expression of LIGHT (P
= <0.0001) and deltaLIGHT (P = 0.002) than the control group. Whereas the levels of
HVEM, LTβR, DcR3 and INF-γ mRNA expression in the periphery were not statistically
different from that of the control cohort. The SLE patients showed a lower expression of
LIGHT (P = 0.002), no change was seen in the levels of DcR3 and elevated levels of
deltaLIGHT (P = 0.05), HVEM (P = <0.0001), INF-γ (P = <0.0001) and LTβR (P = 0.024)
were seen when compared to the control cohort.
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Fig 3.09 Expression of LIGHT mRNA in PBL of the patient cohorts. The number in
brackets indicates the number of patients within the test group and the yellow line marks
the mean of the group. ** Indicates a group that is significantly different from the controls.
No difference was seen between the controls and the CD patients (P = 0.831). However, a
statistically significant lower expression of LIGHT mRNA was seen in the WG (P
<0.0001) and SLE patients (P = 0.002).
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Fig 3.10 Expression of deltaLIGHT mRNA in PBL of the patient cohorts. The number
in brackets indicates the number of patients within the test group and the yellow line marks
the mean of the group. ** Indicates a group that is significantly different from the controls.
No difference was seen between the controls and the coeliac (CD) patients (P = 0.345). A
statistically significant lower expression of deltaLIGHT mRNA was seen in the WG group
(P <0.0001). The SLE patients showed a statistically significant higher expression of
deltaLIGHT mRNA than the normal controls (P = 0.017).
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Fig 3.11 Expression of HVEM mRNA in PBL of the patient cohorts. The number in
brackets indicates the number of patients within the test group and the yellow line marks
the mean of the group. ** Indicates a group that is significantly different from the controls.
No difference was seen between the controls and either the CD patients (P = 0.798) or the
WG patients (P = 0.484).

The SLE patients showed a statistically significant higher

expression of HVEM mRNA than the control group (P = < 0.0001).
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Fig 3.12 Expression of DcR3 mRNA in PBL of the patient cohorts. The number in
brackets indicates the number of patients within the test group and the yellow line marks
the mean of the group. No difference was seen between the controls and either the CD
patients (P = 0.232), the WG patients (P = 0.596), or the SLE patients (P = 0.521).
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Fig 3.13 Expression of LTβ
β R mRNA in PBL of the patient cohorts. The number in
brackets indicates the number of patients within the test group and the yellow line marks
the mean of the group. ** Indicates a group that is significantly different from the controls.
No difference was seen between the controls and the CD patients (P = 0.118) or the WG (P
= 0.275). A statistically significant higher expression of LTβR mRNA was seen in the SLE
group (P = 0.024).
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**

Fig 3.14 Expression of INF-γγ mRNA in the PBL of the patient cohorts. The number in
brackets indicates the number of patients within the test group and the yellow line marks
the mean of the group. ** Indicates a group that is significantly different from the controls.
No difference was seen between the controls and the WG patients (P = 0.589).

A

statistically significant higher expression of INF-γ mRNA was seen in the CD (P = 0.008)
and SLE (P <0.0001) patient groups.
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3.3.6

Adjustment of mRNA expression based on lymphocytes counts

Lymphocyte counts were obtained for all patients included in the study with the exception
of 2 CD and 1 SLE patient. Lymphocyte counts were only available for 6 samples of the
control group at the time that blood was donated for the study. Re-adjustments were made
to the Real-time quantitative RT-PCR data based on these lymphocyte counts. As we had
speculated the expression of LIGHT in both SLE and WG was no longer significantly
reduced when the data was analysed in this manner (Fig 3.15). The mRNA expression of
deltaLIGHT, DcR3 and INF-γ was identified to be significantly elevated in the SLE cohort
(P <0.05). The levels of LIGHT mRNA were identified as being elevated in the CD cohort
(<0.05).

The WG cohort showed very similar levels of expression for LIGHT,

deltaLIGHT, DcR3 and INF-γ as the control group. Correlations between LIGHT or
deltaLIGHT and DcR3 and INF-γ mRNA expression were made for the SLE cohort (Fig
3.16). LIGHT mRNA expression correlates strongly with both DcR3 (Rs =0.643; P < 0.05)
and INF-γ (Rs = 0.687; P < 0.05) mRNA levels in the SLE patients. DeltaLIGHT mRNA
expression also positively correlated with DcR3 (Rs = 0.676; P < 0.05) and INF-γ (Rs =
0.775; P < 0.05) levels of mRNA.
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Fig 3.15 Adjustment of LIGHT, deltaLIGHT, DcR3 and INF-γγ mRNA expression
based on lymphocyte counts. The yellow line indicates the mean of each group, **
indicates a cohort that was significantly different form the control group (NC) i.e. P ≤ 0.05.
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Fig 3.16 Positive correlation of LIGHT/deltaLIGHT with both DcR3 and INF-γγ in
SLE patients.

Correlations were tested using the Spearman’s rank correlation test.

Spearman’s correlation rank coefficient (Rs) and P value are included with each separate
graph.
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3.3.7

Stratification of CD patients based on tTG serology

For further analysis of the CD cohort we divided the samples into 2 groups based on
whether they were positive or negative for anti-tissue transglutaminase autoantibodies (antitTG) at the time of sample collection (Fig 3.17 A). Based on this subdivision of the
samples the anti-tTG positive CD patients show a higher expression of LIGHT mRNA than
the normal controls (P = 0.018). The tTG negative CD samples fall in between the positive
tTG patients and the NC cohort, not being significantly different from either group. The
expression of deltaLIGHT mRNA follows a similar trend to that of LIGHT, with the
highest expression in the tTG positive patients, the negative tTG patients in the middle and
the NC showing the lowest expression of deltaLIGHT (Fig 3.17 B), however the results
were not deemed to be statistically significant. The HVEM mRNA data was also stratified
based on the tTG serology and these results were reciprocal to that of LIGHT (Fig 3.17 C).
The highest levels of expression were found in the NC cohort. The tTG positive patients
showed a significant reduction in HVEM compared with the NC group (P = 0.025). The
tTG negative patients, in a similar manner to LIGHT and deltaLIGHT expression, are
situated between the NC and tTG positive cohort.
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Fig 3.17 Gene expression in CD patients stratified on basis of tTG serology.
** Indicates that groups are significantly different (P<0.05) from the NC group.
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3.3.8

Upregulation of HVEM mRNA in granulocytes

PBMCs and granulocytes were isolated from two control and two SLE samples to test the
hypothesis that HVEM was being overexpressed on cells other than lymphocytes. The
results of this experiment showed that there was a statistically significant decrease in
HVEM mRNA expression in PBMCs isolated from SLE samples when compared with
controls (P = 0.025). However, there was a very significant increase in HVEM mRNA
expression in the granulocyte cells isolated from SLE samples when compared with
controls (P = 0.031). Both LIGHT and deltaLIGHT mRNAs were significantly increased
in the PBMC isolated from SLE patients with very little mRNA for both variants being
detected in the granulocyte cell population (Fig 3.18).
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Fig 3.18 mRNA expression in PBMCs and granulocytes isolated from normal control
(NC) and SLE patients. P values are indicated above each group, P <0.05 was taken to be
statistically significant.
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3.3.9

Gene expression within the coeliac intestinal lesion

As LIGHT overexpression has a predilection to cause intestinal inflammation, we analysed
the expression of LIGHT, deltaLIGHT, HVEM, LTβR and INF-γ in the lamina propria of
untreated CD (9 samples), treated CD (2 samples) and non-CD (4 samples) patients.
LIGHT mRNA is significantly increased in untreated CD patients when compared with the
non-CD group (P = 0.05). LIGHT mRNA also remained elevated in the treated CD
patients however statistical significance was not achieved due to the small number of
samples in this group (Fig 3.19). The expression of deltaLIGHT did not reach statistical
significance difference between the untreated CD and control samples, however a general
expression pattern similar to that of LIGHT was identified (Fig 3.20). The expression of
HVEM mRNA in the different groups was reciprocal to that of LIGHT. The untreated CD
patients had a significant decrease in mRNA expression when compared with both the nonCD (P = 0.032) and treated CD (P = 0.0003). HVEM levels in the treated CD were
comparable to that of the non-CD cohort (Fig 3.21). LTβR expression patterns were
similar in all three tested groups (Fig 3.22). As to be expected, the expression of INF-γ
mRNA was significantly elevated in the lamina propria of the untreated CD patients when
compared with the non-CD patients (P = 0.05). As was the case with HVEM, the levels of
INF-γ mRNA in the treated CD were comparable with non-CD patients (Fig 3.23).

In addition to the expression of the above mRNA species, we also examined the levels of
IL-2, LT-β and BTLA mRNA in the intestinal biopsy samples. IL-2 a Th1 cytokine that
promotes the expansion of T cells has been previously reported to be elevated in CD
(Lahat, 1999). Therefore, like INF-γ it acts as a positive control as it should be elevated in

198

the untreated CD patients. As expected, there is a significant difference (P <0.05) between
the untreated CD and control cohorts (Fig 3.24 A). As LTα1β2 can also act as a ligand for
LTβR, the mRNA expression of the LTβ subunit was also quantified. Our quantitative
analysis shows that LTβ is not regulated at least at the mRNA level in the CD lesion (Fig
3.24 B). BTLA a recently discovered ligand for HVEM (Sedy, 2005; Gonzalez, 2005) can
suppress T cell responses. In our cohort of untreated CD patients, there is a significant
reduction in the level of BTLA expressed in the lamina propria when compared to the
control group (Fig 3.24 C). The expression of BTLA in the treated CD patients was similar
to that of the controls and was significantly higher than the untreated patients (P < 0.05).
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Fig 3.19 Expression of LIGHT mRNA in intestinal lamina propria. Controls, green;
Untreated CD, blue; treated CD, red. The yellow line indicates the mean of each group. A
significant increase in mRNA expression was seen between the control and untreated CD
groups (P = 0.05). No statistically significant difference was seen between the control and
treated (P = 0.111) and the untreated and treated (P = 0.495) groups.
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Fig 3.20 Expression of deltaLIGHT mRNA in intestinal lamina propria. Controls,
green; Untreated CD, blue; treated CD, red. The yellow line indicates the mean of each
group.
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Fig 3.21 HVEM mRNA expression in intestinal lamina propria.

Controls, green;

Untreated CD, blue; treated CD, red. The yellow line indicates the mean of each group.
No significant change was seen between the control and treated CD groups (P = 0.404). A
statisically significant difference was seen between the control and untreated (P = 0.032)
and the untreated and treated (P = 0.0003) groups.
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Fig 3.22

LTβ
βR mRNA expression in intestinal lamina propria.

Controls, green;

Untreated CD, blue; treated CD, red. The yellow line indicates the mean of each group.
No significant change was seen between the control and treated CD patients (P = 0.283)
and the untreated cohort (P = 0.722).
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Fig 3.23

INF-γγ mRNA expression in intestinal lamina propria.

Controls, green;

Untreated CD, blue; treated CD, red. The yellow line indicates the mean of each group.
No significant change was seen between the control and treated CD groups (P = 0.991). A
statistically significant difference was seen between the controls and untreated (P = 0.034).
The change seen between the untreated and treated groups did not reach statistical
significance (P = 0.108).
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Fig 3.24 Expression of IL-2, LTβ and BTLA in the lamina propria. Controls, green;
Untreated CD, blue; treated CD, red. **Indicates a groups that is significantly different
from the control samples (P<0.05)
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3.4

DISCUSSION

3.4.1 Gene expression analysis using Real-time quantitative PCR

Cells have the ability to alter their mRNA copy numbers; this is a crucial element in the
regulation of gene expression in response to a wide range of endogenous and exogenous
stimuli. Many disease processes are also associated with alterations in gene expression
patterns within cells. In recent years, quantitative Real-time RT-PCR has become the gold
standard technique for quantifying alterations in gene expression (Bustin, 2004). This
technique has a wide dynamic range (10-1010 copies) (Saunders, 2004), is highly sensitive
and specific for the amplicon of interest when specific probes are used.

In this study, the aim was to develop a quantitative Real-time RT-PCR to measure the
levels of LIGHT, its splice variant deltaLIGHT and associated receptors (HVEM, LTβR
and DcR3). INF-γ was also included in the study as its role in Th1 mediated diseases is
well documented. In designing the RT-PCR protocol, we decided on a one-step RT-PCR
approach, due to the ease of RT-PCR set up, which helps to reduce pipetting steps, and
hence possible errors. There is also be a reduced risk of cross-contamination of samples
with this approach. Of the various enzymes on the market, Tth polymerase was selected for
use in this study. This enzyme, as mentioned previously, is capable of performing both RT
and PCR stages when Mn++ ions are present. This allows the use of one enzyme to perform
both stages rather than having to employ separate RT and PCR compatible enzymes such as
AMV-RT and Taq polymerase. Tth also works optimally at a specific concentration of
Mn++ ions (3.25 mM), thereby reducing the need to optimise this parameter, as would be
206

the case when using Mg++ ions with Taq polymerase. Tth is also a thermostable enzyme
and works optimally at 61oC. This has the advantage of relaxing secondary structure that
forms within mRNA molecules, which can prevent them from being efficiently reverse
transcribed (Bustin, 2000).

We initially approached this study with the idea of performing relative quantification by
expressing our target mRNA as a ratio of a housekeeping gene. Housekeeping or reference
genes are those whose expression should remain at a constant level within a cell. At the
outset of this study, the levels of six commonly used housekeeping genes (HPRT, ALAS,
beta-globin, beta-2-microglobulin, G6PDH and PBGD) were measured in 11 normal
control samples (data not shown). It was found that the expression varied from sample to
sample, by up to 2 log fold for some of the genes tested. These results indicated that none
of these housekeeping genes were suitable for performing relative quantification. Hence,
we switched to performing absolute quantification instead.

Absolute quantification provides a more accurate and reliable, albeit more labour intensive
method for the quantification of nucleic acids (Ke, 2000). A series of standards are
generated and a plot of Cp verses log concentration allows the Cp of the unknown samples
to be compared to the standards. Using this method, our standard curves were highly
reproducible (Fig 3.04) from assay to assay, allowing accurate quantification data to be
obtained. Normalisation of the data was done by quantifying the total RNA in each sample
using Ribogreen fluorescent dye and copy number of each mRNA molecule was expressed
per 50 ng of total RNA. The use of Ribogreen is a proven method for normalisation of
samples for quantitative RT-PCR (Hashimoto, 2004).
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3.4.2

Gene expression in Jurkat T cells

Once the quantitative Real-time RT-PCR assays were optimised, the next stage was to
ensure that changes in mRNA copy numbers could be measured with our system.
Consequently, it was decided to use the Jurkat T cell line stimulated with PMA and
ionomycin as an in vitro model of T cell activation. In the first experiment using the Jurkat
cell line, we showed that the optimal induction of LIGHT mRNA in these cells requires the
synergistic stimulation by both PMA and ionomycin. Cells that were incubated with both
PMA and ionomycin showed a marked increase in LIGHT mRNA expression, which was
dose-dependent on PMA concentration (Fig 3.06). This result is similar to previously
reported findings (Granger, 2001).

Following on from the initial Jurkat results, we performed a time-course experiment to
show the kinetics of LIGHT mRNA expression over a 48-hour period post stimulation with
PMA and ionomycin. From a previous study, it had been demonstrated that there is a
reciprocal expression of HVEM and LIGHT upon activation of primary T cells (Morel,
2000). This study used a combination of FACS analysis and semi-quantitative PCR to
demonstrate that there was a reciprocal expression pattern of HVEM and LIGHT in
activated T cells.

Our results from the Jurkat T cell time course experiments also

demonstrated this.

Resting T cells, in this case Jurkat cells at time zero, express little or no LIGHT mRNA
whereas HVEM mRNA is at maximum levels. Following activation, as LIGHT levels
begin to increase, HVEM mRNA is downregulated as seen in Figs 3.07 and 3.08
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respectively. We also demonstrated that deltaLIGHT mRNA transcripts follow a similar
pattern to that of the full-length variant of LIGHT. By 48 hrs HVEM mRNA levels are
starting to return to high basal levels and the level of LIGHT mRNA expressed has been
downregulated to that of non-stimulated cells. Conversely, deltaLIGHT mRNA, remained
approximately 2.5 fold higher than the RPMI control at the 48 hr time-point. This may
indicate that either downregulation, post activation, of deltaLIGHT mRNA transcription
takes longer than that of LIGHT or that once activated, T cells continue to express
deltaLIGHT transcripts even as the cell returns to a resting state. Evidence to support the
latter option comes from a study where memory T cells from the periphery were isolated
and it was demonstrated that these cells had an intracellular pool of LIGHT (Morel, 2003).
This study did not identify which variant of LIGHT protein was detected in their system.
The deltaLIGHT protein is retained in the cytosol as it loses its transmembrane domain as
part of the splicing process (Granger, 2001). Therefore it is possible that this intracellular
store of LIGHT in resting central and effector memory CD4+ T cells is actually
deltaLIGHT, hence the increased level of expression of deltaLIGHT in our Jurkat cells
even after LIGHT has returned to low basal levels.

3.4.3

Gene expression in peripheral blood leukocytes

Once we had established that we could measure changes in mRNA expression using our
Real-time RT-PCR protocol we set about collecting patient samples. The diseases chosen
to be included in the study were SLE, CD and WG, diseases whose symptoms were related
to autoimmune manifestations seen in LIGHT-Tg mice (Shiakh, 200; Wang, 2001).
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LIGHT-Tg mice as mentioned previously, have high levels of autoantibodies such as antiDNA antibodies, a hallmark of SLE (Hochberg, 1997), they also have chronic
inflammation in the small intestine with villous atrophy and crypt hyperplasia which are
symptoms strongly associated with CD (Marsh, 1992). WG was included in the study as it
is also characterised by the production of autoantibodies and glomerulonephritis (van der
Woude, 1985; Fauci, 1983).

We initially measured the mRNA expressed in PBLs from each of the cohorts. The mRNA
copy numbers were expressed per 50 ng of total RNA added to the quantitative RT-PCR.
This did have some advantages; most notably, it allowed us to see that the HVEM
expression was possibly elevated in cells other than lymphocytes in the SLE cohort.
However, by relating the expression back to total RNA we inadvertently skewed the results
because the SLE and WG had lower lymphocyte counts compared to the other two groups.
Consequently, the true expression levels of LIGHT, deltaLIGHT, DcR3 and INF-γ mRNA
were masked due to the presence of RNA from many cells that were not expressing these
molecules. We readjusted the way in which mRNA copy numbers were expressed so that
they were based on lymphocyte counts at the time of blood sampling. This proved to be
another advantage of using absolute quantification, as once the mRNA copy numbers are
obtained the denominator (ie per µg total RNA or cell number etc) can be altered to be
more reflective of the circumstances.
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3.4.4

LIGHT, associated receptors and SLE

SLE is a prototypical autoimmune disease that is genetically complex and characterised by
the presence of many different autoantibodies, formation of immune complexes (ICs) and
inflammation in multiple organs, including the skin, blood vessels, kidneys and central
nervous system (Rönnblom, 2002; Bennett, 2003). The major pathogenic antibodies are
directed against nuclear components such as dsDNA, nucleosomes and snRNP (Mok,
2003). Overexpression of LIGHT in Tg mice induced the development of anti-DNA
antibodies and lupus-like glomeruolnephritis (Wang, 2001). This indicated that LIGHT
might be a good candidate gene to play a contributing role in the pathogenesis of human
SLE.

When the expression of LIGHT mRNA in PBLs of our control and SLE cohorts were
analysed (Fig 3.09) a significant reduction in LIGHT mRNA was identified in the SLE
cohort. A lymphocytopenia is common in SLE, we speculated that the reduction in LIGHT
was artifactual, due to the lower number of lymphocytes (the primary cells expressing
LIGHT) within these samples compared to the controls. Therefore, as mentioned the
results were adjusted to reflect the amount of lymphocyte mRNA contained in each sample
(Fig 3.15). This showed there was no reduction in LIGHT mRNA expression in SLE, and
some patients had infact higher amounts of LIGHT mRNA than the controls. To further
prove that the actual levels of LIGHT mRNA were been masked PBMCs were isolated
from SLE patients. Subsequent Real-time PCR analysis established that the levels of
LIGHT mRNA in SLE PBMCs was elevated by approximately 6-8 fold over that of normal
control PBMCs (Fig 3.18). This is similar to the fold increase in expression that we
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demonstrated in P/I stimulated Jurkat T cells (Fig 3.07). A recent genome wide gene
profiling study on CD4+ T cells from a patient with severe SLE before and after
chemotherapy showed that LIGHT was upregulated on these cells during active SLE
(Deng, 2005), thus confirming our data.

The SLE cohort showed elevated levels of deltaLIGHT mRNA when compared to the
control cohort (Fig 3.10 and Fig 3.15).

PBMCs isolated from SLE patients also

demonstrated a significant increase in deltaLIGHT mRNA of approximately 6-7 fold (Fig
3.18). Little is known about the expression of deltaLIGHT protein in cells other than it is
held intracellularly (Granger, 2001). To date there have been no reports indicating the
function of this splice variant, making it very difficult to speculate as to its role in the
pathogenesis of SLE. Nevertheless, it is likely to function in the activation/proliferation of
T cells, as it is rapidly expressed by Jurkat T cells following stimulation with P/I (Fig 3.07).

Elevated levels of LIGHT in SLE would strongly promote a Th1 response and the release
of cytokines such as INF-γ (Shiakh, 2001; Wang, 2001; Cohavy, 2004; Brown, 2005).
INF-γ has been reported to be elevated in both murine models of SLE (Peng, 1997) and in
human subjects (Csiszár, 2000). We too in this study have also confirmed that there is
elevated levels of INF-γ mRNA in the periphery of SLE patients (Fig 3.14). It has also
recognised that there is a significant correlation with the amount of INF-γ secreted by
PBMCs and the severity of SLE (Ferry, 1997; Viallard, 1999). In particular, elevated levels
of INF-γ are known to contribute to the development of glomerulonephritis (Uhm, 2003;
Kikawada, 2003; Masutani, 2001). In this study, there is significant correlation between
mRNA levels of INF-γ and both LIGHT and deltaLIGHT in our SLE cohort (Fig 3.16).
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The SLE patients who participated in this study show a significant increase in HVEM
mRNA expressed in their PBLs a when compared to the control cohort (Fig 3.11). This too
was a surprising result, as we know from the Jurkat experiments that there is a
downregulation of HVEM in activated T cells (Fig 3.08). This result indicated that HVEM
was either not regulated as normal (Morel, 2001) in SLE or that it was upregulated on
another cell type. We speculated that in SLE patients that there was aberrant expression of
HVEM mRNA in cells other than lymphocytes as it is expressed on a wide variety of cells
(Harrop, 1998; Morel, 2001; Kwon, 2003). To narrow down the possible cell type that
HVEM is overexpressed in, PBMCs were separated from granulocytes using standard
density centrifugation techniques. This experiment showed that the level of HVEM mRNA
expression in the PBMC population was actually significantly lower than the control
samples

(Fig

3.18).

This

demonstrates

that

the

reciprocal

expression

of

LIGHT/deltaLIGHT and HVEM is conserved within the lymphocyte cell population of
SLE patients. The majority of HVEM overexpression seems to occur in granulocytic cells
(Fig 3.19). Admittedly, the number of samples in this experiment is small. Nevertheless,
the result does clearly indicate that HVEM mRNA is overexpressed in SLE and this is most
likely due to altered expression in cells other than T cells.

HVEM is constitutively expressed by neutrophils (Kwon, 2003; Heo, 2006), which have
been associated with kidney disease and vasculitis in SLE patients (Hotta 1996; Qasim,
1996). A recent report has demonstrated the significance of the LIGHT/HVEM interaction
on neutrophils (Heo, 2006). In vitro addition of soluble LIGHT to neutrophils enhances
their ability to secrete IL-8, TNF-α, nitric oxide (NO) and reactive oxygen species (ROS)
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(Heo, 2006). IL-8 acts as a strong chemoattractant for neutrophils that has been implicated
in the pathogenesis of renal inflammation and glomerulonephritis (Rovin, 2002). NO,
whilst an important innate defence mechanism (Nathan, 1997), in excessive amounts it can
promote tissue injury and contribute to the development of several human diseases
(Abramson, 2001) including SLE (Belmont, 1997). Administration of inhibitors of NO
production to the MRL-lpr/lpr murine model of lupus suppresses the development of
glomerulonephritis (Weinberg, 1994). The pathogenic anti-DNA antibodies found in SLE
have a greater capacity to bind DNA that has been modified by ROS (Blount, 1994). The
resulting immune complexes deposit in the kidneys resulting in inflammation. TNF-α has
also been found deposited in the kidneys of patients with lupus nephritis (Aringer, 2003).
This would indicate that the dysregulated expression of HVEM in SLE could be a major
contributing factor to the development of glomerulonephritis. Whether the overexpression
of HVEM in granulocytes is constitutive in SLE or is an effect of cell activation would
need to be addressed. A recent report examining the expression of HVEM protein on
granulocytes from peripheral blood and synovial fluid in RA indicated that HVEM
expression was not upregulated following activation of granulocytes as indicated by
increased CD11b expression (Kim, 2005). This may indicate that the increased expression
of HVEM mRNA in SLE is constitutive. This finding warrants further investigation.

In a previous study, which used semi-quantitative RT-PCR it was shown that DcR3 mRNA
levels were elevated in PBMCs from SLE patients (Otsuki, 2000). This study, which uses a
better quantification technique, also demonstrates that DcR3 is overexpressed in the
periphery of our SLE cohort (Fig 3.15). DcR3 is secreted from activated PBMCs (Wan,
2003), which is supported by our data as its mRNA levels signifcantly correlate with the
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expression of both LIGHT and deltaLIGHT (Fig 3.16).

DcR3 as its name suggests

functions as a decoy receptor that is capable of neutralising both FasL- and LIGHT- (Yu,
1999) induced apoptosis. Besides it inhibitory effects, DcR3 has also been reported to play
a role in modulating DC differentiation and maturation (Hsu, 2002). DCs incubated with
recombinant DcR3 show alterations in the surface expression of the B7 family of T cell costimulatory molecules (Hsu, 2002). DcR3 induces B7.1 (CD80) downregulation with the
simultaneous upregulation of B7.2 (CD86) (Hsu, 2002). It has been shown that while both
B7.1 and B7.2 equivalently stimulate IL-2 and INF-γ production, B7.2 can induce more IL4 production than B7.1 (Kuchroo, 1995; Freeman, 1995). This would indicate that DcR3
could cause a shift from Th1 to Th2 cytokine production, as IL-4 is an integral cytokine in
the Th2 pathway. The cytokine profile in SLE is quite complex, as both Th1 and Th2
cytokines have been reported to be elevated (Singh, 2005).

SLE patients also showed an elevated levels of LTβR mRNA expressed in peripheral blood
leukocytes (Fig 3.13). Increased apoptosis is thought to be an important trigger for the
development of SLE (Casicicola-Rosen, 1994). LTβR is also known to induce caspase
activation and ultimately apoptosis of cells by interacting with LIGHT.

It has been

reported that INF-γ may sensitise cells to LTβR mediated apoptosis (Browning, 1997). We
have shown in this study that SLE patients express elevated mRNA levels for all three
molecules indicating that this pathway could contribute to the increase in apoptosis seen in
SLE (Berden, 2003; Tsokos, 2001).
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3.4.5

LIGHT, associated receptor and CD

Coeliac disease is characterised by chronic inflammation of the small intestine due to an
abnormal immune response to dietary gluten in genetically susceptible individuals (Sollid,
2000). The chronic inflammation results in destruction of the villi in the small intestine
(Marsh, 1992). While many aspects of how the disease develops remain to be determined,
CD is unique from the respect that the environmental trigger (gluten), the major genetic
susceptibility locus (DQ2) and the autoantigen (tTG) are all known. While LIGHT-Tg
mice show symptoms of systemic autoimmunity the main site of inflammation is the gut.
Following histological analysis villous atrophy, crypt hyperplasia and infiltration of
immune cells into the lamina propria was identified in these Tg mice (Wang, 2001; Shiakh,
2001). These are all features of the gut lesion seen in CD, indicating that LIGHT may play
a role in its pathogenesis.

It has been previously reported that there is a relationship between cytokine mRNA levels
expressed in the intestine and peripheral blood of CD (Lahat, 1999). This indicates that
there is a continuous recirculation of activated immune cells between the inflamed small
intestine and the periphery (Lahat, 1999; Nilsen, 1996; Kertula, 1995). Hence, we initially
examined the mRNA expression of LIGHT and associated receptors in the peripheral blood
of a cohort of CD patients. The initial analysis of mRNA expression in PBL isolated from
CD patients showed no significant differences from that of the normal control cohort for
LIGHT (Fig 3.09), deltaLIGHT (Fig 3.10), HVEM (Fig 3.11), DcR3 (Fig 3.12) and LTβR
(Fig 3.13).
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When the data was re-examined based on lymphocyte counts, there was a significant
elevation in LIGHT mRNA in PBLs isolated from coeliac patients (Fig 3.15). The CD
patients were then stratified based on their anti-tTG serology results at the time blood
samples were collected for this study.

Detection of anti-tTG antibodies has become

standard practice to assit in the diagnosis of CD. Their levels give an indication to disease
activity, as they become undectectable during a GFD (Dewar, 2004). Our results show that
the expression of LIGHT mRNA is elevated in the periphery of CD patients with positive
anti-tTG autoantibodies when compared to a control cohort (Fig 3.17 A). The expression
of deltaLIGHT mRNA also follows a similar trend to that of LIGHT (Fig 3.17 B). HVEM
mRNA levels in PBLs are lower during active CD than in normal control cohort (Fig 3.17
C). Indicating, that the reciprocal expression of LIGHT and HVEM mRNA (Morel, 2001)
is maintained in CD. This result indicates that active CD patients have higher levels of
LIGHT-expressing activated T cells in their circulation than normal controls. The LIGHTTg mice have shown that increased LIGHT on peripheral T cells can lead to the breakdown
of peripheral tolerance leading to the development of autoimmunity (Wang, 2001). The
rate of autoimmune diseases in CD is 10 times that of the general population (Green, 2003).
Long term exposure to gluten could expand the number of T cells that express LIGHT in
the periphery and then in a similar manner to the of the LIGHT-Tg mice self-tolerance
could breakdown and symptoms of autoimmune disease could occur.

As mentioned earlier, LIGHT-Tg mice have profound inflammation in the small intestine
(Shiakh, 2001; Wang, 2001) and more recently it has been shown that there is increased
expression of LIGHT in the intestine of patients with active Crohn’s disease (Cohavy,
2005; Cohavy, 2004, Wang, 2004). CD4+ T cells within the lamina propria are speculated
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to play a central role in the pathogenesis of CD (Sollid, 2000). Using our established Realtime RT-PCR protocols to measure mRNA expression in PBLs, we aimed to identify if
there was also dysregulation of LIGHT expression in the small intestine of CD patients.

Duodenal biopsies (15) were collected from 9 untreated CD, 2 treated CD and 4 controls
that had neither CD or IBD. Total RNA was extracted and subsequent quantitative Realtime RT-PCR analysis was performed. Our results indicate, in a manner similar to that
seen in Crohn’s disease (Cohavy, 2005, Wang, 2005), that the levels of LIGHT mRNA are
increased in CD patients with active disease (Fig 3.18). The expression of HVEM mRNA
in the coeliac lesion is normally regulated, as during active disease it is downregulated (Fig
3.20). Hence, the regulatory mechanisms that control HVEM expression in the periphery
are conserved within the intestinal compartment.

LIGHT signalling via HVEM is costimulatory and augments proinflammatory cytokine
expression and T cell proliferation (Harrop, 1998). CD is characterised by a predominance
of the Th1 profile and our results are consistent with this as the mRNA copy numbers for
INF-γ (Fig 3.23) and IL-2 (Fig 3.24 A) are elevated in our untreated patients.

The

increased expression of LIGHT within the coeliac lesion would allow increased cell
signalling via HVEM, which has been shown to be an important secondary signalling event
for the full activation of T cells causing enhanced secretion of Th1 cytokines such as INF-γ,
IL-2, TNF-α and GM-CSF (Harrop, 1998). HVEM signalling alone is enough to induce the
INF-γ production by lamina propria T cells (Cohavy, 2004). Unlike Crohn’s disease, the
trigger for CD is known (gluten), and removal of this from the diet seems to cause a
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reversal, at least in the case of HVEM, INF-γ and BTLA, of mRNA expression patterns to
that of the control cohort.

The development of a Th1 response in CD does not seem to involve the main Th1
promoting cytokine, IL-12 (Nilsen, 1998). Increased levels of IL-18 and IFN-α, both of
which promote Th1 cell differentiation, have been detected in coeliac tissue (Monteleone
2001; Salvati 2002). Interestingly, LIGHT mediation of a Th1 response is independent of
IL-12 signalling (Brown, 2005). This may indicate that LIGHT expression could be an
important factor for the development of a Th1 response in CD in place of IL-12 signalling.
Cytokine upregulation in the lamina propria in response to gliadin is rapid. Using in vitro
small intestine biopsy cultures incubated with gliadin, a significant increase in
proinflammatory cytokines can be seen as early as 2-6 hours (Nilsen, 1998). As mentioned
previously, CD4+ T cells that infiltrate the lamina propria in active CD are of a memory
phenotype as characterised by the positive expression of CD45RO (Halastensen, 1990).
LIGHT protein expression at the cell surface is very rapid on memory T cells showing a
marked increase after 1-2 hours (Cohavy, 2004; Morel, 2003). Consequently, the rapid
expression of LIGHT on gut homing T cells may facilitate the rapid increase in
proinflammatory cytokines in response to gliadin.

BTLA can regulate T cell activation through its interactions with HVEM (Sedy, 2005,
Gonzalez, 2005). This study shows that active CD patients, have significantly reduced
levels of BTLA mRNA when compared to either the control or treated CD cohorts (Fig
3.24 C). Naïve T cells are first stimulated by the TCR engaging with a MHC-peptide
complex on APCs. The fate of T cells is also dependent on delivery of a secondary signal,
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which can be costimulatory or coinhibitory. Costimulatory signals allow clonal expansion
of T cells and effective immune responses, the coinhibitory signals maintain T cell selftolerance and prevent autoimmunity (Gonzalez, 2005). The balance of these two signals
will determine the outcome of an immune response. With increased levels of LIGHT
mRNA in active CD, along with reduced levels of BTLA, the balance between
costimulation and coinhibition is greatly skewed in favour of an active T cell response.
Furthermore, as HVEM levels are also decreased during active disease (Fig 3.21) will
further facilitate the binding of LIGHT, as it has a higher affinity for it than BTLA,
(Cheung, 2005). The sustained costimulation signals from LIGHT with little coinhibitory
signal for BTLA this would lead to the strong proinflammatory response.

The expression of LTβR is not transcriptionally regulated during inflammation of the small
intestine in active CD (Fig 3.22). LTβR can also act as a receptor for the hetrotrimeric
protein LTα1β2 (Ware, 1995). To identify if changes small intestine in CD could be
attributed to increase LTα1β2 expression we measured the expression of LTβ.

This

demonstrated that LTβ expression is unchanged in the coeliac lesion, as there is no
difference between the control and untreated cohorts (Fig 3.24 B). LIGHT and LTα1β2 are
known to cooperate in lymphoid organogenesis and the development of lymphoid
structures by signalling through LTβR (Scheu, 2002; Wang, 2002). As LTβ expression is
not elevated in untreated CD and that LIGHT is, would suggest that any alterations in
coeliac lesion are due to additional signalling through LTβR by LIGHT.
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During active CD, there is recruitment of CD4+ T cells and B cells into the lamina propria
(Sollid, 2000). The engagement of LIGHT with LTβR can help to create an environment
suitable for the recruitment of lymphocytes into the lamina propria by upregulating several
adhesion molecules and chemokines. Integrin family members are associated with the
trafficking of lymphocytes to and maintaining them within immune effector sites.
MAdCAM-1 specifically promotes α4β7 integrin bearing lymphocytes to migrate to
intestinal effector sites (Berlin, 1993).

LIGHT-Tg mice showed increased levels of

MAdCAM-1 as demonstrated by immunohistochemisty (Wang, 2004).

Recombinant

human LIGHT also stimulates increased expression of MAdCAM-1 (Wang, 2005). It has
been recently reported that LIGHT expression in the small intestine is almost exclusively
found on integrin β7+ T cells (Cohavy, 2004). Therefore, LIGHT expressing T cells that
are β7+ can home to the gut, where they can interact with LTβR to further increase the
expression of MAdCAM-1, which can cause increased levels of T and B lymphocytes to
infiltrate the lamina propria.

Transgenic mice that overexpress LIGHT show increased apoptosis of intestinal epithelial
cells (Wang, 2004). This increase in apoptosis could be mediated directly via LTβR
(Rooney, 2000) or indirectly via the proapoptotic effect of cytokines secreted (INF-γ, TNFα) by various cells in response to HVEM-LIGHT interactions (Harrop, 1998).
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3.4.6

LIGHT, associated receptor and WG

WG is a rare condition characterised by the presence of autoantibodies (c-ANCA) directed
towards PR3 an antibiotic protein expressed by activated neutrophils (Van der Woude,
1985). The disease seems to have two phases a localised phase where disease activity is
restricted to the upper respiratory tract and a generalised phase where systemic disease
occurs. It is speculated that early WG is characterised by a Th1 type cytokine profile with
high levels of INF-γ in both granulomatosus lesion and peripheral blood (Mueller, 2001).
The major autoantibody c-ANCA is not often detected in the early stages of WG
(Lamprecht, 2005). After a period of localised disease, generalised c-ANCA positive WG
usually develops. At this time, there is a switch from Th1 cytokine expression to increased
levels of Th2 cytokines such as IL-4 with little expression of INF-γ (Balding, 2001).

As LIGHT has strong Th1 inducing properties, it is tempting to speculate that the very low
expression of LIGHT mRNA in much of the WG cohort is because of a switch from a Th1
to a Th2 profile. The low expression of INF-γ and the positive titres for c-ANCA would
also indicate that our cohort had generalised disease. In hindsight it would have been
worthwhile quantifying the levels of Th2 cytokines, namely IL-4, in these patients to
identify if there was a negative correlation between them and LIGHT mRNA expression in
peripheral blood. There was no altered expression of HVEM (Fig 3.11), LTβR (Fig 3.13)
or DcR3 (Fig 3.12) between our WG and control cohorts. This may further indicate that
these pathways do not significantly contribute to the pathogenesis of WG.
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3.4.7

Conclusion

In summary, during this study we have gained knowledge about the use of real-time PCR
for quantitative analysis and effectively applied this to investigating the expression of
LIGHT and associated receptors in human autoimmune diseases. In doing so, we have
provided evidence that increased expression of LIGHT and its associated receptors in SLE
and CD and thereby confirming our hypothesis, that LIGHT overexpression may be
involved in the pathogenesis of both diseases. Elevated levels of LIGHT promote a strong
Th1 response, particularly INF-γ secretion. The role of INF-γ in the development of lupus
nephritis has been well characterised. Hence, LIGHT could play a critical role in the
pathogenesis of glomerulonephritis and may serve as a potential target for theraputic
intervention.

In CD, there are increased levels of LIGHT expressing cells in peripheral circulation and
the lamina propria of patients with active disease. Increased LIGHT-HVEM signalling
would promote Th1-type cytokines that are known to play a role in the pathogenesis of CD.
Furthermore, increased LIGHT-LTβR signalling would enhance the upregulation of
adhesion molecules and chemokines and cause immune cells to infiltrate the lamina
propria, which is a feature of the coeliac mucosal lesion. Further research into the effects
of LIGHT expression in the intestine may lead to the development for novel therapies for
chronic inflammatory diseases.
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Chapter 4

EXPRESSION OF SOLUBLE LIGHT PROTEIN
IN AUTOIMMUNE/PROINFLAMMATORY
DISEASES

4.1

INTRODUCTION

4.1.1

Soluble LIGHT

Many members of the TNFSF can be cleaved from the cell surface where they can act as
soluble cytokines. The release of the soluble form allows modulation of systemic immune
responses whereas the cell restricted forms will only effect the local environment. As
described previously, there are three forms of the mature LIGHT protein; the cell
membrane and intracellular forms are the products of pre-mRNA splicing (Morel, 2001).
The third form is identical to the membrane form except it has been cleaved from the cell
surface and is shorter by approximately 80 aa. This cleaved version of LIGHT is now free
to act as a soluble cytokine.

The matrix metalloproteinases (MMPs) are a family of more than 24 enzymes (Pender,
2004). They are subdivided based on their primary substrate specificity such as collagen,
gelatin, elastase and stromolysin. The natural endogenous inhibitors of MMPs are known
as the tissue inhibitors of metalloproteinases (TIMPs). TIMPs form a 1:1 complex with
MMPs and control the local activity of these enzymes in tissues. MMPs have been widely
associated with the turnover, degradation and destruction of the extracellular matrix (ECM)
(Parks, 2004). However, they can also function in the cleavage of cell surface ligands to
release them as soluble cytokines. LIGHT and FasL show significant amino acid (31%)
homology in their extracellular domains (Granger, 2001), a MMP cleavage site in FasL is
also conserved in LIGHT between amino acids 81-84.

The use of MMP inhibitors

dramatically decreases the release of soluble LIGHT in to tissue culture supernatants
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(Granger, 2001). This indicates that release of soluble LIGHT is due to the activity of an
MMP. A specific MMP for this role has not yet been identified.

4.1.2

In vitro activity of soluble LIGHT

Several in vitro studies have shown that soluble LIGHT retains its biological activity.
These studies have also demonstrated that LIGHT can modulate the activity of cells in both
the innate and adaptive immune responses.

The addition of soluble LIGHT to T cells in conjunction with CD3 stimultion enhances T
cell proliferation through HVEM signalling (Harrop, 1998).

In addition, HVEM

stimulation by soluble LIGHT enhances the production of proinflammatory cytokines such
as INF-γ, GM-CSF and IL-2 by T cells (Tamada, 2000). Dendritic cell maturation is also
enhanced by soluble LIGHT. In conjunction with CD40L, soluble LIGHT can costimulate
the maturation of DC and significantly increase their ability to secrete IL-12 (Morel, 2001).
IL-12 signalling through IL-12R is a critical factor in the induction of a Th1-type response
(ref).

LTβR signalling can promote upregulation of adhesion molecules including VCAM-1
(Dejardin, 2002), ICAM-1 (Zhang, 2003) MAdCAM-1 (Wang, 2004). MAdCAM-1 plays
an important role in the recruitment of inflammatory cells into the intestine. Soluble
LIGHT directly upregulates the expression of MAdCAM-1 by engaging with LTβR (Wang,
2005).
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A recent report demonstrated that soluble LIGHT enhances the bactericidal activity of
monocytes and neutrophils (Heo, 2006). The addition to soluble LIGHT to monocytes and
neutrophils at concentrations ranging from 1-100 ng/ml increased their ability to kill
Listeria monocytogenes and Staphylococcus aureus cultures. This enhanced bactericidal
activity was attributed to the ability of soluble LIGHT to enhance nitric oxide (NO) and
reactive oxygen species (ROS) production by monocytes and neutrophils by interacting
with HVEM. They also reported that soluble LIGHT could significantly enhance the
production of the proinflammatory cytokines IL-8 and TNF-α (Heo, 2006). This was dosedependent on soluble LIGHT concentrations and noticeable changes were identified at
concentrations above 1ng/ml. Kim et. al., reported that there is a synergistic effect between
INF-γ and soluble LIGHT to enhance the production of TNF-α and MMP-9 by
macrophages that were isolated from the synovium of RA patients (Kim, 2005).
Macrophages can also secrete other MMPs such as MMP-1 and –13 as well as TIMPs 1
and 2 in response to soluble LIGHT (Lee, 2004). Increased activity of MMPs has been
reported in many human diseases including CD (Daum, 1999).

Soluble LIGHT also retains its ability to induce apoptosis of cells such as the HT-29 human
colonic carcinoma cell line (Rooney, 2000). LIGHT mediated apoptosis is enhanced by
INF-γ in a dose-dependent manner (Chen, 2000; Zhang, 2005).
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4.1.3

Enzyme linked immunosorbent assay (ELISA)

ELISA assays have proved very useful for quantifying antigen in biological fluids and
tissue culture supernatants. There are several approaches to how ELISA can be performed
depending on the nature of the analyte (Carpenter, 1997).

For the detection of

autoantibodies in patient sera, for example, it is useful to coat the surface of the 96-well
plate with the autoantigen, such as tTG in CD, and then sera from the patient is added to the
well.

If autoantibodies are present, they will bind to the antigen where they can be

subsequently detected. The sandwich ELISA is another variation of the techniques and can
be used to quantify (Fig 4.01). During this assay, two antibodies (capture and detection)
that are specific for the target antigen are used. The capture antibody is coated on the
surface of the plate, when test sample is added any specific antigen present will be bound
by the antibody. Not all antibodies are suitable for sandwich ELISA as the capture and
detection antibodies are required to detect different epitopes on the antigen to avoid
competition for binding. The detection antibody is commonly labelled with biotin this
facilitates the binding of avidin to the complex, which in turn can be conjugated to an
enzyme.

The most commonly used enzymes are horseradish peroxidase (HRP) and

alkaline phosphatase (AP).

HRP catalyses the oxidation of substrates by hydrogen

peroxidase and AP catalyses the hydrolysis of phosphate groups from substrate molecules.
HRP has become the enzyme of choice for most applications due to its superior specific
activity, stability, low cost and availability of substrates. Commonly used subtrates for
HRP included

o-phenylenediamine dihydrochloride (OPD)

and

3,

3’, 5,

5’-

tetramethylbenzidine (TMB). TMB is the most commonly used substrate for HRP due to it
high sensitivity of ~5.5 pg/well. The activity of HRP on TMB yields a blue colour which
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when the enzyme reaction is stopped by the addition of sulphuric acid to the well, it is
converted to a yellow product that can be spectrophotometrically detected at 450 nm. If
recombinant proteins are used to generate a standard curve, this allows accurate
quantification of soluble proteins in serum.

Fig 4.01 Format of a sandwich ELISA. Antibody (Ab); horseradish peroxidase (HRP).
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4.1.4

Aim of this chapter

Many members of the TNF superfamily can be cleaved from the cell surface by proteases.
These cleaved ligands have been shown to retain biological activity allowing them to ligate
to their respective receptors. LIGHT is cleaved from the surface of the cell by members of
the MMP family. The aim of this chapter is to identify if serum levels of soluble LIGHT
are elevated in patients with CD and SLE using ELISA. As soluble LIGHT has been
demonstrated to retain its biological activity, elevated levels would promote a strong
proinflammatory response. This work will support our findings of our gene expression
study and provide further evidence that LIGHT is involved in the pathogenesis of these
diseases.
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4.2

MATERIALS AND METHODS

4.2.1

Patient samples

Serum samples were collected from a control cohort (28), which consisted of people with
no known autoimmune of inflammatory condition. Serum samples were also collected
from patients with SLE (50), WG (30) and CD (32). Informed consent was obtained from
all patients in accordance with both the Dublin Institute of Technology’s ethics review
board and St James’s Hospital ethics review board.

4.2.2

Jurkat T cell stimulation

Jurkat cells were stimulated for the time-course assay as desribed in Methods 3.2.1. Cell
culture supernatants were harvested, at timepoints from 0-48 hrs, and stored at –80oC
pending analysis

4.2.3

ELISA for soluble LIGHT

The detection of soluble LIGHT was performed using a commercially available kit (R&D
systems), the manufacturer’s instructions were followed. Briefly,LIGHT capture antibody
was reconstituted to 720 µg/ml in sterile PBS. A 96-well plate was coated with 100 µl of
diluted capture antibody (4 µg/ml) and incubated overnight at RT. Plates were washed 3
times using 400 µl of wash buffer (0.05% tween in phosphate buffered saline (PBS) @ pH
7.2-7.4). After the last wash, any remaining buffer was removed by blotting on clean paper
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towels. All non-specific binding sites on the plate were blocked using 300 µl of reagent
diluent (1% BSA in PBS @ pH 7.2 – 7.4) for a minimum of 1 hr. Washing procedure was
repeated as before. Recombinant human (rh) LIGHT standards were prepared in the range
of 2000 pg/ml to 32.2 pg/ml in reagent diluent. Add 100 µl of rhLIGHT standards or
sample in duplicate and incubate at RT for 2 hours. Washing procedure was repeated.
Plates were coated with 100 µl of diluted detection antibody (100ng/ml) and incubated at
RT for 2 hours. Washing procedure was repeated. Strepavidin-HRP stock was diluted in
PBS (50 µl + 9950 µl PBS), 100 µl of this was then added to each well the plate was
covered and incubated at RT for 20 mins. Avoid placing plate in direct light. Washing
procedure was repeated. The substrate solution was prepared by mixing 5 mls of colour
reagent A and 5 mls of colour reagent B. 100 µl of the substrate solution was added to each
well and incubated at RT for 20 mins. 50 µl of stop solution (2N H2SO4) was then added to
each well, the plate was then gently tapped to ensure adequate mixing. The optical density
of each well was immediately determined using a microplate reader set to 450 nm.
Absorbance mesurments were also taken at 570 nm as recommended by the manufacturer,
this corrects for any imperfections in the plastic of the plate.

4.2.4

Statistical analysis

Statistical analysis of the ELISA data was performed using the non-parametric MannWhitney U-test. P values were two-sided and significance was considered when P <0.05.

4.3

RESULTS
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4.3.1

Evaluation of a suitable diluent for the LIGHT standards

During an ELISA, it is important to block all non-specific binding sites on the plastic
surface of the 96-well plate. This helps to prevent non-specific binding of proteins during
subsequent steps in the procedure, which reduces the background noise and improves the
sensitivity of the assay.

Three different blocking solutions were prepared in PBS: 1% BSA, 20% fetal calf serum
(FCS) and 1%BSA and 20% FCS. In addition to acting as a blocking solution, these
reagents were also used to dilute the rhLIGHT stock to make the standards. The standard
curves produced using each of the diluents were almost identical (Fig 4.02) with a linear
range from 32 pg – 1000 pg per ml. This allowed accurate quantification of samples within
this range. As a 1% BSA solution is the most economical of the three blocking solutions it
was used for all subsequent experiments.
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Fig 4.02 LIGHT ELISA standard curve using three different diluents. Values above
each data point indicate the concentration of recombinant human LIGHT (rhLIGHT) in
pg/ml.
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4.3.2

Determination of the stability of soluble LIGHT

The detection of proteins using ELISA is dependent on the antibody being able to capture
the protein. For this the epitope that the antibody recognises must be available. If any
degradation of the protein, that may destroy this epitope, occurs during storage of the
serum, then the data may be misinterpreted. As there was no information about the stability
of sLIGHT we analysed 5 serum samples that were stored under two conditions: room
temperature (~25oC) and refrigeration temp (~6oC). These two temperatures reflected the
condition that patient serum samples, that we wished to use in this study, may have been
subjected to. Serum samples were collected and an aliquot was immediately stored at –
80oC (fresh frozen) and the remaining serum was left at either room or refrigeration
temperature for up to 6 days at each time point an aliquot was taken and stored at –80oC.
Samples were then analysed for levels of soluble LIGHT.

At room temperature no

significant change was seen at any of the time points when compared to the fresh frozen
aliquot (Fig 4.03 A).

The same pattern was demonstrated for the samples stored at

refrigeration temperature (Fig 4.03 B). This showed that sLIGHT was stable in serum
samples stored at room temperature for up to six days.
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Fig 4.03 Stability of soluble LIGHT in serum stored at room and refrigeration
temperature. Fresh frozen (FF). Panel A shows the stability of soluble LIGHT at room
temperature ; Panel B shows the stability of soluble at 6OC.
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4.3.4

Intra-assay and inter-assay variation

The level of intra- and inter-assay precision was also measured for both the recombinant
standards and the sera samples. The average coefficient of variation (CV) for intra-assay
analysis for the recombinant standards was 5.1% (range: 2.3-7.1), for inter-assay analysis
this was 11.6% (range 5.8-17.1). A similar trend was seen for the sera samples, the CV for
intra-assay analysis was 8.1% (range 6.1-10.2) and inter-assay 13% (range 11.3-14.9).
These CVs are within the generally accepted variation for both intra and inter assay
analysis (Carpenter, 1997).

4.3.5

Expression of soluble LIGHT from Jurkat T cells

To identify if LIGHT protein and mRNA levels correlate, we analysed the expression of
sLIGHT in tissue culture supernatants collected from P/I stimulated Jurkat T cells over a
period of 48 hrs (Fig 4.04). The mRNA expression results from the previous chapter are
overlaid on Fig 4.04 to directly show the mRNA and protein levels in context with each
other. The levels of soluble LIGHT were seen to steadily rise from 8 hrs post-stimulation
up to 32 hrs at which point the increase began to plateau. After 48 hrs there was an
approximate 7-fold increase in the level of soluble LIGHT present in the tissue culture
supernatants.
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Fig 4.04 Kinetics of soluble LIGHT (sLIGHT) release from stimulated Jurkat T cells.
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4.3.6

Analysis of patient samples for soluble LIGHT

Once the procedure for the ELISA was established, the analysis of the test sera could begin.
Along with a control group, sera from SLE, CD and WG patients were also tested. All
patients were positive for autoantibodies at the time of obtaining the serum sample. The
SLE patients were ANA positive, the WG patients were c-ANCA positive and the CD
patients were anti-tTG positive. Positive autoantibody titres were an indication that there
was disease activity in the selected patients.

The results of the quantitative ELISA were converted from optical density (OD) units to
pg/ml of soluble protein in the manner specified by the manufacturer (R&D systems). The
manufacturer of the soluble LIGHT ELISA (R&D systems) had previously tested 60
control samples all of which were under 250 pg/ml. In our control group, the majority are
clustered below 300 pg/ml, though three samples have levels greater than 1000 pg/ml (Fig
4.05). The percentage of samples undetectable in the manufacturers control group is 7%
compared to our 10.7%. Therefore, with the exception of three outlying samples our
controls compare very well to those tested by the manufacturer.

Following statistical analysis of the data, the SLE patients showed significantly higher
levels of soluble LIGHT in their sera (P = 0.033). Conversely, the WG patients had
significantly lower amounts of sLIGHT in their sera (P = 0.012) when compared to the
control group. The CD patients were not deemed statistically different from the controls (P
= 0.172). However, in this case the P value does not tell the whole story, as a large
percentage (37.5%) of the CD patients tested had a high level of soluble LIGHT (>1000
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pg/ml) in their sera compared to only 10 % of the controls (Table 4.01). This is comparable
to the 40% of SLE patients that show levels greater than 1000 pg/ml. A large number of
the WG patient failed to show expression of soluble LIGHT (43.3%) compared to only
10.7% of the controls

Samples

Undetectable

>1000 pg/ml

n

%

%

28

10.7

10.7

CD

32

3.1

37.5

WG
SLE

30
50

43.3
6.0

16.7
40.0

Controls

Table 4.01 Percentage of patient cohort that had undetectable or strong positive
soluble LIGHT levels.
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Fig 4.05 Soluble LIGHT levels in different patient groups. ** Indicates a group that is
significantly different from the normal control. Horizontal lines indicate the mean of each
group.
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4.4

DISCUSSION

There are three forms of the LIGHT protein each is present within a different location, the
cytosol, the cell membrane or the extracellular space. The cytosol and cell membrane
associated forms of LIGHT are produced by alternative splicing (Granger, 2001). The third
form of the protein is generated by proteolytic cleavage of the cell surface associated
protein to release it as soluble LIGHT (Granger, 2001; Morel, 2000). While it has been
speculated that this release of soluble LIGHT might be a method of downregulating the
ligand (Granger, 2001), several studies have shown that it retains biological activity
(Zhang, 2003; Zhang, 2004; Heo, 2005).

The aim of this study was to measure the levels of soluble LIGHT in the sera of CD, SLE
and WG patients as well as a control cohort. Based on our findings that there is increased
mRNA expression of LIGHT in both CD and SLE (chapter 3), we speculated that there
would also be increased serum concentrations of soluble LIGHT in these two diseases. By
demonstrating that increased mRNA expression is also reflected in elevated protein levels,
this would provide further evidence that LIGHT may play a role in the pathogenesis of both
CD and SLE.

To measure the amount of soluble LIGHT present in the test sera a

commercially available sandwich ELISA (R&D systems) was employed a commonly used
method for quantifying antigen in biological fluids and cell culture medium.

As there was no information on the stability of soluble LIGHT our initial experiments setout to demonstrate that the protein was stable for an extended period at both room and
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refrigeration temperatures. These temperatures would reflect possible storage conditions
that the serum samples may be exposed to.

Five serum samples were tested in this

experiment. Each sample showed similar levels of soluble LIGHT whether the aliqout was
fresh frozen (-70oC at time of collection) or stored for up to 144 hrs at each of the
temperatures (Fig 4.03). This ensured that any changes seen in the expression of soluble
LIGHT would not be due to degradation of the protein, which may affect the epitopes
recognised by the capture and detection antibodies used in the sandwich ELISA.

Jurkat T cell have been used extensively to elucidate many aspect of T cell activation and
initiation of an immune response (Abraham, 2004). In this study, Jurkat T cells were used
to demonstrate that increases in LIGHT mRNA corresponded with a similar fold increase in
the release of soluble LIGHT. As demonstrated in chapter 3, P/I stimulation of Jurkat cells
induces an 8-fold increase in the expression of LIGHT mRNA. By collecting the cell
culture supernatants from these activated cells, it was possible to measure the release of
soluble LIGHT using ELISA. The levels of LIGHT mRNA peak at ~ 24 hrs whereas the
peak of soluble LIGHT protein occurs between 8-24 hrs later (Fig 4.04). This demonstrates
that increases in LIGHT mRNA are also reflected in the release of soluble LIGHT from
activated Jurkat T cells.
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4.4.1

Soluble LIGHT and CD

CD is characterised by chronic inflammation that leads to severe destruction of the small
intestine in response to gliadin ingestion by genetically susceptible individuals (Sollid,
2002). Activated CD4+ T cells in the lamina propria of the small intestine with a Th1
phenotype have been proposed to be central to the disease process (Schuppan, 2000). In
chapter 3 it was demonstrated that patients with positive anti-tTG antibody titres have
elevated levels of LIGHT mRNA expressing cells in peripheral circulation (Fig 3.17).
Therefore, in this study serum samples were only selected if they had positive titres for
anti-tTG antibodies indicating that there was disease activity, as these antibodies tend to
disappear following the removal of gluten from the diet (Sulkanen, 1998).

Following soluble LIGHT quantification using the desribed ELISA protocol, a statistically
significant difference between the control and CD cohorts was not observed (P = 0.172)
(Fig 4.05). During in vitro stimulation studies using soluble LIGHT, noticeable changes in
the levels of proinflammatory cytokines and adhesion molecules can be seen at
concentrations of >1000 pg/ml (Zhang, 2003; Zhang, 2004; Heo, 2005). During this study,
to identify stongly postitive samples a cut-off value of >1000 pg/ml were used. When
samples above the cut-off are considered, a large number of the CD cohort (37.5%) have
high levels of soluble compared with only 10.7 % of the controls (Table 4.01). This result
indicates that a considerable proportion of CD patients may have excessive soluble LIGHT
in their serum, which could have significant implications for those patients.
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CD has been linked to the development of secondary autoimmune diseases such as IDDM
(Cronin, 1997), rheumatoid arthritis (Collin, 1994) and autoimmune hepatitis (Volta, 1998)
to name but a few. The expression of LIGHT has also been demonstrated to play a role in
the development of various autoimmune diseases including IDDM (Wang, 2001), RA
(Kim, 2005) and autoimmune hepatitis (Anand, 2006) among others.

Furthermore,

chronically elevated levels of LIGHT in mice can cause a breakdown in self-tolerance that
leads to systemic autoimmunity (Wang, 2001; Shiakh, 2001). CD patients are 10 times
more likely to develop an autoimmune disease than the general population (Green, 2003).
Sustained increases in soluble LIGHT concentrations could be one contributing factor to
this phenomenon.

4.4.2

Soluble LIGHT and SLE

SLE is a prototypical autoimmune disease in which multiple organs can become inflamed
and damaged.

The major autoantibodies present in these patients are anti-nuclear

antibodies (ANA) that are directed against various nuclear components including DNA.
Increased levels of Th1 cytokines have been found in the serum of SLE patients,
particularly those with renal involvement (Uhm, 2003). As soluble LIGHT retains its
ability to induce a Th1 type response (Tamada, 2000), increased serum levels could have a
major role to play in the pathogenesis of SLE.

244

The SLE patients analysed in this study showed significantly increased levels of soluble
LIGHT (P = 0.033) in their sera when compared to the control cohort (Fig 4.05) when
quantified using the aforementioned ELISA protocol.

When the samples with

concentrations above the cut-off value (>1000pg/ml) are considered, 40% of the SLE
cohort showed high levels of soluble LIGHT present in their serum.

In vitro stimulation of T cells using soluble LIGHT causes significant increases in INF-γ
expression with little or no increases in Th2 cytokines (IL-4 or IL-10) (Tamada, 2000).
INF-γ plays a significant role in the development of lupus nephritis in both human
(Akahoshi, 1999) and mouse studies (Schwarting, 1998; Haas, 1998).

Anti-INF-γ

treatment for the lupus prone NZB/NZW mouse prevents renal disease (Ozmen, 1995),
whereas the administration of INF-γ greatly accelerates its progression (Jacob, 1987).
Likewise, knocking out the INF-γ gene in two different models (MRL/lpr and NZB/NZW)
protects them from the development of nephritis (Schwarting, 1998; Haas, 1998). In
humans, an increased ratio of Th1/Th2 cytokines (INF-γ/IL-4) is thought to promote lupus
nephritis (Akahoshi, 1999). Lupus patients with glomerulonephritis have increased levels
of Th1 cytokine producing cells present in their kidneys (Uhm, 2003), which correlate with
histological analysis of disease activity (Masutani, 2001; Kikawada, 2003). In addition,
INF-γ levels secreted by PBMCs from SLE patients significantly correlate with disease
activity scoring systems such as the systemic lupus activity measure (SLAM) (Viallard,
1999; Sturfelt, 1997).

Transgenic mice that over-express INF-γ have also been

demonstrated to produce anti-DNA antibodies (Seery, 1997), which are believed to be
critical for the development of renal disease. Given the role of the LIGHT-HVEM pathway
in INF-γ upregulation (Zhai, 1998) it is likely that the elevated levels of soluble LIGHT
could contribute to the deterioration in the health of these patients.
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LIGHT and INF-γ can work in synergy to increase TNF-α secretion by monocytes (Kim,
2005). The role of TNF-α in the pathogenesis of SLE is debated; some reports indicate that
it may have a protective role (Dean, 2000; Manson, 2003), while others have shown that
TNF-α can contribute to the inflammation seen in these individuals (Aringer, 2003).
Several animal studies would also indicate that TNF-α participates in the development of
lupus nephritis (Boswell, 1988; Yokohama, 1995; Tsai, 1995). NZB/NZW mice have high
levels of TNF-α deposited in their kidneys, once nephritis is established (Brennan, 1989).
A finding that has also been demonstrated in humans (Herrera-Esparza, 1998; Malide,
1995; Takemura, 1994).

Furthermore, the level of TNF-α expression correlates with

histological assessment of renal inflammation (Herrera-Esparza, 1998).

Given the effect that soluble LIGHT has on increasing both INF-γ and TNF-α among other
proinflammatory molecules it is reasonable to assume that it could very well contribute
significantly to the development of glomerulonephritis in these patients. Incidentally, about
40% of patients with SLE develop nephritis during the course of the disease (Cervera,
1993) a figure which is strikingly similar to the number of our test cohort that show highly
elevated levels of soluble LIGHT.

4.4.3

Soluble LIGHT and WG

WG is an autoimmune disease characterised by granulomatous and vasculitic lesions. The
disease usually presents as localised WG, in which granulomatous lesions are restricted to
the upper airways, and progresses to generalised WG. Autoantibodies specific for PR3 are
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detected in the vast majority of patients with generalised WG (Lamprecht, 2005).
Granulomatous lesions in localised disease predominantly express Th1-type cytokines
whereas a shift towards Th2-type cytokine expression is found in generalised disease
(Mueller, 2000; Balding, 2001).

All WG serum samples included in this study were positive for autoantibodies directed
against PR3. The results of this study showed a statistically significant lower expression of
soluble LIGHT between the WG and control sera (P = 0.012). Furthermore, the WG cohort
had a very high proportion (43%) of samples in which no soluble LIGHT could be detected
(Table 4.01). This is a significantly higher proportion of samples with no detectable
soluble LIGHT than either our controls (10.7%) or the controls tested by the manufacturer
(7%). This finding provides further evidence that overexpression of LIGHT is not likely to
participate in the pathogenesis of WG. The absence of soluble LIGHT in anti-PR3 positive
WG patients would support the hypothesis of a skewed Th-2 cytokine profile in these
patients.
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4.4.4

Conclusion

To conclude, the aim of this chapter was to measure the levels of soluble LIGHT in our
three test cohorts, which was achieved using a commercially available sandwich ELISA
specific for soluble human LIGHT. The data generated in this study shows that soluble
LIGHT is significantly elevated in the serum of SLE patients. Soluble LIGHT can induce a
strong Th1-type response predominantly causing the secretion of large amounts of INF-γ.
Increased INF-γ levels are well documented to play a role in the development of lupus
nephritis in both human and murine studies.

Hence, it is reasonable to suggest that

increased soluble LIGHT levels may be a contributing factor to renal involvement in SLE.

A large proportion of the CD cohort showed elevated levels of soluble LIGHT in their
serum despite the site of inflammation being localised to the small intestine. Constitutive
expression of LIGHT in Tg-mice induces a breakdown of self-tolerance and leads the onset
of autoimmune disease. An extremely high incidence of secondary autoimmune disease is
found in patients diagnosed with CD. We speculate that patients with chronically elevated
levels of soluble LIGHT in their serum may be more prone to developing some of the other
autoimmune conditions that are associated with CD.

The WG patients showed significantly lower levels of soluble LIGHT compared with the
controls. This results confirms that at least in our cohort of anti-PR3 autoantibody positive
WG patients that LIGHT overexpression is not a contributing factor to disease
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Chapter 5

GENERAL DISCUSSION

Since its discovery, LIGHT has proved to be an important secondary co-stimulatory
molecule for the activation of T cells (Harrop, 1998; Tamada 2000). The co-stimulation
signal caused by LIGHT-HVEM interactions induces a strong Th1 type reponse (Tamada,
2001; Wang, 2001).

Additionally, roles in dendritic cell maturation (Morel, 2001),

negative selection of thymocytes (Wang, 2002; Wang 2001) and secondary lymphoid
organogenesis (Wang, 2002) have also been attributed to LIGHT. Evidence that LIGHT
may play an important role in human disease came from two papers that specifically
overexpressed LIGHT in T cells of mice (Wang, 2001; Shaihk, 2001). The mice generated
in these studies developed profound inflammation of the intestine as well as severe
glomerulonephritis and autoantibody production. The small intestinal inflammation seen in
these transgenic mice resulted in villous atrophy, crypt hyperplasia and the loss of goblet
cells (Shiahk, 2001). This destruction of the small intestinal structure, while not specific to
CD alone, is similar to the gut lesion seen in human subjects with the disease (Marsh,
1992).

The development of glomerulonephritis and the production of anti-DNA

autoantibodies in LIGHT-Tg mice resembles manifestations seen in established models for
SLE (Wang, 2001). From these two studies we speculated that upregulation of LIGHT may
play a role in the development of CD or SLE in humans. Therefore, the overall aim of this
thesis was to assess the expression of LIGHT and its associated receptors in these two
immune-mediated diseases. We also included a cohort of WG patients in this study as it is
characterised by the presence of multiple autoantibodies, vasculitis and glomerulonephritis
(Langford, 1999). In order to obtain data on the expression of LIGHT in these diseases,
Real-time quantitative RT-PCR methodologies were to be optimised.
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Real-time PCR has emerged as a powerful technique for quantitative analysis (Bustin,
2000). While microarray technology is popular for monitoring the expression of many
thousands of genes at a time, it is now common practice to validate these results using
quantitative real-time PCR. Much of this is to do with the sensitivity, wide dynamic range
and the adaptability of Real-time PCR technology for quantitative analysis (Logan, 2004).
Before embarking on a logistically complex and expensive gene expression study it was felt
that gaining hands-on experience with developing Real-time PCR assays, where the end
results could be predetermined, would yield beneifits in the long-term. To this end, two
disease models were chosen to study various aspects of Real-time PCR assay design. In
order to look at SNP detection we used cystic fibrosis as a model as it is a common genetic
disease and, while over 1000 mutations (Tsui, 2003) have been associated with it
development, as few as five of these account for ~90% of mutations seen in the Irish
population (Scotet, 2003). The model chosen for quantitative analysis was the examination
of PMP22 gene dosage in relation to two herediatary peripheral neuropathies: CMT1A and
HNPP. These are traditionally very difficult conditions to diagnose at the molecular level
due to the subtle differences between a normal and abnormal genotype. Therefore, this
study provided a strong challenge to the capabilities of quantitative Real-time PCR
analysis.
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5.1

Review of results

The ultimate aim of chapter 2 was to explore the use of Real-time PCR as a methodology
and to push its capabilities to the limit. In chapter 2.1, Real-time PCR was used to develop
an assay to detect the five most common CFTR mutations in the Irish population. A
previous study had compared Real-time PCR to traditional PCR techniques for detecting
the delF508 mutation in CF, and had shown that it was as accurate and a much more rapid
technique (Dempsey, 2002). Hence, we wanted to expand on this to produce a multiplex
Real-time PCR that could detect the five most common CF mutations in Ireland. This
would account for approximately 90% of mutant alleles present in the Irish population
(Scotet, 2003). The initial approach was to develop the multiplex in a manner similar to
other groups (Bestmann, 2002, Gundry, 2001, Bernard, 1998) by placing the hybridisation
probes at the site of the mutation. Nonetheless, it was quickly realised that there would be
significant problems with this technique as it did not allow us to differentiate more than one
mutation per colour channel during melting curve analysis. To avoid these problems a
novel approach to performing multiplex mutation detection on the LightCycler instrument
was developed (Dempsey, 2004). This involved combining ARMS PCR (Newton, 1989)
with Real-time melting curve analysis (Wittwer, 1997). Our approach proved to be quite
successful, allowing easy discrimination of melting curve peaks that corresponded to
particular CFTR genotypes (Figs 2.06-2.08). This assay also passed a blinded trial carried
out in conjunction with the National Centre for Medical Genetics, Our Lady's Hospital for
Sick Children. The use of Real-time PCR for CF mutation detection allows for a much
faster turnaround time for genetic analysis. This is of particular importance for newborns
that may have the potential for developing the disease. Newborn infants have healthy
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sterile lungs (Wine, 1999), but they can quickly become colonised with bacteria that are
pathogenic to CF patients such as Staphylococcus aureus (Hutchison, 1999) and
Pseudomonas aeruginosa (Emerson, 2002). Early treatment of these infants can slow
down the progression of lung colonisation and ultimately the progression of the disease
(Starner, 2005). Therefore, it is vital that a diagnosis can be made as rapidly as possible.
The use of Real-time PCR for mutation detection in newborns also has the advantage of
requiring only small amounts of starting genomic DNA, as the technique is highly
sensitive. If necessary, successful PCR analysis can be performed using only picogram
quantities of starting template helping to reduce the amount of cells/blood that need to be
donated for genetic analysis.

In chapter 2.2, Real-time quantitative PCR was used for gene dosage analysis in two
hereditary peripheral neuropathies, CMT1A and HNPP.

Gene dosage analysis using

traditional techniques such as southern blotting (Lupski, 1991) can be time-consuming and
require large amounts of high quality DNA. Real-time PCR a truly quantitative technique
is sensitive, rapid and requires only small amounts of DNA (Logan, 2004) making it very
suitable for gene dosage analysis. The PMP22 gene is contained within a 1.5 Mb region of
chromosome 17p11.2. The gene can be duplicated leading to CMT1A (Lupski, 1991;
Raeymaekers, 1991) or deleted and thus cause HNPP (Chance, 1993). Consequently, a
normal individual will possess two copies of the PMP22 gene, CMT1A individuals will
have three and a HNPP patient will have only a single copy. The quantification of such
sutble changes would push Real-time PCR to the limits of its capabilities. In this study,
relative quantification was used where β-globin acted as a reference that is present at two
copies per genome. PMP22 copy numbers were then expressed as a ratio of β-globin. The
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development of a multiplex PCR, that allowed the simultaneous quantification of both βglobin and PMP22 in the same capillary, was an important aspect of this study. Otherwise,
the test sample would have to be added to two separate PCRs, therefore creating the
potential for error to be introduced into the assay.

However, the generation of both

amplicons in the same PCR would mean that extensive optimisation was required so that
the PCR efficiencies were similar. If this were not so it could potentially lead to over/under
estimation of the PMP22 ratio. Once the quantitative multiplex was optimised and shown
to be reproducible, we tested a number of samples for PMP22 copy numbers. The results
generated were similar to the findings of other groups (Thiel, 2003; Choi, 2005). Normal
controls had a ratio of PMP22 to β-globin of approximately 1, CMT1A had a ratio of >1.4
and HNPP had a ratio of <0.55. All normal control samples tested fell within a range of 0.8
– 1.2 showing a clear division between normal and pathogenic ratios (Fig 2.15).

During these two studies, model diseases (CF, CMT and HNPP) were used to generate a
better understanding of how to effectively use Real-time PCR as a tool in molecular
biology. A lot of knowledge about was gained about the general design and positioning of
hybridisation probes for the development of a successful real-time PCR assay. Steps were
made to improve the multiplexing capabilities of real-time mutation detection (Dempsey,
2003). We also demonstrated that Real-time PCR is a very sensitive technique capable of
discriminating between samples that differed by as little as 1.5 fold change. This work
gave us a good foundation when designing primers and hybridisation probe pairs for the
gene expression work performed in chapter 3. It also demonstrated the power of Real-time
PCR as a quantitative tool for detecting even the subtlest alterations in copy number.
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The aim of chapter 3 was to utilise real-time PCR to achieve the ultimate aim of the thesis:
to analyse the expression of LIGHT and its associated receptors in human immunemediated diseases. In this chapter, we successfully developed Real-time RT-PCR protocols
allowing us to quantify changes in mRNA expression profiles.

The reciprocal expression of LIGHT and HVEM on activated T cells had been previously
characterised using semi-quantitative RT-PCR (Granger, 2001). Therefore, we used Jurkat
cells stimulated in a timecourse with P/I to verify the reciprocal expression of LIGHT and
HVEM upon T cell activation (Figs 3.07 & 3.08) using our Real-time PCR protocols.
These results showed that deltaLIGHT follows a similar pattern to that of LIGHT
upregulation in these cells (Fig 3.07). To our knowledge, this is the first time this has been
demonstrated. The success of these initial studies allowed us to progress to the collection
of samples from patients. Over 90 samples were obtained for the first part of this study: to
characterise the mRNA expression profile of LIGHT and its receptors in PBLs isolated
from our test cohorts (CD, SLE and WG patients).

Subsequent Real-time RT-PCR analysis revealed that LIGHT mRNA is elevated in CD
PBLs when compared to healthy controls (Fig 3.17). It has been previously reported that
PBLs isolated from active CD express increased levels of mRNA for Th1-cytokines (Lahat,
1999). From previous studies on Crohn’s disease, it is highly likely that these LIGHT+ T
cells have had previous antigen exposure (CD45RO+) and secrete INF-γ (Cohavy, 2005).
LIGHT-Tg mice have revealed that increased LIGHT on peripheral T cells can lead to the
breakdown of peripheral tolerance leading to the development of autoimmunity (Wang,
2001). The exposure of coeliacs to gluten as indicated by anti-tTG positivity can increase
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the number of T cells that express LIGHT in the periphery. In a similar manner, as occurs
in LIGHT-Tg mice, long-term exposure to gluten could cause a breakdown in selftolerance. The expression of HVEM is normally regulated (reciprocal expression to that of
LIGHT) in PBLs from CD patients (Fig 3.11). The mRNA copy numbers for LTβR (Fig
3.13) and DcR3 (Fig 3.12) did not vary from that of the control cohort.

In chapter 3 it was also demonstrated that LIGHT and its associated receptors may
contribute in the pathogenesis of SLE. The expression of LIGHT and deltaLIGHT mRNA
was elevated in PBMCs isolated from SLE patients (Fig 3.19). Furthermore, the levels of
both LIGHT and deltaLIGHT mRNA strongly correlated with the increased levels of INF-γ
mRNA seen in our patients (Fig 3.16). The levels of mRNA for LIGHT’s three receptors
(HVEM, DcR3 and LTβR) were also identified as being significantly elevated in our cohort
of SLE patients (Figs 3.11 & 3.15), indicating, that there is a profound dyregulation of
these signalling pathways in SLE.

One of the more interesting results generated in this thesis was the significant elevation of
HVEM in PBLs isolated from SLE patients. It was initially thought that this might indicate
that HVEM mRNA was not regulated as normal in these patients. However, upon further
investigation it seems that the reciprocal expression of HVEM and LIGHT is maintained in
PBMCs and the overexpression of HVEM is within cells of the granulocyte population (Fig
3.18). HVEM is expressed by neutrophils, (Kwon, 2003) making it is tempting to speculate
that the increased expression is on this cell type. The addition of soluble LIGHT, at
concentration of >1000 pg/ml, to neutrophils causes the release NO and ROS as well as
TNF-α and IL-8 (Heo, 2006), all of which have been implicated in the pathogenesis of
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lupus nephritis (Blount, 1994; Nathan, 1997; Rovin, 2002; Aringer, 2003). SLE patients
may express high levels of HVEM on their neutrophils, in conjunction with high levels of
soluble LIGHT (>1000 pg/ml) in their serum (Fig 4.05), suggesting that the LIGHT-HVEM
pathway might be of particular importance in the development of glomerulonephritis, one
of the most serious manifestations of SLE.

Elevated levels of soluble HVEM have been identified in the serum of SLE patients (Jung,
2003). However, the authors did not speculate as to the biological significance of increased
soluble HVEM.

Both LIGHT and BTLA need to be considered when assessing the

potential role of soluble HVEM in SLE pathogenesis.

LIGHT is capable of reverse

signalling by interacting with solid phase DcR3-Fc protein (Shi, 2002; Wan, 2002), which
serves to further enhance Th1 responses. It might be possible that soluble HVEM could
also function in this manner by cross-linking LIGHT on the surface of T cells.
Nevertheless, it could be just as likely that soluble HVEM can block cell membrane bound
HVEM from interacting with LIGHT or BTLA. The interaction of HVEM and BTLA
transmits co-inhibitory signals into T cells (Sedy, 2005; Gonzalez, 2005). Anergic T cells
have been reported to express high levels of BTLA (Hurchla, 2005). If soluble HVEM
acted as a decoy ligand for BTLA this may have the effect of preventing co-inhibitory
signals being transduced into T cells and therefore increasing the likelihood of uncontrolled
T cell activation. While it can be equally argued that soluble HVEM can block LIGHT costimulation of T cells and maturation of DC, by switching off the BTLA-HVEM circuit
other co-stimulatory circuits could induce activation of T cells that should by right be
anergic. T cells from HVEM knockout mice show hyper-responsiveness during in vitro
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stimulation (Wang, 2005), which indicates to the importance of the BTLA-HVEM
interactions in maintaining balance between stimulation and inhibition.

In chapter 3 the expression of DcR3 mRNA was also examined in PBLs isolated from our
test cohorts. The gene expression analysis showed that DcR3 expression was unaltered in
both CD and WG, although a significant increase was identified in the SLE cohort (Fig
3.15) confirming a previous study (Otsuki, 2000). The biological role of DcR3 is quite
complex as it acts as a soluble receptor for LIGHT (Yu, 1999), FasL (Pitti, 1998) and
TL1A (Migone, 2002).

In addition, it has been speculated that it may have other

unidentified ligands (Yang, 2005). DcR3 has been typically associated with anti-apoptotic
activities by blocking the function of its three ligands (Yu, 1999; Roth, 2001; Migone,
2002).

The commonly used knockout mice MRLlpr/lpr (Fas) and gld/gld (FasL) spontaneously
develop a lupus-like disease (Watanabe, 1992; Takahashi, 1994). In vitro studies have
shown that Fas-FasL is critical for activation induced cell death (AICD) a mechanism used
to delete lymphocytes in peripheral circulation at the end of an immune response
(Ashkenazi, 1999). T cells from SLE patients have been shown to resist AICD (Lu, 2004).
A potential mechanism for this resistance could be the increased presence of DcR3, which
can interfere with the activity of Fas (Roth, 2001).

However, DcR3 can also modulate the activity of many cells. DcR3 increases monocyte
adhesion to endothelial cells by upregulating ICAM-1 and VCAM-1 expression (Yang,
2005). It can also modulate the maturation of dendritic cells so that they favour the
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production of Th2 type cytokines (Hsu, 2002). Furthermore, in vitro DcR3 has been shown
to induce reverse signalling via LIGHT to enhance the secretion of Th1 cytokines (Wan,
2002). DcR3 can be partially cleaved in vivo by proteolysis to produce two functional
fragments that have different activities against FasL and LIGHT (Wroblewski, 2003). The
cleaved fragment of DcR3 (amino acids 1-218) does not bind to FasL but retains its ability
to bind to LIGHT. This may explain the wide range of functions that DcR3 seems to
display. While the full biological significance of DcR3 expression is still to be elucidated,
this study shows that further investigation into its altered expression in SLE is warranted,
particularly into the source and levels of the different DcR3 fragments, their effects on
AICD and the effects they have on different cytokine profiles secreted by DC and T cells.

Real-time PCR analysis of the WG cohort shows that LIGHT and its associated receptors
do not show a dysregulated profile. No significant changes were seen in the levels of
mRNA for LIGHT, any of its receptors or INF-γ when compared to the control cohort. All
patients used in the study were positive for c-ANCA, indicating they may have progressed
to generalised WG, which seems to be dominated by a Th2-type cytokine profile, (the lack
of INF-γ mRNA expression would support this).

The second part of this chapter was the examination of mRNA expression in the lamina
propria of intestinal biopsies collected from patients with active CD. The results from this
study showed that LIGHT was elevated in the gut lesion during active CD when compared
to controls. These results are similar to those seen in Crohn’s disease, another chronic
inflammatory disease of the gastrointestinal tract, where LIGHT is elevated in sites of
inflammation (Cohavy, 2005; Wang, 2005). The LIGHT-HVEM pathway promotes a
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strong Th1 response independent of CD-28 of IL-12 signalling (Brown, 2005). It is well
recognised that CD is characterised by increases in Th1 cytokines. Both INF-γ and IL-2
mRNA and protein have been previously reported to be elevated in CD (Nilsen, 1998;
Lahat, 1999). Our data also confirms this as both are significantly elevated in our active
CD cohort (Fig 3.25).

LTβR also acts as a receptor of LIGHT (Mauri, 1998; Zhai, 1998; Harrop; 1998), it has a
different expression pattern to that of HVEM (Zhai, 1998) and is thought to function as a
communication link between T cells and stromal cells (Gommerman, 2003). Our results
show that LTβR mRNA is not upregulated during active CD (Fig 3.22). Besides LIGHT,
LTβR can also bind LTβ when it forms a heterotrimer with LTα (Ware, 1995). To identify
if LTβ could be responsible of some of the dysregulated immune response in CD we
analysed the levels of its mRNA and showed that it was not upregulated during active CD.
This suggests that any function LTβR plays in the pathogenesis of CD is mostly like not to
involve increased signalling via interactions with LTβ. However, as LIGHT expression is
increased in the active CD it is highly probable that any increases in LTβR activity is due to
LIGHT.

T cells that mediate an inflammatory response must first migrate from

sensitisation areas to sites where they may exert their function. This migration is dependent
of the expression of tissue-specific adhesion molecules and chemokine gradients
(Brandtzaeg, 2001; Butcher, 1996). Infiltration of the lamina propria by large number of
immune cells is a feature of the coeliac lesion (Sollid, 2000; Marsh, 1992). Signalling
through LTβR by LIGHT would serve to increase the expression of various adhesion
molecules and chemokines (Dejardin, 2002; Zhang, 2003; Wang, 2004), which would
direct a large number of cells towards the intestinal mucosa.
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Increased apoptosis of enterocytes is one contributing factor to the villus atrophy seen in
CD (Moss, 1996). Transgenic mice that overexpress LIGHT show increased apoptosis of
intestinal epithelial cells (Wang, 2004). LIGHT can directly cause apoptosis via LTβR
(Rooney, 2000), particularly if the cells have been exposed to INF-γ (Zhang, 2004; Chung,
2004). As both LIGHT (Fig 3.19) and INF-γ (Fig 3.23) (Nilsen, 1998; Lahat, 1999) are
upregulated in active CD, it is feasible that the LIGHT-LTβR pathway could directly
contribute to apoptosis of enterocytes.

From our quantitative analysis, it seems that BTLA is strongly down-regulated in the
lamina propria in untreated CD (Fig 3.25).

This molecule functions to attenuate

lymphocyte activity by acting as a co-inhibitory molecule (Watanabe, 2003) and it has just
been recently linked to the LIGHT-HVEM pathway (Sedy, 2005; Gonzalez, 2005). It is
speculated that if BTLA and LIGHT are expressed on the same cell then the binding of
HVEM to both results in a cancellation of any positive signals from LIGHT (Croft, 2005).
As LIGHT is upregulated in active CD, the lack of BTLA expression in the gut lesion
would allow LIGHT-signalling activity through HVEM to predominate.

This would

further enhance the activation of T cells, upregulation of Th1 cytokines, immune cell
infiltration to the lamina propria and result in profound inflammation and damage to the
surrounding tissue.

In chapter 4, we investigated the levels of soluble LIGHT protein in the serum of patients
with CD, SLE or WG using ELISA. Soluble LIGHT is generated from the cleavage of cell
surface LIGHT to release the extracellular portion (Granger, 2001) and can effectively
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promote a Th1 type response (Tamada, 2000). Using P/I stimulated Jurkat T cells as a
model, it was established that upregulation of LIGHT mRNA correlated with a similar fold
increase in soluble LIGHT levels in the tissue culture supernatants (Fig 4.04). Subsequent
analysis of patient samples provided further proof that LIGHT could be an important factor
in the pathogenesis of CD and SLE as a large percentage of both cohorts had elevated
levels of soluble LIGHT in their serum (Fig 4.05 & Table 4.01).

As LIGHT mRNA and INF-γ mRNA levels correlate (Fig 3.16) in SLE, it is also likely that
the protein levels correlate. We speculate that increased soluble LIGHT may play a role in
lupus nephritis by promoting INF-γ upregulation. This important Th1 cytokine is known to
function in the development of renal disease in SLE (Akahoshi, 1999; Schwarting, 1998;
Haas, 1998). Soluble LIGHT can also induce monocytes and neutrophils to secrete a wide
range of proinflammatory molecules including TNF-α, IL-8, NO and ROS (Kim, 2005;
Heo, 2006) all of which can cause renal damage (Blount, 1994; Nathan, 1997; Rovin, 2002;
Aringer, 2003).

There is a high incidence of secondary autoimmune disease associated with CD (Green,
2003). LIGHT-Tg mice, whilst having severe inflammation of the intestine, also develop
many symptoms of autoimmune diseases (Wang, 2001; Shaikh, 2001).

Many of the

autoimmune diseases have been associated with LIGHT’s activity, including IDDM (Wang,
2001), RA (Kim, 2005) and autoimmune hepatitis (Anand, 2006). Interestingly, many of
the same autoimmune conditions are associated with CD (Alaedini, 2005). We speculate
that chronic exposure to gliadin, the triggering antigen for CD, could serve to keep LIGHT
at elevated levels and over a period of time this could lead to a breakdown of self-tolerance
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and result in secondary autoimmune diseases. However, in order to show this a long term
study would need to be performed using coeliac patients, which could be a direction for
future work.

The WG cohort had a number of patients who expressed lower amounts of soluble LIGHT
than the controls (Fig 4.05). The evidence from our study would indicate that LIGHT and
associated receptors are not involved in the pathogenesis of WG, at least to the point the
there is not increased levels of soluble LIGHT in their serum or there are no increases in
circulating cells that express high levels of LIGHT mRNA. As all of our WG patients were
positive for ANCA directed against PR3 this suggests that their disease had progressed to
the generalised form (Lamprecht, 2005). Generalised WG is characterised by a switch
from a Th1 to a Th2 cytokine profile (Mueller, 2000; Balding, 2001). This could be one
explanation for the low levels of soluble LIGHT in this cohort as it is typically seen as a
Th1 promoting cytokine. In hindsight, Th2 cytokine protein levels should have been
measured in these patients to provide proof of this.

5.2

Treatment of human disease by targeting LIGHT

The treatment of CD with a GFD provides a satisfactory therapy for the majority of
patients. However, some patients fail to respond to this treatment and are deemed to have
refractory CD. It has been reported that refractory CD has a prevalence of 7-8% within the
CD population (O’Mahony, 1996). As there is strong evidence of a link between CD and
malignancies of the gastrointestinal tract (Catassi, 2002; Green, 2001; O’Farrelly, 1986),
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there is a necessity to provide these patients with alternative treatment.

The use of

immunosupressants in these refractory patients has had mixed results, with reports of
patients responding to the treatment but later succumbing to opportunistic infections
(Vaidya, 1999).

Anti-TNF therapy is commonly used in the treatment of autoimmune conditions such as
rheumatoid arthritis (Elliott, 1993) and Crohn’s disease (Targan, 1997) and has been used
to treat refractory CD patients (James, 2005). The most common TNF-α antagonists used
are a murine/human chimeric monoclonal antibody (infliximab) and a soluble TNF-α
receptor fused to the Fc portion of human IgG1 (etanercept). There are some drawbacks to
the use of anti-TNF therapy.

A number of reports have shown the treatment with

infliximab or etanercept can cause new-onset SLE (Mohan, 2002; Hanauer, 2002; Shakoor,
2002) and neurological disease resembling multiple sclerosis (Mohan, 2001). Anti-TNF-α
therapy has been avoided in SLE because of this despite the increase of the cytokine in
these patients (Aringer, 2002; Gabay, 1997).

The research of others has demonstrated that LIGHT may be useful as an alternative target
for the treatment of Th1 associated diseases. Murine models of IBD (Wang, 2005) and
IDDM (Wang, 2001) have been successfully treated by administering the chimeric LTβRIg protein, an antagonist of the LIGHT- LTβR pathways. Our research shows that LIGHT
is upregulated in both CD and SLE. In addition, a recently published study looking at
genes expressed by CD4+ T cells in individuals with severe SLE has also demonstrated that
LIGHT is upregulated during active disease (Deng, 2005). Although treatment of CD
patients with anti-LIGHT therapy would be extreme it could prove useful in the treatment
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of severe refractory disease. In the case of patients with SLE, where anti-TNF therapy is
avoided in their treatment, anti-LIGHT therapy could prove to be an effective method of
downregulating their uncontrolled T cell response. As INF-γ is strongly associated with
lupus nephritis, anti-LIGHT therapy could be of particular use in patients with renal
involvement.

It has been demonstrated that forced expression of LIGHT within tumours causes the influx
of immune cells and elimination of the tumour (Yu, 2004). Not only is the local tumour
destroyed but memory tumour-antigen specific CD8+ T cells were generated that cleared
tumours at other sites in the body. This is another exciting facet of LIGHT’s function as a
therapeutic agent. However, it does warn that manipulation of LIGHT could also have
some serious side effects such as the development of malignancy. Specific targeting of
HVEM and/or LTβR with monoclonal antibodies may be a better route for potential
therapies rather than completely blocking LIGHT altogether with chimeric recombinant
proteins. As LIGHT has diverse roles to play in both the adaptive and innate immune
response, completely switching it off could result in opportunistic infections and possibly
malignancy in the long term. By specifically targeting either HVEM or LTβR, this would
allow for the fine-tuning of the activity of LIGHT in the treatment of disease.
Nevertheless, a much greater understanding of how LIGHT functions within different
environments of the body is needed before the step to treating humans with anti-LIGHT
therapy can be made.
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5.3

Future work

As the scope of this thesis has been quite broad and from the results generated there are a
number of possible avenues for further research.

Our results have demonstrated that

LIGHT mRNA expression is elevated in the lamina propria of patients with active CD.
Therefore, analysing protein levels would provide further evidence as to the potential
involvement of LIGHT in the pathogenesis of CD.

This could be done using

immunohistochemistry, a technique that can be used to quantify as well as localise antigen
in tissue sections. It is also possible to culture duodenal biopsies for up to 48 hrs in an
organ culture system (Nilsen, 1998). The addition of gliadin to biopsies from treated CD
patients induces rapid changes in the expression of proinflammatory cytokines (Nilsen,
1998). Using a combination of quantitative Real-time PCR, immunohistochemistry and
ELISA it would then be possible to analyse the expression of LIGHT in these biopsies in
response to gliadin. Mouse models of IBD have been treated using a soluble LTβR-Fc
chimeric protein (Wang, 2005; An, 2005). A study in which biopsies from treated CD
patients were incubated with gliadin and where LIGHT’s expression was blocked, using
LTβR-Fc/HVEM-Fc, would allow cytokine profiles and any morphological changes that
are a function of LIGHT expression to be identified. This study would further define the
role of LIGHT in the pathogenesis of CD.

Elevated levels of LIGHT have also been identified in IBD, particularly Crohn’s disease
(Cohavy, 2004). Interestingly a susceptibility locus of IBD (Rioux, 2000) overlaps with the
region of Chr 19 in which the gene for LIGHT is located (Granger, 2001). Similarly,
susceptibility loci for SLE (Lindqvist, 2000) and CD (van Belzen, 2003) have been
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localised to this area. While the promoter region of LIGHT has been characterised, no
study to date has been performed to identify polymorphisms that may effect its expression.
Polymorphisms have been characterised for several cytokines, including TNF-α (Wilson,
1992; D’Alfonso, 1994), which effects the expression of their mRNA and can contribute to
the development of autoimmune diseases (Nath, 2004; Dean, 2000). Therefore, it is a
possibility that LIGHT mRNA expression could be altered due to the presence of SNPs
within the promoter region. Particular genotypes may lead to higher or longer sustained
peak levels of LIGHT, which could be a risk factor for a wide range of human diseases.
Further characterisation of the promoter region and identification of possible SNPs leading
to altered expression would be useful in the assessment of LIGHT’s role in the
development of autoimmunity.

We have revealed that deltaLIGHT is upregulated, with similar kinetics to that of LIGHT,
in activated Jurkat T cells (Fig 3.07). Little is known about deltaLIGHT other than it is
held intracellularly (Morel, 2001). Our results demonstrate that it is upregulated in SLE
(Figs 3.10 & 3.15) therefore it may play a role in the development of autoimmunity. The
commonly used method to elucidate the function of a gene is to create a knockout model
and examine the phenotype of the animal. However, small interfering RNAs (siRNAs)
have emerged as a useful technology for knocking out specific mRNAs (Shi, 2003;
Dykxhoorn, 2003).

The use of siRNAs would have the advantage of allowing the

expression of specific splice variants of an mRNA to be eliminated and thereby allowing its
specific function to be elucidated. Separately targeting LIGHT and deltaLIGHT using
siRNAs would determine the function of each during the activation and proliferation of T
cells.
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Our initial finding of lower expression levels of BTLA mRNA in the lamina propria of CD
patients warrants further investigation. The discovery that BTLA is linked to the LIGHTHVEM pathway is a very recent discovery (Sedy, 2005; Gonzalez, 2005). As a result, we
did not get to thoroughly investigate its expression patterns during this thesis. BTLA has
been demonstrated to be highly polymorphic in mice (Hurchla, 2005).

Given the

importance of BTLA in maintaining a balance between T cell activation and the induction
of anergy (Watanabe, 2003), any genetic factor that predisposes to its underexpression
would allow self-reactive T cells to escape anergy, and thereby facilitate the induction of
autoimmune diseases. Further investigation into LIGHT-HVEM-BTLA crosstalk would
yield information as to how these molecules effect T cell activation and the induction of
anergy.

To formally prove our hypothesis that HVEM mRNA is overexpressed in neutrophils it
would be necessary to selectively isolate different cell populations in SLE patients and
analyse their mRNA expression patterns. It may be possible to investigate if neutrophils
constitutively express higher amounts of HVEM in SLE or if it is upregulated in response
to neutrophil activation. A recent report would suggest that HVEM is not upregulated on
the surface as neutrophils become activated (Kim, 2005), which may indicate that the
increased expression of HVEM in SLE patients is constitutive. PR3 is normally contained
in the cytosol, but following neutrophil activation, by cytokines such as TNF-α, it is
translocated to the cell surface (Reumaux, 2004). It has been reported that constitutive
expression of PR3 on the surface of resting neutrophils is genetically predetermined
(Schrieber, 2003) and is a risk factor for WG development. In a similar manner, surface
expression of HVEM may be altered due to potential polymorphisms in its promoter
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region. If HVEM is constitutively expressed at higher levels on neutrophils in SLE patients
this would provide further evidence that targeting the LIGHT-HVEM pathway could be a
potential therapeutic approach.

There are several animal models, including the NZB/NZW and MRL/lpr mice, which show
similar disease manifestations to that of human SLE.

These mice have been used

extensively to establish the role of proinflammatory cytokines in SLE (Boswell, 1988;
Ozmen, 1995; Schwarting, 1998). To test the hypothesis that LIGHT plays a significant
role in the development of lupus nephritis, recombinant proteins, such as LTβR-Ig or
HVEM-Ig, which block LIGHT signalling (Wang, 2001; Wang, 2005; An, 2005) could be
administered to these mice and disease activity monitored. If LIGHT plays a significant
role in the pathogenesis of SLE, particularly lupus nephritis, the administration of blocking
proteins would at least delay the onset of disease in these animals. This would be a key
step in identifying if anti-LIGHT therapy could be used in the treatment of SLE.
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5.4

Conclusion

In summary, the aim of this thesis was to characterise the expression of LIGHT and it’s
associated receptors in human immune-mediated diseases. Using a combination of Realtime RT-PCR and sandwich ELISA methodologies we have successfully achieved this
goal. The work of this thesis has provided strong evidence that LIGHT and its associated
receptors may play an important role in the pathogenesis of both SLE and CD and less so in
WG. LIGHT mRNA expression is elevated in both the peripheral blood and lamina propria
of active CD patients. A large number of our CD cohort also had high levels of soluble
LIGHT present in their serum. LIGHT can enhance the proliferation of Th1 T cells that
can in turn secrete large amounts of INF-γ and IL-2 among other proinflammatory
cytokines. LIGHT can also participate in the maturation of DC, and in doing so, cause
them to be strong activators of CD8+ CTL responses. Increased amounts of INF-γ as well
as high levels of active CTLs can bring about the apoptosis of enterocytes and induce the
destruction of the villous leading to the formation of the characteristic CD lesion.

In SLE, there is a more profound dysregulation of LIGHT and its associated receptors.
Increased levels of LIGHT can stimulate secretion of INF-γ, which is well known to
contribute to the pathogenesis of SLE, particularly renal disease. A significant elevation in
the serum levels of soluble LIGHT was also identified in SLE. Furthermore, elevated
levels of all three receptors for LIGHT were identified in the peripheral blood of our SLE
patients. We have revealed that HVEM is strongly elevated on granulocytes, possibly
neutrophils, although this still needs to be formally proved. Triggering of the HVEMLIGHT pathway on these cells induces the release of NO and ROS as well as TNF-α and
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IL-8 all of which are speculated to play a role in lupus nephritis.

Therefore, increased

levels of LIGHT in SLE patients may contribute to the development of lupus nephritis in a
number of ways.

Targeting of LIGHT effector pathways could be a potential treatment for both SLE and
refractory CD. Further research into LIGHT will lead to a better understanding of the
development of Th1 mediated diseases and it should lead to the development of new
therapies for chronic inflammatory and systemic autoimmune diseases.
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Appendices

Appendix I

Preparation of 10% Acrylamide gel for analysis of the sizing PCR products

Clean glass plate with 70% ethanol solution. Arrange the rubber gasket around the ridge of
one plate and place the flat plate on top of it. Arrange the gasket as necessary to give a
watertight seal. Use bulldog clips to hold the plates together. Pour distilled water in
between the plates to check for leaks. If there are no leaks, empty out the water and leave
on tissue to drain.
Prepare 10 mls of 10% Acrylamide solution as follows:
40% acylamide (19:1)
TBE 10X
H2O
APS (10%)
TEMED

2.5 ml
1.0 ml
6.5 ml
200 µl
40 µl

Fresh 10% ammonium persulfate (APS) should be made daily using distilled H2O. This is
double the amount of TEMED and APS normally used, but it is necessary for proper well
formation in the mini ATTO gel system. Mix well and pour into the gel template, insert the
comb to make wells for loading sample. Allow the gel to set for approximately 20 minutes.
When the gel is set, remove the comb, bulldog clips and the gasket. Place the gel, which is
still encased by the glass plates into the electrophoresis box. The ridged plate should face
inwards and another plate should be arranged similarly on the other side. Pour running
buffer (1X TBE) in between the two plates and allow the wells of the gel to fill up. Pour
running buffer in to the chamber outside of the plates, check for air bubbles underneath the
gels, as these will distort the DNA bands as they move through the gel. Prepare samples to
run on gel by adding 5µl of PCR, 5µl H2O and 2µl 6X loading buffer to a tube. Spin the
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contents down in a microfuge and load all 12µl into one of wells. Place the lid on the box,
connect to the power supply, run the gel at 150 volts for approximately 3.5 hours (until the
xylene cyanol has just run off the bottom of the gel). When the dye front reaches the base
of the gel, turn off the power supply and disconnect the leads. Remove the gel plate from
the tanks and separate the glass plates with the end of a spatula. With a scalpel carefully
cut the gel free from the ridged plate and place it in a 10µg/ml ethidium bromide solution
for 10-20 minutes. The ethidium bromide will bind to the DNA and can be visualised
under UV light. Use a transilluminator to visualise the DNA bands and photograph.
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